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Abstract 
Elevated arterial blood pressure, or hypertension, is a major modifiable risk 
factor for the development of cardiovascular disease, the largest known cause of 
mortality in the world today. While it is clear that lifestyle factors contribute to 
the risk of developing hypertension, there is a strong genetic component too. 
Clinical studies have shown that up to 15% of patients with essential 
hypertension have elevated plasma levels of aldosterone relative to renin. 
Aldosterone is the principal mineralocorticoid steroid hormone in man, and plays 
a key role in regulating body fluid balance. Aldosterone acts on the distal 
tubules and collecting ducts of the kidney nephron where it regulates sodium 
uptake, potassium excretion and water retention. Drugs that antagonise 
aldosterone action lower blood pressure. Unfortunately, many of the existing 
therapeutics have unfavourable side effects. An alternative approach for 
lowering plasma levels of aldosterone in people is to inhibit aldosterone 
synthase (CYP11B2) (the rate-limiting enzyme involved in aldosterone 
production). Aldosterone synthase is a cytochrome p450 enzyme that has ~93% 
sequence homology with 11β-Hydroxylase (CYP11B1) (which catalyses the final 
step in cortisol biosynthesis). Detailed three-dimensional structures of both 
enzymes will facilitate the development of specific small molecule inhibitors of 
aldosterone synthase for the treatment of hypertension. Structural studies and 
drug-screening experiments require large amounts of pure, active protein. Here, 
systems have been developed that allow milligram quantities of human 
aldosterone synthase and 11β-Hydroxylase to be routinely prepared along with 
their electron donors adrenodoxin and adrenodoxin reductase. 
An in-house expression system specifically tailored for the recombinant 
expression, purification and immobilisation of human (membrane) proteins was 
created. The Pichia pastoris expression vector pPICZA was engineered to have a 
“3C protease recognition site - iLOV - biotin acceptor domain - His10” (CLBH) tag 
immediately downstream of the target protein. The CLBH expression system was 
characterised using the cholesterol biosynthetic enzyme sterol isomerase, a 
highly stable human integral membrane protein. iLOV is a novel fluorescent 
reporter derived from the LOV2 domain of Arabidopsis thaliana phototropin 2. 
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Optimal wavelengths for selectively exciting as well as measuring fluorescence 
emission from iLOV were identified. Using these wavelengths, it was possible to 
monitor CLBH-tagged membrane proteins both in vivo (as a reporter of 
recombinant protein production) and in vitro (for assessing the aggregation 
status of membrane proteins by fluorescence size exclusion chromatography). 
Human rhinovirus 3C protease was purified, and its catalytic properties 
characterised using SI-CLBH as substrate. Using the CLBH tag, a simple protocol 
was developed that allowed recombinant (membrane) proteins to be purified to 
homogeneity in four easy steps (nickel-affinity purification, cleavage with human 
rhinovirus 3C protease, reverse nickel-affinity purification and gel filtration). 
Where necessary, however, a second affinity purification step could be 
introduced by biotinylating the CLBH tag in vitro with recombinant biotin ligase, 
and then applying the protein mixture to (strept)avidin beads. The ability to 
immobilise target (membrane) proteins on (strept)avidin-coated surfaces 
platforms using the CLBH tag opens up the possibility of studying the interaction 
of small molecules and proteins of interest by techniques such as surface-
plasmon resonance. 
Efforts to express adrenodoxin reductase using the P. pastoris CLBH system were 
abandoned, as the production levels of the recombinant protein were too low to 
allow its purification on a milligram scale. However, adrenodoxin and 
adrenodoxin reductase were successfully expressed in E. coli using a modified 
version of the pET21a expression vector which contained the CLBH tag. In this 
system, adrenodoxin and adrenodoxin reductase could both be purified to 
homogeneity in four steps. Thermostability assays were performed with pure 
adrenodoxin and adrenodoxin reductase to identify the optimal buffer conditions 
for use with both electron transfer proteins. This was particularly important for 
adrenodoxin reductase as it is very unstable. Analysis of sequence data from the 
1000 genomes project revealed a substantial number of non-synonymous single-
nucleotide polymorphisms in the adrenodoxin and adrenodoxin reductase genes. 
The contribution that these natural variants make to blood pressure regulation 
in people is not yet understood. However, as a first step towards expressing, 
characterising and understanding the properties of the naturally occurring 
variants of adrenodoxin and adrenodoxin reductase in vitro, a biophysical 
characterisation of the wild-type proteins was performed. Circular dichroism 
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spectra for both electron carriers were obtained in the far- and near-UV regions. 
Crystallisation trials with adrenodoxin and adrenodoxin reductase were 
attempted. As yet, however, no diffracting crystals have been obtained. 
Aldosterone synthase and 11β-Hydroxylase are both monotopic membrane 
proteins and were, therefore, expected to be challenging to make in a 
heterologous host on a milligram-scale as well as purify in an active form. No 
expression of either aldosterone synthase or 11β-Hydroxylase was observed in P. 
pastoris using the CLBH system. However, both enzymes were successfully 
expressed in E. coli using the pET21a-CLBH vector. Optimal expression 
conditions for aldosterone synthase were identified. Furthermore, it was shown 
that aldosterone synthase is sensitive to proteolysis at its C-terminus by 
bacterial metalloproteases. This problem was overcome by adding EDTA to all of 
the purification buffers. A novel technique called ELISA size-exclusion 
chromatography (ESEC) was developed which allowed the simultaneous 
assessment of the aggregation state and the polar surface exposure of 
aldosterone synthase in a range of different detergents. Using ESEC, sodium 
cholate was identified as the optimal detergent for solubilising and purifying 
aldosterone synthase. Using pET21a-CYP11B1/B2-His6 constructs, aldosterone 
synthase and 11β-Hydroxylase were both purified in a functional form by 
sequential nickel-affinity, ion-exchange and size-exclusion chromatographies. To 
ensure successful purification of both enzymes, it was essential to break the E. 
coli cells open by sonication in the presence of sodium cholate and Tween-20. 
Furthermore, the nickel-affinity step had to be performed using nickel sepharose 
beads and not a pre-packed column to ensure efficient binding of the 
recombinant protein. The identities of the purified proteins were determined by 
tandem mass spectroscopy. Reduced carbon monoxide difference spectra for 
pure aldosterone synthase and 11β-Hydroxylase both had a prominent absorption 
maximum at ca. 450 nm, which is characteristic of all members of the 
cytochrome p450 superfamily. Furthermore, the purified enzymes could be 
shifted from their low- to their high-spin state by adding substrate. These 
spectroscopic measurements showed that aldosterone synthase and 11β-
Hydroxylase had retained their functionality throughout the purification process. 
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In summary, systems have been developed that allow human aldosterone 
synthase, 11β-Hydroxylase, adrenodoxin and adrenodoxin reductase to be 
purified on a milligram-scale in a functional form. This work provides a solid 
foundation for future efforts to solve the structures of aldosterone synthase and 
11β-Hydroxylase to atomic resolution. Furthermore, using all four proteins, 
activity assays for both aldosterone synthase and 11β-Hydroxylase can now be 
established which will allow the identification of novel specific inhibitors of 
aldosterone synthase for the treatment of hypertension.  
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 Chapter 1 - Introduction 
1.1 Hypertension 
Elevated arterial blood pressure, or hypertension, is an important modifiable risk 
factor for the development of cardiovascular disease, the most common cause of 
morbidity and early mortality worldwide (Chobanian et al., 2003; Lawes et al., 
2008; Ruilope, 2012). Hypertension is a substantial global health problem, 
affecting over a quarter of the world’s adult population (Kearney et al., 2004). 
Although a considerable number of therapeutics have been developed to treat 
hypertension, what causes people to have high blood pressure is poorly 
understood. What is clear, however, is that blood pressure is affected by a wide 
variety of environmental and genetic factors (Kaplan and Opie, 2006). 
Blood pressure is a highly variable quantitative trait making it difficult to define 
precisely parameters for diagnosing hypertension. For convenience, however, 
hypertension is defined as having a resting blood pressure measured consistently 
at values above 140/90 mmHg, in accordance with the JNC VII report1 
(Chobanian et al., 2003). 
1.1.1 Blood pressure regulation 
The body employs a complex network of control mechanisms to maintain blood 
pressure in people at rest. Blood pressure increases in response to external 
stimuli such as exercise or stress and decreases when such demands cease 
(Guyton, 1991). Arterial blood pressure is a function of total peripheral 
resistance (the sum of resistance in the vasculature) and cardiac output (the 
volume of blood ejected from the heart), each of which are under independent 
control (Figure 1.1) (Cowley, 2006). 
  
                                         
1
 The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure 
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Figure 1.1  Mechanisms involved in the regulation of arterial blood pressure
Arterial blood pressure is the product of cardiac output and the total peripheral resistance. Total 
peripheral resistance is affected by changes in the structure and function of the vascula
heart. Cardiac output is affected by the extracellular fluid volume, blood volume and resistance to 
systemic blood flow. The structure and function of the kidney plays a key role in regulating these 
factors. Neuroendocrine stimuli have an importan
the vasculature through the actions of hormones such as aldosterone. Homeostatic feedback 
mechanisms (red dashed line) regulate arterial blood pressure through a variety of sensory 
mechanisms. Figure adap
 
 
t influence on the function of both the kidneys and 
ted from (Cowley, 2006). 
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1.1.2 Risk factors for the development of essential hypertension 
Essential hypertension (where the cause of hypertension in an individual can not 
be identified) accounts for 95% of all people with high blood pressure (Cowley, 
2006). Essential hypertension is a multifactorial disease that has both an 
environmental and genetic component. Investigative studies have shown that the 
development of hypertension can be influenced by environmental factors such as 
high salt intake (Stamler et al., 1989), low potassium intake (Whelton et al., 
1997) and alcohol consumption (Puddey et al., 1987). The development of 
essential hypertension also has a strong genetic component with multiple genes 
from many different physiological systems contributing. Research effort has 
been made worldwide to identify those genes that affect blood pressure. Only a 
few genes are known to cause hypertension through variations in their coding 
regions. However, it is striking that many of these monogenic causes of 
hypertension relate to aspects of corticosteroid biosynthesis and metabolism 
(Section 1.6.1). Further to this, several studies in recent years have shown that 
certain single-nucleotide polymorphisms in the promoters of genes encoding 
enzymes crucial to the synthesis of corticosteroids predispose an individual to 
the development of hypertension (Section 1.6.2). 
The mineralocorticoid aldosterone plays a key role in regulating body fluid 
balance (Section 1.4), and elevated plasma aldosterone levels are known to 
cause high blood pressure (Connell et al., 2008). Drugs that block aldosterone 
action through antagonising mineralocorticoid receptor function have been 
shown to lower blood pressure in hypertensive patients (Cranston and 
Jueljensen, 1962; Chapman et al., 2007) as well as having a beneficial effect on 
patients with moderate to severe heart failure (Pitt et al., 1999). Unfortunately, 
blocking mineralocorticoid receptor activity can lead to undesirable side effects 
such as gynecomastia and a lowered libido (Section 1.7.3). Aldosterone action in 
vivo can also be antagonised by blocking its production. 
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1.2 Corticosteroidogenesis in the adrenal gland
Corticosteroids are made in the adrenal gland cortex from cholesterol through a 
series of enzyme-catalysed reactions, and can be divided into two functional 
groups: the mineralocorticoids
the glucocorticoids, which primarily control intermediary metabolism. The 
principal mineralocorticoid and glucocorticoid hormones are aldosterone and 
cortisol, respectively 
1.2.1 The adrenal gland cortex
The adrenal glands lie superior to each kidney. They comprise an inner medulla 
and a surrounding cortex. The adrenal gland cortex contains three 
and enzymatically distinct zones (
zona glomerulosa (ZG) 
zona fasciculata (ZF)
where the sex steroids are synthesised.
 
Figure 1.2  The histological zones of the adrenal gland
(A) The adrenal glands consist of an inner medulla and outer cortex surrounded by a fibrous 
capsule. The adrenal gland cortex consists of three histologically distinct zones presented (B) as a 
schematic diagram and (C) in a histological section. The zona glomerulosa produces and secretes 
aldosterone; cortisol is synthesised in the zona fasciculata. The sex st
reticularis. Figure adapted from McGraw Hill online learning centre.
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1.2.2 The human
The corticosteroids are synthesised from cholesterol in a series of enzyme
catalysed reactions. Common names fo
Table 1.1 and their structures described in 
Figure 1.3  The human corticosteroid biosynthetic pathway
The corticosteroids aldosterone and cortisol are 
cholesterol. Aldosterone and cortisol biosynthesis takes place in the zona glomerulosa (green 
dashed line) and the zona fasciculata (yellow dashed line) of the adrenal gland cortex, respectively. 
In total, five cytochrome p450 enzymes (side
Hydroxylase, 11β-Hydroxylase and aldosterone synthase) and one HSD (3
for aldosterone and cortisol biosynthesis. Chemical reactions that take place in the mitochondria 
and at the membrane of the smooth endoplasmic reticulum are denoted by red and blue arrows, 
respectively.  
 
 corticosteroid biosynthetic pathway
r the reaction intermediates are listed in 
Figure 1.3. 
 
synthesised from the common substrate 
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Figure 1.4  The chemical structure of cholesterol
Cholesterol has a four-ring structure (labelled A
carbon atoms. All steroid hormones contain the cyclopentanophenanthrene ring structure of 
cholesterol. 
1.2.2.1 Cholesterol
Cholesterol is the precursor of all steroid hormones. 
cholesterol for steroid biosynthesis are: (i) from dietary cholesterol incorporate
into low-density lipoproteins
from acetyl coenzyme 
lipid droplets by cholesterol ester hydrolase 
2012). 
The first step in corticosteroidogenesis is the translocation of cholesterol from 
the outer to the inner mitochondrial membrane. This is facilitated by 
steroidogenic acute regulatory protein (StAR) 
Following import, cholesterol is converted to aldosterone and cortisol through a 
series of enzyme-catalysed steps. All steroid hormones have the cholesterol 
cyclopentanophenanthrene four
 
 
 
-D) with an aliphatic tail. In total, cholesterol has 27 
 transfer into the mitochondria 
The major sources of 
 (LDLs), (ii) the de novo synthesis of cholesterol 
A, and (iii) the hydrolysis of cholesterol esters 
(Ikonen, 2008; 
(Stocco and Clark, 1996
-ring structure (Figure 1.4).
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1.2.2.2 Corticosteroid biosynthesis 
Cholesterol side-chain cleavage 
In the first step of corticosteroid biosynthesis, cholesterol is converted to 
pregnenolone by side chain cleavage enzyme (SCC) (Figure 1.3). The conversion 
of cholesterol to pregnenolone requires three enzymatic reactions. Initially, 
side-chain cleavage enzyme stereospecifically hydroxylates cholesterol: first at 
C22 yielding 22(R) hydroxycholesterol, then at C20 giving 20(R),22(R) 
hydroxycholesterol. Finally, side-chain cleavage enzyme catalyses the oxidative 
scission of the C20-C22 bond to produce pregnenolone (Payne and Hales, 2004). 
Pregnenolone is the precursor for both aldosterone and cortisol biosynthesis.  
Cortisol biosynthesis 
Cortisol can be synthesised from pregnenolone in the zona fasciculata by one of 
two ways (Figure 1.3). In the first pathway, pregnenolone is converted to 
progesterone by 3β-HSD(II) in two steps: first, the C3-hydroxyl group is 
dehydrogenated to a keto group; second, the double bond in the B ring is 
isomerised to the A ring. Thereafter, 17α-Hydroxylase converts progesterone to 
17α-OH-progesterone by 17α-hydroxylation. In the second pathway, this order of 
reactions is reversed: pregnenolone is first converted to 17-OH-pregnenolone by 
17α-Hydroxylase, and thereafter to 17-OH progesterone by 3β-HSD(II). As 17α-
Hydroxylase is only expressed in the zona fasciculata it is this enzyme that 
determines the site of cortisol synthesis (Narasaka et al., 2001). Next, 17α-OH-
progesterone is hydroxylated at the C21 position by 21-Hydroxylase to form 11-
deoxycortisol (Figure 1.3). The final step in cortisol biosynthesis is catalysed by 
11β-Hydroxylase, which is located on the matrix face of the inner mitochondrial 
membrane. 11β-Hydroxylase catalyses the 11β-hydroxylation of 11-deoxycortisol 
to form cortisol (Payne and Hales, 2004; Miller and Auchus, 2011) 
Aldosterone biosynthesis 
In aldosterone biosynthesis, pregnenolone is converted to 11-
deoxycorticosterone by the sequential activity of 3β-HSDII and 21-Hydroxylase 
(Figure 1.3). The conversion of 11-deoxycorticosterone to aldosterone occurs via 
three consecutive reactions: (i) 11β-hydroxylation of 11-deoxycorticosterone 
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yielding corticosterone, (ii) 18-hydroxylation of corticosterone to give 18-
hydroxycorticosterone, and finally (iii) 18-methyloxidation of 18-
hydroxycorticosterone producing aldosterone. In humans, these three steps are 
all catalysed by aldosterone synthase, which is located on the matrix face of the 
inner mitochondrial membrane (Payne and Hales, 2004; Miller and Auchus, 
2011). Aldosterone synthase is the rate-limiting enzyme in aldosterone 
biosynthesis and is, therefore, the best candidate protein for blocking 
aldosterone production in vivo. 
 
1.2.3 Enzymes of the corticosteroid biosynthetic pathway 
In total, five cytochrome p450 enzymes and one hydroxysteroid dehydrogenase 
are required to synthesise aldosterone and cortisol (Figure 1.3). Characteristics 
of both enzyme families will now be discussed. 
1.2.3.1 Hydroxysteroid dehydrogenases 
Hydroxysteroid dehydrogenases (HSDs) are non-metalloenzymes that catalyse the 
oxidoreduction of steroids. HSDs belong to two phylogenies: the short chain 
dehydrogenases and the aldo-keto reductase superfamily. HSDs have several 
isoforms and are expressed in various tissues including the placenta, adrenal 
gland, ovary and testis (Penning, 1997; Miller and Auchus, 2011). Within the 
adrenal gland cortex, the type II isoform of 3β-HSD plays an essential oxidative 
role in the synthesis of both mineralocorticoids and glucocorticoids. 3β-HSDII is a 
membrane-associated short-chain dehydrogenase and requires electrons from 
the co-factor NADH for activity (Simard et al., 2005). 
1.2.3.2 Cytochrome p450 enzymes 
Corticosteroid synthesis requires the catalytic activity of five members of the 
cytochrome p450 superfamily (side-chain cleavage enzyme, 17α-Hydroxylase, 
21-Hydroxylase, 11β-Hydroxylase and aldosterone synthase). Cytochrome p450 
enzymes were first discovered by Tsuneo Omura and Ryo Sato in 1964 who 
observed an unusual cytochrome absorption in mammalian liver microsome 
samples that had an absorption maximum at 420 nm which shifted to 450 nm 
when complexed with carbon monoxide under reducing conditions (Omura and 
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Sato, 1964). From this observation, the term “pigment-450” or “p450” was 
coined, and all enzymes that have this property are known as “cytochrome 
p450” enzymes. 
Cytochrome p450s (referred to hereafter as “p450s”) are widespread in nature 
occuring in plants, archea, microbes as well as mammals. The number of p450s 
in different species varies greatly (Werck-Reichhart and Feyereisen, 2000; 
Bernhardt, 2006). In the human genome, there are 57 genes encoding p450s2. 
p450s are monooxygenases capable of regio- and sterospecific oxygenation of a 
broad range of substrates. Consequently, p450s have a large number of 
biological functions including xenobiotic degradation, metabolism of chemical 
carcinogens and, of particular relevance to this thesis, the biosynthesis of 
physiologically important molecules such as steroid hormones (Sono et al., 
1996). 
1.2.3.2.1 The catalytic cycle of cytochrome p450 enzymes 
Cytochrome p450s use electrons provided by NADPH to hydroxylate substrates 
via the activation of molecular oxygen (Figure 1.5). The overall stoichiometry of 
this reaction is: 
       RH + O2 + NADPH + H+  ROH + H2O + NADP+ 
The catalytic cycle of all p450s consists of five distinct steps (Figure 1.5).        
(1) The cycle is initiated by substrate binding. (2) The haem-iron is reduced from 
its ferric (Fe3+) to its ferrous (Fe2+) state. (3) The Fe2+ ion is able to bind 
molecular oxygen creating a stable dioxygen adduct. (4) The superoxide complex 
is reduced to a negatively charged iron-peroxo intermediate. (5) The distal 
oxygen atom is protonated and the O-O bond undergoes heterolytic cleavage 
causing the formation of a highly reactive iron-hydroxyperoxy species (compound 
I). Compound I reacts with the substrate incorporating the remaining oxygen 
atom to yield the hydroxylated substrate (Denisov et al., 2005). Each p450 is 
highly specific for the orientation and location of the created hydroxyl group as 
well as the particular substrates that they bind. 
                                         
2
 http://drnelson.uthsc.edu/CytochromeP450.html 
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Figure 1.5  The catalytic cycle of cytochrome p450 enzymes
(1) Substrate binds to the p450 enzyme. (2) The
Oxygen binds to the Fe
Fe2+ creating an iron-peroxo intermediate. (5) In the final step, the double bond between the 
oxygen atoms is cleaved. A highly reactive species named compound I is created, which reacts 
with the substrate resulting in its hydroxylation.
1.2.3.2.2 Redox partner 
Electrons required for the activity of p450s are provided by NADPH via an 
electron transfer chain. Mammalian p450s can be divided into two classes 
depending on their subcellular localisation and mode of ele
(Guengerich, 2004)
reticulum (commonly referred to as ‘microsomal p450s’) and receive their 
electrons from a single electron transfer protein; type II p450s are located in 
mitochondria and receive their electrons from a two
transfer chain. 
Microsomal cytochrome p450 enzymes
Microsomal cytochrome p450s constitute by far the larger sub
higher eukaryotes. 50 of the 57 human cytochrome p450s are located at the 
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endoplasmic reticulum (Miller and Auchus, 2011). Microsomal p450s catalyse the 
breakdown of exogenous compounds and receive their electrons from 
cytochrome p450 reductase (CPR). They are anchored to the smooth 
endoplasmic reticulum through a single-spanning transmembrane domain. 
Like the microsomal p450s to which it provides electrons, CPR is N-terminally 
anchored to the ER membrane giving both enzymes the correct spatial 
orientation for efficient electron transfer from the CPR to the p450. The C-
terminal catalytic domain of CPR contains two prosthetic groups, FMN and FAD. 
CPR accepts a pair of electrons from NADPH and transfers these one at a time to 
the p450 enzyme (Wang et al., 1997). 
Mitochondrial cytochrome p450 enzymes 
In humans, mitochondrial cytochrome p450s constitute the sub-families 11, 24 
and 27; there are only 7 human mitochondrial p450s (Miller and Auchus, 2011). 
Unlike their microsomal counterparts, the mitochondrial enzymes are not 
anchored to a membrane by a transmembrane helix. Rather, following removal 
of their N-terminal mitochondrial targeting sequence, the mature enzyme 
becomes embedded within the inner mitochondrial membrane protruding into 
the matrix (Werck-Reichhart and Feyereisen, 2000).  
Mitochondrial p450s receive their electrons via a two-component electron 
transfer chain. Electrons are transferred from NADPH to a [2Fe-2S] containing 
protein called adrenodoxin (Adx) via a FAD-containing protein called 
adrenodoxin reductase (AdxRed). Electrons are then transferred from the 
reduced form of Adx to p450 enzymes at two different points in the catalytic 
cycle (Hannemann et al., 2007) (Figure 1.5). Three models have been proposed 
to describe the way that electrons are transferred from AdxRed to mitochondrial 
p450s via Adx (Figure 1.6). The “shuttle model” proposes that Adx acts as a 
mobile electron carrier moving between AdxRed and the p450 enzyme. The 
“ternary complex model” suggests that a AdxRed:Adx:p450 complex is formed 
with a 1:1:1 ratio. Finally, the “quarternary complex model” proposes a complex 
is formed between AdxRed, Adx and p450 with a ratio of 1:2:1 (Ewen et al., 
2011). The recent structure of a SCC-Adx complex showed that the region of Adx 
that interacts with AdxRed also interacts with side-chain cleavage enzyme, 
Introduction 
suggesting that both the ternary and 
with electron transfer occurr
al., 2011). 
 
Figure 1.6  Models of electron transfer from
adrenodoxin 
The mechanism by which AdxRed transfers its electrons to mitochondrial p450 enzymes remains 
unclear. There are three possible ways by which this may happen. (A) The ‘shuttle model’, in which 
Adx acts as a molecular electron shuttle between AdxRed and the p450. (B) In the ‘ternary model’ 
Adx, AdxRed and a p450 are suggested to form a 1:1:1 complex. (C) In the ‘
Adx proteins are thought to form a complex with AdxRed and a p450 enzyme. 
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1.3 Control of corticosteroid biosynthesis 
Steroid secreting cells do not store steroid hormones following their synthesis. 
Therefore, the rate of steroid secretion by the adrenal glands is determined 
solely upon the rate of hormone synthesis. When required, corticosteroid 
synthesis can be upregulated in one of two ways. On a timescale of minutes, 
increased expression and phosphorylation of StAR results in increased transport 
of cholesterol into the mitochondria stimulating corticosteroid synthesis. Over 
the course of several hours, increased transcription of the CYP11B1 and CYP11B2 
genes results in increased accumulation of 11β-Hydroxylase and aldosterone 
synthase, which causes increased production and secretion of cortisol and 
aldosterone, respectively. 
Cortisol synthesis is regulated by adrenocorticotrophic hormone (ACTH), the 
main component of the hypothalamic-pituitary-adrenal (HPA) axis. Aldosterone 
synthesis is regulated by a range of factors, the principal of which are 
angiotensin II (AngII) and the extracellular potassium concentration ([K+]e). 
Under conditions of severe sodium (Na+) or extracellular fluid loss, ACTH can 
also stimulate the production of aldosterone (Spät and Hunyady, 2004). 
 
1.3.1 Angiotensin II and aldosterone production 
Angiotensin II 
AngII is a pressor octapeptide that causes an increase in blood pressure through: 
(i) vasoconstriction, (ii) stimulating an increase in sodium reabsorption at the 
distal convoluted tubules of the kidney, and (iii) promoting aldosterone release 
from the adrenal cortex. This last effect is mediated through the renin-
angiotensin-aldosterone system (RAAS), of which AngII is the major effector 
peptide (Timmermans et al., 1993). 
The renin-angiotensin-aldosterone system 
The RAAS becomes activated in response to a decreased intravascular volume or 
sodium (Na+) concentration at the macula densa in the distal tubule of the 
kidney.  
Introduction 
 
Figure 1.7  The Renin-
Angiotensinogen secreted by the liver is cleaved by renin, secreted by the kidney, to form 
angiotensin I (AngI). AngI is converted to angiotensin II (AngII) by angiotensin converting enzyme 
(ACE). AngII is the active component of the RAAS. Among other effects on blood pressure 
regulation, AngII stimulates aldosterone secretion by the adrenal gland cortex.
The initial step in the RAAS is the release of renin from the juxtaglomerular cells 
of the kidney. Renin is an 
(secreted by the liver) to form angiotensin I (AngI). AngI is a biologically inert 
decapeptide that is further cleaved by angiotensin converting enzyme (ACE) to 
form AngII (Tomaschitz
The RAAS plays a key role in fluid and electrolyte home
one of the principal blood pressure regulatory systems. Many treatments 
developed to lower hypertension have targeted the RAAS. These are further 
discussed in Section 1.7
Acute effects of Angiotensin II
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This increases the rate of cholesterol uptake into mitochondria which increases 
flux through the aldosterone biosynthetic pathway. The CaMKs also 
phosphorylate the transcription factor cAMP response element-binding protein 
(CREB). Phosphorylated CREB binds to the promoter of the StAR gene, increasing 
its expression. Ultimately, elevated StAR production results in enhanced 
cholesterol import into the mitochondria. Two other signalling pathways 
downstream of the AT1 receptor activation converge on CREB 
phosphorylation/StAR transcription. DAG, released on PIP2 hydrolysis, activates 
protein kinase D (PKD) which phosphorylates and activates CREB (Figure 1.8). 12-
hydroxyeicosatetraenoic acid (12-HETE) (which is generated from DAG via 
arachidonic acid by the sequential activity of DAG lyase and 12-lipoxygenase) 
induces the phosphorylation (and activation) of CREB also (Figure 1.8). 
Chronic effects of Angiotensin II 
Prolonged stimulation of the zona glomerulosa with AngII causes increased 
aldosterone production through transcriptional regulation of the CYP11B2 gene 
(Figure 1.9). CaMKs, activated following binding of AngII to the AT1 receptor, 
phosphorylate selected transcription factors (including activating transcription 
factor (ATF) 1, ATF2, CREB, NURR1, NGF1B) that bind to specific DNA sequences 
(CRE, NBRE-1) in the promoter of the CYP11B2 gene. Increased transcription of 
the CYP11B2 gene results in more aldosterone synthase being made which leads, 
in turn, to an increase in the synthesis and subsequent release of aldosterone 
from the adrenal glands (Bassett et al., 2004; Nogueira and Rainey, 2010). 
1.3.2 The effects of potassium on aldosterone synthesis 
Aldosterone production is extremely sensitive to small fluctuations in [K+]e. The 
zona glomerulosa membrane has a negative resting potential maintained by the 
TWIK-related acid-sensitive K+ (TASK) channels. An increase in [K+]e causes 
depolarisation of the plasma membrane, opening voltage-dependent transient 
(T)- and long lasting (L)-type Ca2+ channels on the cell surface. The inward 
movement of Ca2+ ions results in a rapid rise in the intracellular calcium 
concentration ([Ca2+]i). Subsequent CaMK activation stimulates StAR 
transcription and activity as well as increases CYP11B2 gene transcription in the 
same way as AngII (Spät, 2004). 
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Figure 1.8  Acute regulation of aldosterone production
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Figure 1.9  Chronic regulation of aldosterone synthesis
The actions of AngII and potassium on the zona glomerulosa both result in an increase in 
intracellular Ca2+ followed by 
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feedback regulation which is mediated by cortisol binding to glucocorticoid 
receptors in the hypothalamus, switching off ACTH production 
1992; Waterman and Bischof, 1996
of cortisol production, it has also been shown to exert a small effect on 
aldosterone synthesis through cAMP mediated phosphorylation of StAR 
(Betancourt-Calle et al.
Figure 1.10  The Hypothalamic
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such as stress, corticotrophin hormone (CRH) is secreted by the hypothalamus. CRH stimulates 
the secretion of adrenocorticotrophic hormone (ACT
to MC2R receptors in the adrenal gland, activating a 
cascade that causes increased synthesis and secretion of cortisol through increased transcription 
of the CYP11B1 gene. ACTH secretion is subject to negative feedback regulation through cortisol 
binding to glucocorticoid receptors in the hypothalamus switching off ACTH production.
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1.4 Physiological actions of aldosterone 
Aldosterone mainly acts on the distal tubules and collecting ducts of the kidney 
nephron where it causes sodium conservation, potassium secretion and water 
retention. The overall effect of aldosterone action is to increase blood volume, 
which causes an increase in blood pressure. These classical effects of 
aldosterone action are known as its “genomic effects”, and are mediated via 
mineralocorticoid receptors which regulate the transcription of specific target 
genes. In addition, aldosterone can also cause rapid effects within the body 
through the activation of, as yet, poorly-defined signalling cascades. These are 
termed its “non-genomic effects”. Although aldosterone traditionally acts on 
epithelial cells, aldosterone has recently been shown to have effects elsewhere 
such as the vascular system, where it acts on the heart and blood vessels, as 
well as the central nervous system (CNS) where it regulates salt appetite and 
sympathetic tone (Spät and Hunyady, 2004). 
1.4.1 Genomic actions of aldosterone 
Aldosterone exerts its genomic actions through binding to mineralocorticoid 
receptors (MRs) located in the cytosol of target cells (Figure 1.11). The MRs 
belong to the nuclear receptor family of ligand-dependent transcription factors. 
In the absence of ligand, MRs are monomeric, transcriptionally inactive and 
bound by chaperone proteins. When aldosterone binds to the C-terminal tail of 
MRs, conformational changes occur which results in release of the receptors 
from their chaperones. The MRs then form dimers which translocate to the 
nucleus where they bind to hormone responsive elements (HRE) in the promoters 
of target genes altering transcription (Funder, 1997) (Figure 1.11). 
MRs are unusual in that they have equal affinity for cortisol and aldosterone. 
This poses a conundrum: as cortisol circulates at concentrations of up to 1000x 
that of aldosterone, one would expected MRs to be primarily activated by 
cortisol. However, aldosterone is the main activator of MRs. This effect is 
mediated by 11β-HSDII, which converts cortisol to the inactive metabolite 
cortisone in mineralocorticoid target tissues, thereby conferring aldosterone-
sensitivity on the MRs (Edwards et al., 1988) (Figure 1.11).  
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Figure 1.11  The genomic actions of aldosterone 
Aldosterone binds to mineralocorticoid receptors (MRs) in the cytosol of target cells. Cortisol is 
converted to cortisone by 11β-HSDII, preventing it from binding to MRs. The MR-aldosterone 
complexes dimerise and translocate to the nucleus where they bind to hormone responsive 
elements (HRE) in the promoters of target genes. Aldosterone stimulates sodium reabsorption 
through the transcriptional regulation of the aldosterone-induced proteins SGK1 (serum and 
glucocorticoid-induced kinase 1), GILZ (glucocorticoid-induced leucine zipper protein), CHIF 
(channel-inducing factor) and Ki-RasA (Kirsten Ras GTP-binding protein 2A). Nedd4-2 (neuronal 
precursor cell expressed developmentally down-regulated protein 4-2) ubiquitinates ENaC 
(epithelial sodium channel), targeting it for degradation. SGK1 increases ENaC (epithelial sodium 
channel) activity by (i) phosphorylation of the channel, increasing the probability of channel 
opening, and (ii) phosphorylation of Nedd4-2, reducing its affinity for ENaC. Ki-RasA increases the 
probability of ENaC channel opening and GILZ regulates sodium reabsorption through decreasing 
Nedd4-2 affinity for ENaC. CHIF regulates Na+/K+-ATPase activity. 
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Aldosterone stimulates sodium reabsorption (and thereby water re-uptake) 
primarily by increasing epithelial sodium channel (ENaC) activity at the apical 
membrane of epithelial cells of the renal distal convoluted tubule and early 
collecting duct (Toddturla et al., 1993). Aldosterone can increase the rate of Na+ 
uptake in three different ways: (i) stimulating ENaC gene transcription, (ii) 
increasing trafficking of ENaC to the apical membrane, and (iii) post-
translational modification of ENaC to increase the probability of channel opening 
(Horisberger, 1998; Butterworth et al., 2009). 
Aldosterone modulates ENaC activity indirectly through regulating the 
transcription of a wide-range of proteins collectively called aldosterone-induced 
proteins (AIPs) (Figure 1.11). The best characterised AIP is the serum and 
glucocorticoid-induced kinase 1 (SGK1). SGK1 is part of the phosphatidylinositol 
3-kinase (PI3K) signalling pathway, and is activated by phosphorylation. SGK-1 
can increase ENaC activity in one of two ways. First, phosphorylation of ENaC by 
SGK-1 increases the probability of channel opening. Second, the E3 ligase Nedd4-
2 (neuronal precursor cell expressed developmentally down-regulated protein 4-
2) ubiquitinates ENaC, targeting the channel for degradation. Phosphorylation of 
Nedd4-2 by SGK1 decreases it affinity for ENaC reducing the channel’s turnover 
(Debonneville et al., 2001; Pearce and Kleyman, 2007). The glucocorticoid-
induced leucine zipper protein (GILZ) is another AIP, and regulates sodium 
reabsorption through decreasing Nedd4-2 affinity for ENaC reducing the amount 
of channel targeted for degradation (Bhalla et al., 2006). Other less well-
characterised AIPs include the channel-inducing factor (CHIF), which regulates 
Na+/K+-ATPase activity, and Kirsten Ras GTP-binding protein 2A (Ki-RasA), which 
increases the probability of ENaC channel opening (Stockand, 2002). 
At the basolateral membrane of epithelial cells, sodium enters the bloodstream 
through active transport mediated by the Na+/K+-ATPase and Na+/H+ exchanger 
(NHE). Thus, aldosterone facilitates sodium (Na+) reabsorption in exchange for 
potassium (K+) and hydrogen (H+) secretion. Through these changes in electrolyte 
balance, aldosterone regulates the extracellular fluid volume (and thereby blood 
pressure) while at the same time influencing K+ distribution and acid-base 
balance.  
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1.4.2 Non-genomic actions of aldosterone 
Aldosterone’s genomic actions (often described as its “classic actions”) are well-
characterised and susceptible to transcription blockade by inhibitors such as 
Actinomycin D. However, physiological responses to aldosterone have also been 
observed in the nephron, distal colon and cardiovascular system that are 
independent of de novo protein synthesis and occur on a rapid time-scale (i.e. 
minutes). 
The non-genomic activities of aldosterone are mediated via the generation of 
second messengers (e.g. Ca2+ and cAMP) and the activation of protein kinases 
(such as PKC and ERK). These signalling events modulate the activity of 
membrane proteins such as ENaC. The precise mechanism by which the rapid 
effects of aldosterone action occur remains under debate: it has been suggested 
that they may involve the MRs; others suspect binding to an as yet unidentified 
novel cell-surface receptor (Wehling, 1994; Dooley et al., 2012). 
1.4.3 Non-epithelial actions of aldosterone 
Aldosterone has physiological effects in non-epithelial tissues, most notably the 
cardiovascular system and CNS. MRs are widely distributed in vascular 
(endothelial and smooth muscle), cardiac (fibroblast and cardiomyocytes) and 
neuronal tissues suggesting that aldosterone has widespread activities 
throughout the body (Odermatt and Atanasov, 2009). Curiously, however, with 
the exception of the vasculature, 11βHSDII is not expressed in the tissues where 
the MRs are found. This suggests the MRs are likely to be occupied by 
glucocorticoids such as cortisol rather than aldosterone. Despite this paradox, it 
is well established that excess aldosterone promotes cardiac remodeling, and 
causes both increased vascular resistance and vasoconstriction. These effects 
are aldosterone-induced, mediated via MRs, dependent on Na+ but independent 
of blood pressure (Brilla and Weber, 1992). It is possible that the ratio between 
glucocorticoid and mineralocorticoid occupied MR rather than the aldosterone 
level is responsible for the observed physiological effects. However, the precise 
mechanism by which aldosterone causes cardiovascular damage remains unclear. 
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1.5 The physiological roles of cortisol 
Cortisol’s biological activity is mediated through glucocorticoid receptors (GRs), 
which function in a similar way to MRs. Upon cortisol binding, GRs dimerise and 
the ligand bound receptor complex translocates to the nucleus where it binds to 
glucocorticoid response elements (GREs) in the promoter regions of target genes 
either inducing or repressing their expression (Funder, 1997). 
In contrast to MRs, which are found in select target tissues only, GRs are 
ubiquitously expressed. This explains why cortisol is able to control a wide-range 
of physiological processes in humans including blood pressure regulation 
(Walker, 2007). Of particular relevance to this thesis, cortisol controls aspects of 
development and remodeling in vascular smooth muscle cells by modulating the 
production of nitric oxide and endothelin. The effects of excess cortisol 
secretion are apparent in conditions such as Cushing’s syndrome where 
exaggerated cortisol activity leads to the development of obesity, insulin 
resistance and hypertension. 
In order to further demonstrate the role that corticosteroids play in the 
regulation of blood pressure, diseases caused by aberrations in aldosterone and 
cortisol production will now be described. 
1.6 The role of corticosteroids in hypertension 
1.6.1 Corticosteroids and secondary hypertension 
The cause of hypertension can only be identified in 5% of people with high blood 
pressure. These cases are termed secondary hypertension. In the general 
population, monogenic syndromes of hypertension caused by aberrations in 
corticosteroid synthesis are rather rare. However, these syndromes highlight the 
importance of corticosteroids in influencing blood pressure, and provide insights 
into the contribution that genetics plays in the development of hypertension 
(Vasan et al., 2004). This Section summarises the types of secondary 
hypertension that have been identified in which corticosteroid production is 
altered. 
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1.6.1.1 Primary aldosteronism  
The first case of primary aldosteronism (PA) was diagnosed by Dr. Jerome Conn 
in 1955. His patient was a 34 year old woman who had elevated blood pressure, 
weakness due to hypokalaemia and muscle spasms. During surgery, a right-sided 
adrenal tumour was discovered. When this was removed, the metabolic and 
clinical abnormalities were reversed (Conn, 1955). This clinical presentation was 
originally termed “primary aldosteronism” but has since been renamed an 
“adrenal producing adenoma” (APA). The term “primary aldosteronism” is now 
used to describe a group of related disorders characterised by high levels of 
aldosterone that occur independently of RAAS activity. Patients with PA have a 
higher risk of further development of cardiovascular diseases than age- and sex-
matched patients with essential hypertension and the same degree of blood 
pressure elevation (Blumenfeld et al., 1994; Milliez et al., 2005). 
There are five subtypes of PA of which the most prevalent forms are bilateral 
idiopathic hyperplasia (IHA) (ca. 60% of cases) and APA (35%). All patients with 
APA have small aldosterone-producing adenomas that produce aldosterone 
independent of AngII stimulation. Indeed, in these patients AngII is often 
suppressed to very low levels. In contrast, patients with IHA are hyper-
responsive to AngII, which leads to expansion of the ZG. Less prevalent forms of 
PA include primary adrenal hyperplasia (ca. 2% of PA cases), familial 
hyperaldosteronism (<1%), pure aldosterone-producing adrenocortical carcinoma 
(<1%) and ectopic aldosterone producing adenoma or carcinoma (<0.1%) (Young, 
2007). 
1.6.1.2 Monogenic diseases of the corticosteroid biosynthetic pathway 
Secondary hypertension can also be caused by mutations in genes encoding 
enzymes of the corticosteroid biosynthetic pathway. These are very rare, 
accounting for only approximately 1% of all hypertensive cases. Here, the 
monogenic forms of hypertension that arise from altered mineralocorticoid 
production are briefly described. 
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Glucocorticoid remediable hyperaldosteronism  
Glucocorticoid remediable hyperaldosteronism (GRH) is caused by the formation 
of a chimeric gene composed of the 5’ end of CYP11B1 fused to the coding 
region of CYP11B2. The chimeric gene is expressed in the ZF and results in the 
production of aldosterone under the regulation of ACTH instead of AngII. GRH 
causes early-onset hypertension with the same biochemical features as primary 
aldosteronism. Upon treatment with glucocorticoids the phenotype is completely 
suppressed as a consequence of the removal of ACTH drive (Lifton et al., 1992).  
Apparent mineralocorticoid excess  
Apparent mineralocorticoid excess is caused by mutations in the gene encoding 
11β-HSDII which prevent the conversion of cortisol to cortisone. This results in 
the non-specific activation of MRs by cortisol, inducing a mineralocorticoid form 
of hypertension (Ulick et al., 1979; Mune et al., 1995; Stewart et al., 1996). 
Aldosterone synthase deficiency 
Aldosterone synthase deficiency is caused by rare loss-of-function mutations in 
the CYP11B2 gene which impede the final three steps of aldosterone synthesis. 
This condition is rare, and is characterised by salt-wasting, hyperkalaemia, 
increased plasma renin activity and hypotension (Ulick et al., 1992). Aldosterone 
synthase deficiency can be divided into two subsets: corticosteroid 
methyloxidase types I and II. Both disorders have similar clinical features but the 
profile of mineralocorticoids present in individuals between types is different. 
Congenital adrenal hyperplasia 
Congenital adrenal hyperplasia (CAH) is caused by loss-of-function mutations in 
genes encoding enzymes involved in cortisol biosynthesis. Reduced cortisol 
production levels stimulate an increase in ACTH secretion which causes adrenal 
hyperplasia. This results in a build-up of corticosteroid intermediates to levels 
where they activate MRs. Symptoms of CAH vary according to which gene the 
causal mutations lie in (White et al., 1987).  
Inactivating mutations in 11β-Hydroxylase cause 11-deoxycorticosterone and 11-
deoxycortisol to accumulate rather than cortisol. Under normal physiological 
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conditions, 11-deoxycorticosterone levels are insufficient to activate MRs. 
However, at the high levels found in people with CAH, 11-deoxycorticosterone 
can bind to MRs causing hypertension, hypokalaemia and low renin activity. CAH 
caused by 11β-Hydroxylase deficiency can be treated by glucocorticoid 
replacement therapy which normalises both the ACTH drive and increased blood 
pressure (White et al., 1994). 
CAH can also be caused by mutations in the gene encoding 17α-Hydroxylase. In 
these individuals, as well as having reduced cortisol levels, sex steroid 
production is also lowered due to inefficient conversion of 17-OH-pregnenolone 
to dehydroepiandrosterone (DHEA). This leads to the feminisation of males and 
the failure to develop secondary sex characteristics in females. All subjects have 
a mineralocorticoid-type hypertension caused by excessive 11-
deoxycorticosterone production (Speiser and White, 2003). 
Summary 
What these rare hypertensive conditions have in common is that they are all 
caused by inappropriately high levels of mineralocorticoid activity resulting from 
either elevated aldosterone secretion, excess production of 11-
deoxycorticosterone (a low-affinity MR agonist), or binding of cortisol to MRs. 
1.6.2 Corticosteroids and essential hypertension  
Although the role of corticosteroids in secondary hypertension is long-
established, there is now compelling evidence that they are implicated in the 
aetiology of essential hypertension too. The CYP11B1 and CYP11B2 genes are 
located in tandem on human chromosome 8 only 40 kbp apart (Figure 1.12). 
Polymorphic variations, including single nucleotide polymorphisms (SNPs), intron 
conversions and insertion/deletions, in the coding and regulatory regions of the 
CYP11B genes are strongly associated with the development of hypertension. 
One of the best studied SNPs is located at position -344 in the promoter of the 
CYP11B2 gene. This polymorphism lies within a binding site for the steroidogenic 
factor (SF-1) transcription factor, and can be either a cytosine (C) or a thymine 
(T). Another well-studied variation is an intron conversion (IC) in which part of 
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2001). However, other groups have reported findings contrary to these studies. 
Tsujita and colleagues did not find any association between the -344 SNP and 
hypertension in a case-control study of Japanese patients (Tsujita et al., 2001), 
while Pojoga and co-workers have reported that the -344C allele is associated 
with increased plasma aldosterone levels in hypertensive patients (Pojoga et al., 
1998). A meta-analysis designed to address these conflicting results found that 
the -344T allele does indeed correlate with an increased risk of hypertension but 
not with the rate of aldosterone excretion (Sookoian et al., 2007). 
Despite the clinical importance of these polymorphisms, how they affect blood 
pressure is poorly understood. The -344 T/C SNP is located with a binding site 
for the steroidogenic factor-1 (SF-1) transcription factor, suggesting that this 
polymorphism may affect CYP11B2 transcription. However, in vitro studies have 
shown that the polymorphism has no significant effect on gene transcription 
even though there is a 4-fold difference in binding affinity for SF-1 between 
alleles (Bassett et al., 2002). It has also been proposed that the -344 and IC 
polymorphisms could be markers of a causal variant in nearby genes. Clinical 
studies have shown that there is a strong association between the -344T 
genotype and an increased ratio of 11-deoxycortisol to cortisol (or their 
metabolites), suggesting that altered 11β-Hydroxylase activity may be related to 
CYP11B2 polymorphisms (Davies et al., 2001). The CYP11B1 gene is highly 
polymorphic, and most variations have been found to be in tight LD with those in 
the B2 locus. Two SNPs in the promoter region of the CYP11B1 gene (-1899 G/T 
and -1859 A/G) were identified by Barr and colleagues in normotensive subjects 
homozygous for the -344T and IC polymorphisms in the CYP11B2 locus (Barr et 
al., 2007). When hypertensive patients from the British Genetics of Hypertension 
Study were genotyped for these polymorphisms, the -1899T and -1859G alleles 
were shown to associate with reduced levels of 11β-Hydroxylase activity in vivo 
(Barr et al., 2007). 
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1.7 Aldosterone as a therapeutic target for treating 
hypertension and heart disease 
Currently, there are several different therapeutic options for treating 
hypertension including ACE inhibitors, angiotensin receptor blockers, calcium 
blockers and diuretics. Despite the broad range of anti-hypertensive drugs that 
are available, however, there is still an urgent need to develop novel 
therapeutic agents for treating resistant hypertension (Paulis et al., 2012). 
1.7.1 Current anti-hypertensive treatment strategies 
The multifactorial pathophysiology of hypertension necessitates therapeutic 
agents that have different mechanisms of action. Briefly, the clinical approach 
for lowering blood pressure regulation relies on either reducing the sensitivity of 
vascular smooth muscle to pressor agonists, or reducing intravascular volume by 
lowering the levels of exchangeable sodium. Often these approaches are 
combined to lower the blood pressure of hypertensive patients (Paulis and 
Unger, 2010). 
Reduction of vascular smooth muscle tone can be obtained by blocking either 
the synthesis of AngII (through ACE inhibition) or its efficacy (through AngII 
receptor blockers (ARB)) (Zaman et al., 2002), antagonising β-adrenergic 
receptor function (Che et al., 2009) or blocking smooth muscle Ca2+ channels 
(Eisenberg et al., 2004; Che et al., 2009). Levels of exchangeable sodium in 
people can be lowered through dietary sodium restriction, the use of diuretics or 
aldosterone blockade. A summary of all these therapeutic approaches is given in 
Table 1.2. 
 Table 1.1 Major classes of pharmacological drugs for treating hypertension 
 
Drug Action Side Effects/limitations Types on market 
ACE inhibitors inhibits conversion of 
AngI to AngII 
- dry cough, angiodema, dizziness, tiredness, 
headaches   
- not suitable if patient has a history of 
kidney/heart disease.  
- not effective in blacks or those over 55 
- AngII escape 
Rampipril, Lisinopril, Perindopril, 
Captopril, Cilazapril, Enalapril, 
Trandolapril 
AngII receptor 
blockers 
prevents activation of 
AT1 receptors  
- headaches, dizziness, diarrhoea, nasal 
congestion, back and leg pain 
- can not be used during pregnancy 
Valsartan, Losartan, Eposartan, 
Irbesartan, Candesartan, Temisartan, 
EXP3174 
β-Blockers prevents activation of   
β-adrenergic receptors  
- wide range of side effects including tiredness, 
cold hands and feet, slow heartbeat, diarrhoea, 
nausea, sleep disturbance, nightmares and 
impotence 
Bisoprolol, Atenolol, Carvedilol, 
Propanolol, Metoprolol, Sotolol, 
Nevibolol 
Calcium channel 
blockers 
prevents opening of 
Calcium channels  
- flushed face, headaches, swollen ankles, 
dizziness, tiredness and skin rashes. 
- not suitable for people with a history of heart 
disease, liver disease or circulation problems 
Ditiazem, Verapamil, Amlodipine, 
Nifedipine 
Diuretics increases water 
excretion  
- can raise potassium and blood sugar levels 
- can cause impotence 
- can not be used if you are pregnant or have gout 
Amiloride, Bendrofluazide, Butanide, 
Chloradilone, Furosemide, Metolazone, 
Torasemide 
Mineralocorticoid 
receptor blockers 
prevents 
mineralocorticoid 
receptor activation 
- gynecomastia 
- lowered libido 
Spironolactone, Eplerenone 
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1.7.2 Inhibiting the renin-angiotensin-aldosterone system: 
angiotensin converting enzyme inhibitors and angiotensin 
receptor blockers 
Currently, ACE inhibitors and ARBs are the first-line therapy in the treatment of 
hypertension. ACE inhibitors are effective therapeutic agents not just for 
treating hypertension (Ondetti and Cushman, 1977) but also substantially lower 
the risk of cardiovascular events such as stroke and heart failure (Heart 
Outcomes Prevention Evaluation (HOPE) Study Investigators, 2000). However, 
ACE inhibitors do have some side effects. Due to concomitant inhibition of 
bradykinin breakdown some patients prescribed ACE inhibitors experience a 
persistent dry cough. Additionally, a risk of angioedema has been reported 
(Zaman et al., 2002). ARBs act by blocking AngII activation of the AT1 receptor. 
ARBs have a similar effect on blood pressure as ACE inhibitors but they have a 
better tolerability profile and, therefore, enhanced patient compliance 
(Timmermans et al., 1993; Dahlöf et al., 2002; Julius et al., 2006). 
1.7.3 Mineralocorticoid receptor blockade: targeting aldosterone 
action 
Prescription of the mineralocorticoid receptor blockers spironolactone or 
eplerenone in addition to triple-combination therapy (an ACE inhibitor or ARB 
supplemented with both a calcium channel blocker and a diuretic) significantly  
reduces blood pressure in patients with resistant hypertension, suggesting that 
this group of anti-hypertensives has great therapeutic potential (Nishizaka et 
al., 2003; Chapman et al., 2007). 
Aldosterone is known to have deleterious effects on heart function independent 
of blood pressure. For example, several studies in rats have linked aldosterone 
excess to both vascular injury (Rocha et al., 1998) and myocardial fibrosis (Brilla 
et al., 1993). The usefulness of spironolactone and eplerenone to treat heart 
failure was probed in two milestone clinical studies conducted in 1999 and 2003 
called RALES and EPHESUS, respectively. Both MR antagonists were found to 
reduce morbidity and mortality among patients with severe heart failure (RALES) 
as well as in individuals who had acute myocardial infarction complicated by left 
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ventricular dysfunction and heart failure (EPHESUS) (Pitt et al., 1999; Pitt et al., 
2003).  
Unfortunately, adverse side effects (such as gynecomastia and hypokalaemia) 
have been observed with spironolactone, which has limited its clinical use. 
These side effects are caused by non-specific interactions between the drug and 
the receptors for progesterone and androgen. Off-target effects have not been 
observed with eplerenone, which has greater specificity than spironolactone 
(Weinberger et al., 2002). 
1.7.4 Inhibiting aldosterone synthase 
Over the last four years, substantial research effort has been made, both in 
academia and the pharmaceutical industry, to develop potent and specific 
aldosterone synthase inhibitors (Lucas et al., 2008; Calhoun et al., 2011; Lucas 
et al., 2011). LCI699 (Novartis) was the first of these to be tested in a phase 2 
clinical trial where its potential for treating essential hypertension was 
evaluated (Calhoun et al., 2011). LCI699 was found to be well tolerated, rapidly 
absorbed following oral administration, and potent in suppressing both plasma 
and urinary aldosterone levels. However, ca. 20% of participants developed 
suppression of ACTH-stimulated cortisol release suggesting that LC1699 was 
partially inhibiting 11β-Hydroxylase too. Although disappointing, this was not a 
great surprise as 11β-Hydroxylase and aldosterone synthase have 93% amino acid 
sequence identity. Thus, while this study has provided proof-of-principle 
regarding the therapeutic potential of aldosterone synthase inhibitors, it has 
also served to underline the need for further work to identify new molecules 
that inhibit aldosterone synthase specifically.  
1.8 Structural knowledge concerning p450 enzymes    
Cytochrome p450s have a common structure comprising a small, N-terminal 
domain consisting of β-strands with a larger, α-helical C-terminal domain which 
contains the prosthetic haem group and enzyme active site. The p450 fold was 
first observed by Kraut and co-workers when they solved the structure of p450cam 
(Poulos et al., 1985). Surprisingly, despite low (10-30%) primary sequence 
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homology among members of the cytochrome p450 superfamily, as the number 
of p450 structures that have been solved increases
superfamily has the same overall fold.
1.8.1 p450cam: a paradigm for 
The first crystal structure of a cytochrome p450 to be elucidated was that of 
p450cam from the bacterium 
resolution of 2.6 Å 
consisting of 12 α-helices (designated A
(Figure 1.13). 
 
Figure 1.13  The structure of p450
p450cam has a compact triangular shape with one side rich in 
mainly of α-helices. The haem is located between helices I (yellow) and L (orange), and is 
positioned directly below the camphor (substrate) molecule (inset). 
Chainbow ribbon representation (N
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Haem-binding region 
The core of p450cam comprises a four-helix bundle, consisting of helices E, F, G 
and I. Helix I transcends the protein diagonally and lies parallel to helices L and 
D. This four-helical bundle is conserved between cytochrome p450 proteins. The 
prosthetic haem group, embedded between helices I and L, is surrounded by 
apolar residues and is co-ordinated by Cys357 (which is located at the N-terminal 
end of helix L). This cysteine is absolutely conserved across the entire 
cytochrome p450 superfamily and is part of the p450 signature amino acid 
sequence motif FxxGx(H/R)xCxG (Denisov et al., 2005). 
1.8.2 Substrate recognition sites 
Despite the highly conserved fold possessed by all cytochrome p450s, there is a 
remarkable variation in the chemical structures of the substrates recognised by 
different members of the superfamily. While certain p450s are both highly regio- 
and stereo-specific in their oxygenation of substrate molecules, other enzymes 
can metabolise a large variety of substrates. Enzyme-specificity is determined 
by regions of variability distributed throughout the p450 primary sequence, 
termed substrate recognition sites (SRS). 
SRS were first identified by Osamu Gotoh who performed a group-to-group 
alignment of mammalian CYP2 DNA sequences with those available from bacteria 
including that from P. putida (whose substrate-binding residues had been 
definitively identified by X-ray crystallography) (Gotoh, 1992). In doing this, 6 
regions of variability (SRS1-6; Table 1.3) which had accumulated more amino-
acid changing DNA substitutions than the rest of the sequence were identified. 
Gotoh predicted that these hypervariable regions were responsible for 
determining the substrate-specificity of individual cytochrome p450s. 
Structures published subsequent to Gotoh’s work have indeed confirmed his 
hypothesis that while the overall three-dimensional structure of cytochrome 
p450s is conserved, the substrate specificity of individual enzymes is determined 
by the 6 SRS. 
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Table 1.2 Substrate recognition sites (SRS) in p450cam 
SRS Residues Position in tertiary structure 
1 103-162 Helix B’ and flanking areas 
2 209-216 Helix F (C-terminal end) 
3 248-255 Helix G (N-terminal end) 
4 302-320 Helix I (N-terminal end) 
5 375-385 β3  
6 485-493 β5 (middle)  
 
1.8.3 Mammalian cytochrome p450 structure: CYP2C5  
Rabbit microsomal p450 2C5 was the first mammalian cytochrome p450 to have 
its structure elucidated. 2C5 selectively hydroxylates the 21-methyl group on the 
17β side chain of progesterone. 
Unlike microbial cytochrome p450s (which are all water-soluble), all mammalian 
cytochrome p450s are membrane associated. Therefore, before the structure of 
any mammalian p450 could be obtained, a method had to be developed for 
working with these proteins in solution. Pioneering work by Eric Johnson’s 
laboratory showed that when the N-terminal membrane anchor was removed 
from 2C5 and a further four amino acids substituted, the modified enzyme was 
soluble and monomeric in high salt containing buffers (Cosme and Johnson, 
2000). The approach of Johnson was sufficient to enable the first purification 
and crystallisation of a mammalian cytochrome p450. 
The structure of rabbit 2C5 was solved to a resolution of 3.0 Å by the groups of 
Johnson and Duncan McRee (Williams et al., 2000). 2C5 has the same overall 
structure (Figure 1.14) as bacterial p450s, and provided the first evidence that 
the p450 fold discovered in prokaryotes was conserved in mammals also. In 
particular, the positions of helix I (where the Cys haem axial ligand is located) 
and the electron transfer site (formed by helix L and the β bulge) in 2C5 are 
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essentially superimposable with those from bacterial p450s. The structure of 2C5 
revealed a broad hydrophobic patch on the surface of the enzyme which 
contributes to the monofacial binding of the protein to the membrane. This 
membrane-interaction surface occurs in close proximity to where the N-terminal 
transmembrane domain is thought to span the lipid bilayer. The two membrane 
interacting regions of 2C5 firmly anchor it to the ER membrane as well as 
determining the specific orientation of the enzyme’s catalytic domain relative to 
the membrane surface. The entrance of the substrate access channel (formed 
between the F-G loop and the N-terminal β-sheet domain) is located within the 
bilayer thereby allowing hydrophobic substrates to enter the enzyme’s active 
site directly from the membrane. In addition, the surface of 2C5 proximal to the 
haem group is perpendicular to the membrane, which facilitates contact with, 
and electron transfer from, CPR. 
1.8.4 The structure of a mitochondrial CYP: 24-Hydroxylase 
Johnson’s genetic engineering approach for increasing mammalian p450 
solubility has facilitated the structure determination of other microsomal 
enzymes including 2A6, 2B4, 2C8, 2C9, 2D6 and 3A4 (Otyepka et al., 2007). The 
first structure of a mitochondrial p450, however, was not obtained until 2010, 
suggesting that this sub-set of the cytochrome p450 superfamily are more 
difficult to work with than their microsomal counterparts.  
Mitochondrial p450s have an N-terminal leader sequence which targets them to 
mitochondria. Upon import, the leader sequence is cleaved from the p450 and 
the mature enzyme binds monotopically to the matrix side of the inner 
mitochondrial membrane. Unlike the microsomal enzymes, mitochondrial p450s 
do not have a transmembrane anchor. Rather, they are embedded in the 
membrane through insertion of surface hydrophobic patches into the core of the 
lipid bilayer. This Section describes how the groups of Eric Johnson and David 
Stout obtained the structure of rat vitamin D 24-Hydroxylase (CYP24A1) 
(Annalora et al., 2010). 
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Figure 1.14  Two views of rabbit cytochrome p450 CYP2C5 
The structure of the first mammalian p450, rabbit CYP2C5, was solved by Eric Johnson and 
colleagues in 2000. 2C5 is displayed in (A) front and (B) rear view. Electron density around the F-G 
loop was not clear and was, therefore, omitted from the final structure. The position of the 
membrane was derived from anti-peptide antibody experiments, and is represented by a line. 2C5 
is displayed in ribbon representation with the chains coloured blue to red from the N- to the C-
terminus. The haem is depicted in stick format and coloured red. PDB 10G2 (Williams et al., 2000). 
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24-Hydroxylase expression optimisation 
An engineered form of 24-Hydroxylase was expressed in E. coli with a production 
level of ~40-50 mg l-1 (Annalora et al., 2004). The original construct was 
modified in several ways: (i) the N-terminal mitochondrial targeting sequence 
(U2-32) was removed; (ii) rare codons at positions three and four in the rat 
sequence were changed to ones that occur more commonly in E. coli; and (iii) a 
stabilising mutation S57D found previously to have no effect on catalytic 
function (Omdahl et al., 2004) was introduced. Enhanced levels of 24-
Hydroxylase were obtained by adding chloramphenicol (which stimulates E. coli 
to make cold-shock proteins) to the expression cultures along with IPTG 
(Annalora et al., 2004). 
Detergent optimisation: a critical step in obtaining diffracting crystals 
Mammalian p450s can be extracted from their membrane environments using 
detergent. The optimal detergent for solubilising and purifying 24-Hydroxylase in 
a stable form was found to be Chaps (Annalora et al., 2004). However, in this 
detergent alone no crystals were obtained. By exchanging 24-Hydroxylase into 
the detergent CYMAL-5 immediately prior to setting up crystallisation trays, 
crystals that diffracted to 3.0 Å resolution were obtained. Interestingly, when 
Chaps was used in combination with other common detergents such as CYMAL-5 
and Fos Choline-12, protein crystals were obtained. The crystals which 
diffracted to highest resolution were obtained when Chaps was used in 
combination with the facial amphiphile 3α-hydroxy-7α,12α-bis[(β-D-
maltopyranosyl)ethloxy]cholane (231-chol) to stabilise CYP24A1. Using this 
detergent combination, crystals were obtained that diffracted to 2.0 Å. The 
dramatic improvement in 24-Hydroxylase crystal quality that was obtained when 
facial amphiphiles were used has also been observed with two other p450 
enzymes (CYP2B6 (Gay et al., 2010) and CYP2B4 (Gay et al., 2011)). Together, 
these results suggest that facial amphiphiles may prove to be particularly useful 
for crystallising mammalian p450s.  
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Understanding mitochondrial p450 function from the structure of 24-
Hydroxylase 
The structure of 24-Hydroxylase has provided the first insights into the way in 
which mitochondrial p450s insert into the membrane, bind substrate and 
interact with adrenodoxin. 
24-Hydroxylase adopts the canonical p450 fold comprising 12 α helices and four 
β-strands (Figure 1.15). However, 24-Hydroxylase has additional helices (A’, B’ 
and G’) on its distal surface with a further two (K’ and K’’) located between β2 
and the conserved haem binding motif (Figure 1.15A). The substrate binding site 
is enclosed by the strands β1 and β4, the B-C loop as well as helices E, F, G, I 
and K. A membrane-directed substrate access channel is stabilised in an open 
conformation by a cluster of aromatic residues from helices B’ (Trp134 and Tyr 
137), F (Phe249) and G (His271, Trp275 and Phe279) (Figure 1.15B) as well as a 
salt bridge formed between Arg138 and Glu322 (Figure 1.15C). These eight 
residues are conserved in all mitochondrial p450s, suggesting a common 
mechanism of substrate access to the enzyme active site from the lipid bilayer.  
The short helices A’ and G’, which flank the substrate access channel, anchor 
CYP24A1 to the inner mitochondrial membrane (Figure 1.15). The corresponding 
regions (sequence following the A helix and the F-G loop) in microsomal p450s 
are involved in membrane association also. Alignment of the CYP24A1 A’ and G’ 
amino acid sequences with those from other mitochondrial p450s identified each 
as a membrane insertion (MIS) domain. It is likely that all mitochondrial p450s 
are anchored to the inner membrane via their two MIS domains. Conserved 
surface features from helices K, K’’ and L as well as the lysine-rich proximal loop 
of the meander region define the adrenodoxin binding site. 
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Figure 1.15  The crystal structure of 
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1.8.5 Structures of p450 enzymes involved in steroidogenesis 
In humans, there are six p450 enzymes that play a role in steroid biosynthesis  
(Miller and Auchus, 2011). These are side-chain cleavage enzyme, 11β-
Hydroxylase, aldosterone synthase, 17α-Hydroxylase, aromatase and 21-
Hydroxylase. In 2009, the 3-dimensional structure of aromatase was published 
(Ghosh et al., 2009). Since then, structures of side-chain cleavage enzyme (Mast 
et al., 2011; Strushkevich et al., 2011), 17α- (DeVore and Scott, 2012) and 21-
Hydroxylase (Zhao et al., 2012) have also been obtained. This Section describes 
the structure of side-chain cleavage enzyme with substrate bound and in 
complex with adrenodoxin. An overview of the structures of aromatase, 17α- 
and 21-Hydroxylase is also presented. The remaining challenges in steroid p450 
structural biology are considered. 
1.8.5.1 The three dimensional structure of side-chain cleavage enzyme 
Side-chain cleavage enzyme catalyses the conversion of cholesterol to 
pregnenolone, the first step in the synthesis of all steroid hormones. Side-chain 
cleavage enzyme catalyses three distinct reactions: (1) the conversion of 
cholesterol to 22-hydroxycholesterol (22-HC); (2) the 20-hydroxylation of 22-HC 
giving 20,22-dihydroxycholesterol (20,22-DHC); and finally (3) cleavage of the 
C20-C22 bond yielding pregnenolone. Although side-chain cleavage enzyme 
performs remarkable chemistry, without structural information little could be 
deduced about the way in which side-chain cleavage enzyme is able to carry out 
three sequential reactions in the same active site. 
In 2011, two structures of side-chain cleavage enzyme were published. The first 
was of bovine side-chain cleavage enzyme co-crystallised with the first reaction 
intermediate 22-HC (Mast et al., 2011). The second paper described the 
structure of human side-chain cleavage enzyme in complex with adrenodoxin 
(Strushkevich et al., 2011). Structures were obtained for the side-chain cleavage 
enzyme-adrenodoxin fusion at all stages of the p450’s catalytic cycle.  
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Substrate mobility in the active site 
Cholesterol is transferred to the active site of side-chain cleavage enzyme 
directly from the inner mitochondrial membrane via a substrate access channel 
similar to that observed in the CYP24A1 structure (Annalora et al., 2010). 
Cholesterol is bound in the active site with its side chain bent at positions C20 
and C22 (Figure 1.16A) (Strushkevich et al., 2011). The residues Leu101, Trp87, 
Phe202 and Ile461 position the side chain above the haem iron for subsequent 
hydroxylations (Figure 1.16A). There are extensive contacts between the 
cholesterol rings and amino acids located in the enzyme active site (Figure 
1.16B-D). Leu450, Leu84 and Phe82 interact with the α-face of the sterol rings 
whereas Ser352, Val353, Thr354 and Gln356 contact the β-face. Phe482 and 
Arg81 interact with the edges of the cholesterol rings. 
By co-crystallising side-chain cleavage enzyme with its reaction intermediates, it 
has been possible to gain insights into the way that this particular p450 works. 
For instance, the crystal structure of bovine side-chain cleavage enzyme with 
bound 22-HC showed that only two-thirds of the substrate cavity is occupied by 
the cholesterol-derivative (Mast et al., 2011). The remaining space at the 
entrance to the active site is filled with ordered water molecules, some of which 
form H-bonds with the sterol’s 3β-hydroxyl group. As there are no direct 
contacts between the 3β-hydroxyl and the protein, the substrate/reaction 
intermediates can make small movements while remaining bound to the protein. 
The shape of the active site is such that any substrate movement would have to 
be either away from or towards the haem. This translational freedom along with 
the torsional changes in the aliphatic tail results in correct positioning of the 
C20 or C22 atoms for stereospecific hydroxylation. 
Interaction of side-chain cleavage enzyme with adrenodoxin 
In order to elucidate how electrons are transferred from adrenodoxin (Adx) to 
side-chain cleavage enzyme (SCC), Park and colleagues solved the structure of a 
side-chain cleavage enzyme-adrenodoxin fusion protein capturing a static 
snapshot of a biologically transient reaction (Figure 1.17) (Strushkevich et al., 
2011).  
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When the structure of adrenodoxin in complex with side-chain cleavage enzyme 
was compared with that between adrenodoxin and adrenodoxin reductase 
(Müller et al., 2001), it was found that the adrenodoxin residues that interact 
with adrenodoxin reductase greatly overlap with those that form contacts with 
side-chain cleavage enzyme. This suggests that adrenodoxin can bind to either 
adrenodoxin reductase or a p450 enzyme but not both at the same time. This 
structural evidence suggests that electron transfer between adrenodoxin 
reductase and mitochondrial p450s can not occur via either the ternary or 
quaternary complex models (Section 1.2.3.2.2). Rather, if binding of 
adrenodoxin to adrenodoxin reductase and p450s is mutually exclusive, it would 
suggest that the “shuttle” mechanism of electron transfer between adrenodoxin 
reductase and mitochondrial p450 enzymes is correct. 
1.8.5.2 Available structural data for other steroidogenic p450s 
The first cytochrome p450 involved in steroid biosynthesis to have its structure 
solved was aromatase (Ghosh et al., 2009). Aromatase is responsible for the 
biosynthesis of all oestrogens from androgens, and catalyses three distinct 
chemical reactions (two C19-methyl hydroxylations and an aromatisation of the 
steroid A ring). Unusually, the aromatase used for crystallisation trials had been 
purified from human placenta rather than obtained from a heterologous 
expression host. To date, aromatase is the only full-length cytochrome p450 
where a structure has been obtained. Aromatase was crystallised in the presence 
of the steroid androstenedione, which was found to bind snugly in an androgen-
specific cleft within the enzyme.  
Recently, the structure of 17α-Hydroxylase has been solved by Emily Scott’s 
laboratory (DeVore and Scott, 2012). 17α-Hydroxylase is required for the 
synthesis of many different human steroids including cortisol as well as the 
androgenic and oestrogenic sex hormones. Consequently, this enzyme is an 
important target in the treatment of breast and prostate cancer. X-ray crystal 
structures were obtained for 17α-Hydroxylase in the presence of two inhibitors 
(arbiraterone and TOK-001).  
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The overall structure has provided a rationale for many non-synonomous 
mutations known to cause steroidogenic disease. Features of the enzyme’s 
active site also helped to explain its dual Hydroxylase and lyase activities. 
Steroid 21-Hydroxylase deficiency accounts for ca. 95% of people with congenital 
adrenal hyperplasia (CAH) (which is characterised by impaired synthesis of 
aldosterone and cortisol with excessive androgen production). Mike Waterman’s 
group has recently solved the structure of bovine 21-Hydroxylase with substrate 
(17-hydroxyprogesterone) bound to a resolution of 3 Å (Zhao et al., 2012). This 
structure has given molecular insights into the genetic causes of CAH.  
To date, there is no structural information available for either aldosterone 
synthase or 11β-Hydroxylase.  
1.9 The structural biology of membrane proteins from 
humans 
From a structural biology perspective, membrane proteins are regarded to be 
one of the most challenging classes of proteins to work with. Although ~30% of 
all proteins are located within lipid bilayers, the number of membrane proteins 
whose structures have been obtained and deposited in the protein data bank 
(PDB) is relatively small compared to the corresponding number for soluble 
proteins (Bill et al., 2011). In recent years, however, there has been a 
substantial increase in the number of membrane protein structures that have 
been solved. This progress has been aided by the considerable technological 
advances that have been made in all aspects (expression, purification, 
stabilisation and crystallisation) of membrane protein structural biology (White, 
2009). 
The first membrane protein to have its structure solved to atomic resolution was 
the photosynthetic reaction centre from purple bacteria (Deisenhofer et al., 
1985). Since then, a further 350 unique membrane protein structures have been 
elucidated of which <20 are from humans3. These statistics suggest that 
obtaining the de novo structure of any human membrane protein is incredibly 
                                         
3
 http://blanco.biomol.uci.edu/mpstruc/listAll/list 
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challenging. This Section outlines the main practical considerations when 
attempting to solve the crystal structure of a novel human membrane protein. 
1.9.1 Recombinant production of human membrane proteins 
There are only a few cases where membrane proteins have a sufficiently high 
natural abundance to allow their purification directly from native sources (e.g. 
bovine rhodopsin (Okada et al., 1998). Therefore, the first step towards solving 
the structure of any membrane protein often involves establishing a robust 
recombinant expression system capable of making milligram quantities of 
functional protein for downstream processing. There are a variety of host 
systems available for producing human membrane proteins. These include 
bacteria, yeast, insect and mammalian cells. The usefulness of each of these 
host systems for making any given human membrane protein can only be 
assessed through experiment. 
Bacterial expression hosts such as E. coli are popular hosts for making membrane 
proteins as the cells grow on cheap media with a short doubling time (ca. 20 
min). Furthermore, a wide range of expression vectors and strains are 
commercially-available. Although E. coli is commonly used to make bacterial 
membrane proteins, its use with human membrane proteins is rather more 
restricted as bacteria are unable to perform many of the post-translational 
modifications required for correct folding and insertion of the protein into the 
membrane. Furthermore, there are substantial differences in the lipid content 
between lower and higher eukaryotes hindering efforts to make human 
membrane proteins in bacteria. However, where these limitations have been 
overcome, for example through protein engineering, bacteria have been 
successfully used to make milligram amounts of selected human membrane 
proteins for structural studies (Weiss and Grisshammer, 2002). 
Yeasts such as S. cerevisiae and P. pastoris are a popular alternative to bacteria 
for making human membrane proteins (Andre et al., 2006; Newstead et al., 
2007). Similar to bacteria, yeasts are cheap to grow. However, yeasts have the 
added benefit of being able to perform many of the post-translational 
modifications that occur in mammalian cells (including N-type glycosylation), 
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making them better suited for expressing human membrane proteins than 
bacteria. When expression has been obtained on a small scale, membrane 
protein production can be readily scaled up by growing the yeast in a fermenter. 
P. pastoris has been shown to be particularly useful for expressing milligram 
quantities of a wide range of human membrane proteins including G-protein 
coupled receptors (Weiss et al., 1998; Andre et al., 2006), transporters 
(Chloupkova et al., 2007; Alisio and Mueckler, 2010), channels (Nyblom et al., 
2007; Lee et al., 2009; Brohawn et al., 2012) and membrane enzymes (Newton-
Vinson et al., 2000). The main advantage that P. pastoris has compared to S. 
cerevisiae is that it can grow to extremely high cell densities (109 cells/ml) in 
fermenter culture using methanol as a carbon source (Cereghino et al., 2002). A 
limitation of using yeast cells for making human membrane proteins is that their 
membranes contain the fungal sterol ergosterol rather than the mammalian one 
cholesterol.  
Insect cells infected with baculovirus are commonly used to make human 
membrane proteins. Indeed, all of the heterologously expressed G-protein 
coupled receptors that have had their structures solved to date have all been 
made in insect cells (Cherezov et al., 2007). Insect cells grow to a density of 108 
cells/ml and can perform most mammalian post-translational modifications. 
However, this expression system is considerably more expensive to use than 
either yeast or bacteria. 
Mammalian cells (e.g. HEK293, CHO) can be considered the optimal hosts for 
making human membrane proteins as their cellular environment is essentially 
the same as that in which the heterologously expressed membrane proteins 
normally reside. However, the media used for growing mammalian cells is very 
expensive, the cells grow to low densities (106 – 107 cells/ml) even in bioreactors  
as well as having long doubling times (typically cell division occurs once every 24 
h). For these reasons, mammalian cells tend only to be used for making human 
membrane proteins for structural studies when expression has not been possible 
in bacteria, yeast or insect cells. 
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1.9.2 Detergent solubilisation 
Before a heterologously-expressed membrane protein can be purified, it must 
first be removed from the lipid bilayer using a detergent. All detergents are 
amphipathic molecules consisting of a hydrophilic headgroup (which interacts 
with the aqueous medium) and a hydrophobic tail (which associates with the 
hydrophobic regions of the protein that ordinarily reside within the core of the 
lipid bilayer).  
There are a large number of biological detergents that can be used with 
membrane proteins. These can be classified into four groups according to the 
type of headgroup that the detergent possesses: zwitterionic, anionic, cationic 
and non-ionic. Ionic detergents (such as members of the Fos Choline family) are 
strong detergents and, therefore, excellent at solubilising membranes. However, 
they are harsh detergents and can often strip essential lipids required for 
functional activity from the surface of the target protein. In contrast, non-ionic 
detergents (such as the alkyl maltosides) are relatively mild, and, therefore, 
commonly used for membrane solubilisation.  
The detergent concentration at which individual detergent molecules 
spontaneously form micelles is termed the critical micelle concentration (CMC). 
This concentration is different for each individual detergent. Proteins can be 
released from membranes by adding (a) detergent(s) at a concentration 5-200 
fold greater than its/their CMC (Figure 1.18). Following membrane 
solubilisation, detergent must be included in all subsequent purification buffers 
to prevent the extracted proteins from aggregating. For integral membrane 
proteins, it is essential that the detergent concentration in the buffer solutions 
is greater than its CMC.  
For membrane associated proteins, however, detergent concentrations less than 
the CMC can be used as only sufficient detergent requires to be added to the 
buffer to ensure that the hydrophobic patches exposed on the surface of the 
protein are “covered up”. 
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Figure 1.18  Membrane solubilisation
Membrane proteins can be removed from a lipid bilayer using amphipathic molecules 
detergents. The hydrophobic tail of the detergent associates with 
within the membrane whereas the hydrophilic
environment. Above the critical micelle concentration (CMC), detergent molecules spontaneously 
form micelles. For integral membrane proteins, it is essential that the detergent concentration in 
solution is always greater than its CMC. For membrane associated proteins, however, detergent 
concentrations less than the CMC can be used as only sufficient detergent requires to be added to 
the buffer to ensure that the hydrophobic patches exposed on the surface of 
“covered up”. 
 
When working with membrane proteins, it is essential to identify a detergent 
that efficiently removes the target protein from the membrane but at the same 
time maintains it in a stable, active form 
1.9.3 Purification of detergent
Following successful expression and solubilisation of a target protein, it must be 
purified to homogeneity before structural trials can be commenced. Isolation 
protocols can be developed based on the protein’s intrinsic properties. Methods 
include ion-exchange, where the protein is purified according to its overall net 
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charge, and size exclusion chromatography, where the protein is purified 
according to its size. However, the most common approach for purifying 
membrane proteins is that of affinity chromatography where the target protein 
is engineered to have an amino acid tag which can be pulled down with high-
affinity using a specific resin (Lichty et al., 2005; Waugh, 2005). Immobilised 
metal affinity chromatography (IMAC) can be used to purify recombinant 
proteins containing a polyhistidine (usually between 6 and 10 His) affinity tag 
(Hochuli et al., 1988). The His tag is bound by a transition metal ion (usually Ni2+ 
but also Zn2+ and Co2+) immobilised on a matrix (Terpe, 2003). Other commonly 
used affinity tags include glutathione-S-transferase (GST) and maltose-binding 
protein (MBP) which allow fusion proteins to be purified by binding to 
immobilised glutathione and amylose agarose, respectively. Recombinant 
proteins bound to an affinity resin by either a His, GST or MBP tag can be eluted 
using imidazole, glutathione or maltose, respectively. In contrast, 
immunoaffinity tags (such as FLAG and myc) bind irreversibly to antibody-coated 
resin. Consequently, these tags are primarily used for Western Blotting or pull-
down experiments rather than purification purposes. 
To simplify both the expression and purification of recombinant membrane 
proteins, it has become routine practice to fuse a fluorescent reporter to the C-
terminus of the target protein (Drew et al., 2001; Newstead et al., 2007). The 
most commonly used reporter is green fluorescent protein (GFP) from the 
jellyfish Aequoria victoria (Chalfie et al., 1994). GFP acquired its name from the 
strong green fluorescence it emits upon illumination with visible light. GFP 
comprises an 11-stranded β-barrel with the chromophore situated in a central α-
helix (Figure 1.19) (Ormö et al., 1996; Yang et al., 1996). The chromophore is 
formed by the autocatalytic cyclisation of the tripeptide Ser65 – Tyr66 - Gly67 
(Remington, 2006; Huang et al., 2007; Malo et al., 2007). As formation of the 
GFP chromophore is oxygen-dependent, GFP can not be used as a fluorescence 
reporter in anaerobic/hypoxic conditions (Drepper et al., 2007). Remarkably, 
however, the GFP chromophore remains intact even upon treatment with SDS. 
This property means that GFP-fusion proteins can be readily visualised on SDS-
PAGE following UV-illumination.  
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1.9.4 Membrane protein stability in detergent solution 
To a greater or lesser extent, all detergents are denaturants. Therefore, 
membrane proteins are often very unstable in detergent solution, giving them a 
propensity to unfold and aggregate. Human membrane proteins are particularly 
delicate, considerably more so than those of bacterial origin. Therefore, it is 
essential when working with human membrane proteins that sufficient time and 
effort is taken to identify buffers and detergents in which stable, monodisperse 
protein can be obtained.  
1.9.4.1 Assessing membrane protein monodispersity in detergent solution 
The aggregation state of a purified membrane protein can be assessed in several 
different ways including analytical ultracentrifugation (AUC) and size-exclusion 
chromatography (SEC). When a pure, stable and monodisperse protein is applied 
to a gel-filtration column the elution profile consists of a single, symmetrical 
Gaussian peak. Conversely, when a sample containing aggregated protein is 
applied to the same column the elution profile will contain multiple peaks, one 
of which will be in the void. Furthermore, the degree of symmetry as well as the 
broadness of the major elution peak is an useful indicator of the stability of the 
membrane protein being analysed in the detergent in which it has been purified 
(Sonoda et al., 2010). However, as all proteins absorb at 280 nm, the target 
protein must be 100% pure before SEC can be used to evaluate its aggregation 
status. Moreover, analytical SEC requires milligram quantities of protein to give 
a measurable absorption with a good signal-to-noise ratio. Therefore, while 
analytical SEC is an easy-to-use technique for assessing membrane protein 
monodispersity, it is a time-consuming process that requires considerable 
resource. A further disadvantage of analytical SEC is that the stability of the 
target protein in the detergent used for its purification can not be assessed until 
the purification process has been completed. 
To overcome these problems, Gouax and colleagues have developed a technique 
called fluorescence size exclusion chromatography (FSEC) which allows the 
aggregation status of a target membrane protein to be assessed even in the 
presence of other proteins (Kawate and Gouaux, 2006). By attaching a 
fluorescent tag to a membrane protein of interest, the aggregation status of the 
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target protein can be assessed at any stage of the solubilisation/purification 
procedure by applying it to a gel-filtration column and then measuring 
fluorescence (target-protein specific) rather than A280 (all proteins) in the 
elution fractions. The presence of a single, symmetric fluorescent peak in the 
elution profile indicates that the target protein is stable. Unlike analytical SEC, 
FSEC is a quick and efficient method for assessing the aggregation status of 
membrane proteins in detergent solution that only requires nanogram quantities 
of material. 
1.9.4.2 Direct measurement of membrane protein thermostability 
The stability of any protein can be measured in terms of its resistance to 
denaturation. Proteins that are unstable denature easily whereas stable proteins 
require harsher conditions (e.g. high temperatures, SDS) before they start to 
unfold. Protein unfolding can be followed using biophysical techniques such as 
circular dichroisim (CD) and nuclear-magnetic resonance (NMR). By measuring 
the changes in a spectroscopic signal from the target membrane protein (e.g. its 
far-UV CD spectrum) with temperature, a melting temperature (Tm) for the 
protein can be determined. A protein’s Tm is a measure of its thermostability as 
Tm is defined as the temperature where 50% of the protein has become 
unfolded. Although melting temperatures can be determined in this way, the 
biophysical techniques used to follow the unfolding process have low sensitivity, 
require large quantities of protein and are not easily compatible with screening 
a range of conditions (e.g. buffers and salts). 
To overcome this problem, Ray Stevens and co-workers have developed a 
sensitive, fluorescence-based (CPM) thermal stability assay that can be used 
with membrane proteins (Alexandrov et al., 2008). In this assay, the solvent-
exposed cysteine residues of the protein of interest are reacted with the thiol-
specific fluorochrome N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl] 
maleimide (CPM) which results in the generation of a fluorescent signal. When a 
protein becomes denatured in the presence of CPM, as the cysteine residues 
located in the protein interior become solvent-exposed, there is an increase in 
CPM fluorescence intensity with time. By altering the assay conditions (e.g. 
different buffers - types and pH; salts - types and concentrations; addition of 
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specific ligands) those reagents that confer thermostability on the target protein 
can be identified. The CPM assay can be adapted for use with 96-well plates 
allowing numerous conditions to be screened at one time. Furthermore, as each 
CPM assay only consumes between 1-10 µg of protein considerably less pure 
protein is required to identify optimal conditions for protein thermostability 
compared to biophysical techniques such as CD. 
1.9.5 Membrane protein crystallisation 
Membrane protein crystals suitable for X-ray analysis can be obtained from 
highly concentrated (>10 mg/ml) solutions of pure protein. When precipitant is 
mixed with pure protein in a sealed environment, the precipitant drives the 
formation of nucleation sites. As the protein concentration within the drop 
increases due to water loss (by way of vapour diffusion to a reservoir containing 
a higher concentration of the precipitant), these nucleation sites can become 
protein crystals (Caffrey, 2003). The formation of well-ordered crystals requires 
slow, regulated crystal growth, and is highly influenced by the protein’s 
concentration and solubility. As the range of possible precipitants is large, the 
process of identifying which will be best for crystal growth can be particularly 
time-consuming. However, the development and use of sparse matrix screens for 
initial crystallisation trials has greatly helped to overcome this rate-limiting 
step. Crystal hits are then optimised through a series of small variations to the 
original crystallisation condition with a view to obtaining good quality diffracting 
crystals (Caffrey, 2003; Kobilka and Schertler, 2008). Depending on the 
orientation of the individual proteins and the position of their lattice contacts, 
crystals of varied shape and symmetry can be formed (Nollert, 2005). Obtaining 
crystals of membrane proteins in surfo is considerably harder than that for 
soluble proteins as the detergent molecules often mask the extra-membranous 
regions of the protein, preventing the formation of crystal contacts (Mohanty et 
al., 2003). 
To increase the probability of obtaining crystals of a membrane protein in 
detergent solution, it is common to try and solve the structure of a target 
protein in complex with a soluble binding partner. The rationale for this 
approach is that the binding partner increases the polar surface area of the 
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membrane protein complex, thereby promoting the formation of crystal lattice 
contacts. For example, co-crystallisation with a Fab fragment has been used to 
obtain the structures of the mitochondrial cytochrome bc1 complex (Hunte et 
al., 2000), a potassium channel (Zhou et al., 2001) as well as the β2 adrenergic 
receptor (Rasmussen et al., 2007). Using a similar strategy, the structure of the 
mitochondrial p450 human cholesterol side-chain cleavage enzyme has been 
obtained in complex with adrenodoxin as an engineered fusion protein 
(Strushkevich et al., 2011). 
1.10 Project context 
In recent years, four of the six p450 enzymes involved in human steroid 
biosynthesis have had their structures solved (Ghosh et al., 2009; Mast et al., 
2011; Strushkevich et al., 2011; DeVore and Scott, 2012; Zhao et al., 2012). As 
yet, however, there is no structural information available for either aldosterone 
synthase or 11β-Hydroxylase. As these two enzymes have 93% primary sequence 
identity, it has not yet been possible to design fully selective inhibitors of either 
aldosterone synthase or 11β-Hydroxylase. Detailed three-dimensional structures 
of both enzymes will facilitate the development of specific small molecule 
inhibitors of aldosterone synthase for the treatment of hypertension.  
1.11 Aim 
The main aim of my Ph.D. was to overexpress and purify aldosterone synthase 
and 11β-Hydroxylase as well as their associated electron transfer proteins, 
adrenodoxin and adrenodoxin reductase, for structural studies.  
1.12 Objectives 
i) develop a generic system for making, purifying and immobilising 
human proteins 
ii) clone, express and purify adrenodoxin and adrenodoxin reductase 
iii) clone, express and purify aldosterone synthase and 11β-Hydroxylase  
iv) biophysically characterise pure adrenodoxin, adrenodoxin reductase, 
aldosterone synthase and 11β-Hydroxylase
 Chapter 2 – Methods and Materials 
  
2.1 Strains 
Plasmids were maintained and propagated in E. coli strain DH5α (Invitrogen). All 
protein production in E. coli was performed in either BL21 (DE3) (Novagen) or 
C43 (DE3) (Lucigen) cells. Recombinant protein production in P. pastoris was 
performed in strain X33 (Invitrogen). 
2.2 Media 
E. coli was routinely grown on either Luria-Bertani (LB) (1% tryptone, 0.5% yeast 
extract and 1% NaCl) or Low-Salt LB (LS-LB) (1% tryptone, 0.5% yeast extract and 
0.5% NaCl) media according to the antibiotic being used for selection. Bacteria 
containing ampicillin-resistant plasmids were grown on LB ([ampicillin] = 100 
µg/ml), zeocin-resistant ones on LS-LB ([zeocin] = 25 µg/ml). Production of 
biotin ligase and 3C protease in E. coli was accomplished in LB media. 
Recombinant expression of Adx, AdxRed, aldosterone synthase and 11β-
Hydroxylase was performed in Terrific Broth (TB) (1.2% tryptone, 2.4% yeast 
extract, 4% glycerol, 17 mM KH2PO4 and 72 mM K2HPO4). 
P. pastoris was routinely cultured in YPD medium (1% yeast extract, 2% peptone 
and 2% glucose). For small-scale expression experiments, the yeast 
transformants were grown on Buffered-complex Glycerol (BMGY) medium (1% 
yeast extract, 2% peptone, 100 mM potassium phosphate, 1.34% yeast nitrogen 
base, 4x10-5% biotin and 1% glycerol, pH 6.0), and then induced using Buffered-
complex Methanol (BMMY) medium (the same as BMGY except that it contains 
0.5% methanol instead of 1% glycerol). 
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2.3 Expression plasmid construction 
2.3.1 Sub-cloning strategies 
Standard DNA manipulation techniques were used to construct the plasmids for 
recombinant protein expression (Sambrook et al., 1989). 
2.3.1.1  Polymerase chain reaction 
DNA oligonucleotide primers were synthesised by Sigma Genosys (UK) or Eurofins 
MWG Operon (Germany). Primers were resuspended in sterile, distilled H20 to a 
final concentration of 50 pmol/µl and stored at -20°C. All primers had at least 21 
bases complimentary to the template DNA with a GC content of ca. 40%. 
All polymerase chain reaction (PCR) amplifications were performed using KOD 
HotStart DNA polymerase (Merck Biosciences) using appropriate template and 
primer combinations. A typical PCR reaction consisted of an initial 2 min 
Polymerase activation step at 98°C followed by between 25-35 cycles, each 
consisting of a DNA denaturation step (98°C, 20 s), primer annealing (55°C, 10 s) 
and DNA extension (70°C, 20 s per Kb of DNA being amplified). After the last 
cycle, the PCR cocktail was incubated at 70°C for a further 10 min to ensure that 
all de novo DNA synthesis had been completed. 
2.3.1.2  Agarose gel electrophoresis and gel-extraction 
Following PCR amplification or restriction digestion, DNA fragments were 
resolved by electrophoresis through a 1% agarose gel in Tris-Acetate EDTA (TAE) 
buffer (1 mM EDTA in 40 mM Tris-Acetate pH 8.0). A 1kb DNA ladder (Promega) 
was used to estimate DNA fragment size. DNA was visualised using SYBR Safe 
DNA gel stain (Invitrogen). DNA fragments were extracted by cutting the band of 
interest out with a sterile blade, and then purified using a QIAGEN gel extraction 
kit according to the manufacturer’s instructions. 
  
Methods and materials  59 
2.3.1.3 Plasmid DNA purification 
Plasmid DNA was isolated from small (5 ml) and large (100 ml) bacterial cultures 
using the QIAprep Spin MiniPrep and Maxi kits (both QIAGEN), respectively, 
according to the manufacturer’s instructions. Plasmid DNA concentrations were 
determined using a NanoDrop 1000 (ThermoScientific). 
2.3.1.4  Restriction digestion 
Restriction enzymes were purchased from Roche Applied Science, Promega and 
New England Biolabs. Plasmid DNA was digested in the appropriate buffer 
according to the manufacturer’s instructions. 
2.3.1.5  DNA ligation 
Unless stated otherwise, all DNA ligations were carried out using T4 DNA ligase 
(New England Biolabs) according to the manufacturer’s instructions. 
2.3.1.6  DNA sequencing 
Recombinant plasmids were sequenced at the DNA Sequencing and Services Unit 
in the College of Life Sciences, University of Dundee using an Applied Biosystems 
model 3730 automated capillary DNA sequencer. 
2.3.2 PCR amplification of human adrenodoxin, adrenodoxin 
reductase, aldosterone synthase and 11β-Hydroxylase 
cDNAs encoding human Adx, AdxRed, aldosterone synthase and 11β-Hydroxylase 
were provided by Dr. Gordon Inglis (University of Glasgow). 
A modified human Adx cDNA lacking the mitochondrial leader sequence was 
created by PCR using the primers GAATTCATGAGCAGCTCAGAAGATAAAATAACAG 
and GCGGCCGCTGGAGGTCTTGCCCACATCAATG that contained restriction sites 
(coloured red) for EcoRI and NotI, respectively. Similarly, a cDNA for human 
AdxRed without the mitochondrial leader sequence was generated using the 
primers GAATTCATGTCCACACAGGAGAAGACCCCCCAG and GCGGCCGCTGTGGCCC 
AGGAGGCGCAGCATCTC. 
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Modified human 11β-Hydroxylase and aldosterone synthase cDNAs were created 
by PCR amplification using a common forward primer CTTAATGAATTCATGGCCAC 
GAAGGCCGCCCGGG with different reverse primers (11β-Hydroxylase: CAGATTTT 
CAGCGGCCGCGTTGATGGCTCTGAAGGTGAGGAG; aldosterone synthase: CAGATTT 
TCAGCGGCCGCGTTAATCGCTCTGAAAGTGAGGAG). The sequence of the forward 
primer encoded the protein sequence MATKAAR instead of the mitochondrial 
targeting sequences found in the full-length proteins. The forward and reverse 
primers contained restriction sites for EcoRI and NotI, respectively. 
The PCR fragments were cloned first into pGEM T-Easy (as described in Section 
2.3.4) and then later transferred to either a yeast (Section 2.3.5) or bacterial 
expression vector (Section 2.3.6 and 2.3.7). 
2.3.3 PCR amplification of the CLBH tag 
The CLBH tag was amplified by PCR using primers GCGGCCGCTGTCCTATTCCAGG 
GCCCAACTAGTATAGAGAAGAATTTCGTC and GGATCCTCAGTGATGGTGATGGTGAT 
GGTGATGGTGATGCCCGAT using the pPICZA-SI-CLBH vector as template. The 
forward and reverse primers contained NotI and BamHI restriction sites, 
respectively, for eventual cloning of the CLBH tag into pET21a. First, however, 
the PCR product was introduced into pGEM T-Easy (Section 2.3.4). 
2.3.4 Cloning PCR products into pGEM T-Easy 
PCR products were generated as described in Section 2.3.1.1, and then resolved 
on a 1% (w/v) agarose gel according to Section 2.3.1.2. The gel-purified PCR 
fragments were A-tailed by incubating the DNA fragment with Taq DNA 
polymerase (New England Biolabs) and 1 mM dATP at 70°C for 30 min. A-tailed 
PCR products were ligated into pGEM T-Easy (Promega) according to the 
manufacturer’s instructions. The ligation mixture was transformed into 
competent DH5α cells by heat shock (Section 2.4.1.2). Transformed cells were 
plated onto LB-agar plates containing 100 µg/ml ampicillin (Sigma-Aldrich) and 
100 µg/ml 5-bromo-4-chloro-3-indolyl-β-D galactopyranoside (X-gal) (Roche 
Applied Science), and then incubated for 16 h at 37°C. Colonies containing 
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recombinant plasmid were white whereas those that contained vector without 
an insert were blue. 
Several putative white colonies for each pGEM construct were grown up in 5 ml 
of LB containing 100 µg/ml ampicillin overnight at 37°C in a shaking incubator. 
Plasmid DNA was isolated from cultures according to Section 2.3.1.3. Correct 
recombinant plasmids were identified first by restriction digestion (Section 
2.3.1.4) and then by DNA sequencing (Section 2.3.1.6). 
2.3.5 Sub-cloning cDNAs for adrenodoxin reductase, aldosterone 
synthase and 11β-Hydroxylase into the pPICZA-CLBH vector 
The cDNAs for AdxRed, aldosterone synthase and 11β-Hydroxylase were released 
from pGEM T-Easy by digestion with EcoRI and NotI. Digests were resolved on an 
agarose gel. The cDNAs were purified by gel extraction (Section 2.3.1.2) and 
ligated to pPICZA-CLBH vector (which had also been digested with EcoRI and 
NotI). The ligation mixture was transformed into DH5α cells according to Section 
2.4.1.2. Recombinant plasmids were identified first by restriction digestion 
(Section 2.3.1.4) and then DNA sequencing (Section 2.3.1.6). Later, the 
recombinant plasmids were transformed into P. pastoris strain X33 by 
electroporation (Section 2.4.2.2). 
2.3.6 Engineering the pET21a-Adx(Red)-CLBH constructs 
The cDNAs encoding Adx and AdxRed were released from pGEM T-Easy by 
digestion with NdeI (which cleaved a sequence located within the vector's multi-
cloning site) and NotI. The –CLBH cDNA was released from pGEM T-Easy by 
digestion with NotI and BamHI. The cDNAs were purified by gel extraction 
(Section 2.3.1.2). The –CLBH cDNA was ligated individually to the Adx and 
AdxRed cDNAs. Subsequently, the Adx-CLBH and AdxRed-CLBH fragments were 
cloned into pET21a (which had been previously digested with NdeI and BamHI). 
The ligation mixture was transformed into E. coli strain DH5α (Section 2.4.1.2). 
Recombinant plasmids were identified by restriction digestion.  
Methods and materials  62 
Later, pET21a-Adx-CLBH was transformed into the E. coli expression strain 
BL21(DE3). pET21a-AdxRed-CLBH was transformed into BL21(DE3) cells that 
contained the pGro7 plasmid (TaKaRa Bio). Glycerol stocks were prepared, snap-
frozen with liquid nitrogen and stored at -80°C. 
2.3.7 Assembling the pET21a - CYP11B1/B2 - CLBH constructs 
The cDNAs encoding aldosterone synthase and 11β-Hydroxylase were excised 
from pGEM T-Easy using NdeI and NotI, and then purified according to Section 
2.3.1.2. The enzyme cDNAs were ligated to the CLBH cDNA (which had been 
digested with NotI and BamHI). CYP11B1- and CYP11B2-CLBH DNA fragments 
were ligated with pET21a (which had been digested with NdeI and BamHI), and 
then transformed into E. coli strain DH5α (Section 2.4.1.2). Recombinant 
plasmids were identified by restriction digest (Section 2.3.1.4).  
Later, the pET21a - CYP11B1/B2 - CLBH plasmids were transformed into E. coli 
expression strains BL21(DE3) and C43(DE3), in which the chaperone plasmid 
pGro7 (TaKaRa Bio) had been previously introduced. Glycerol stocks were 
prepared, snap-frozen with liquid nitrogen and stored at -80°C. 
2.3.8 Making pET21a - CYP11B1/B2 - His6 expression constructs 
Aldosterone synthase/11β-Hydroxylase cDNAs were released from pGEM T-Easy 
by digestion with NdeI and NotI. The DNA fragments were purified by gel 
extraction and then ligated to pET21a, which had been digested with NdeI and 
NotI also. Recombinant plasmids were identified by restriction digestion (Section 
2.3.1.4), and then transformed into the E. coli expression strain C43(DE3), in 
which the pGro7 plasmid (TaKaRa Bio) had already been introduced. Glycerol 
stocks were prepared, snap-frozen with liquid nitrogen and stored at -80°C. 
2.3.9 Constructing a pET15b-BirA expression plasmid 
The biotin ligase (BirA) gene was amplified from E. coli 0157 genomic DNA (a gift 
from Dr. Mads Gabrielsen, University of Glasgow) by PCR using the primers TGAC 
CACATATGATGAAGGATAACACCGTGCCACTG and CGTAGAGGATCCTTATTTTTCTGC 
ACTACGCAGGGA. The forward and reverse primers contained NdeI and BamHI 
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restriction sites, respectively, which were eventually used for cloning the BirA 
cDNA into pET15b. First, however, the PCR product was introduced into pGEM T-
Easy according to Section 2.3.4. Recombinant plasmids were identified by 
restriction digestion (Section 2.3.1.4), and then sequenced (Section 2.3.1.6) to 
ensure that no mutations had been introduced during the PCR step. The BirA 
cDNA was sub-cloned into pET15b (Novagen Biosciences) between the NdeI and 
BamHI restriction sites. 
pET15b-BirA was transformed into E. coli strain BL21(DE3) for expression and 
purification purposes. Glycerol stocks were made and stored at -80°C. 
2.4 DNA transformation 
2.4.1 Transforming plasmid DNA into bacteria 
2.4.1.1  Preparation of competent cells 
DH5α cells used for cloning were purchased from Invitrogen. E. coli expression 
strain BL21(DE3) was purchased from Novagen Biosciences. C43(DE3) cells were a 
gift from Dr. Frank Kroner (University of Glasgow). 
BL21(DE3) and C43(DE3) cells that had been transformed with the pGro7 plasmid 
(which encodes the molecular chaperones GroEL/ES) had to be made competent 
before any of the pET expression constructs could be introduced. The E. coli 
strain to be made competent was grown in 5 ml of Psi broth (0.5% yeast extract, 
2% tryptone, 0.5% magnesium sulphate) overnight at 37°C in a shaking incubator. 
The next morning, 1 ml of the starter culture was used to inoculate a further 
500 ml of Psi broth in a 2000 ml unbaffled Erlenmeyer flask. The cells were 
grown to an optical density at 600 nm (OD600) of 0.6, before they were incubated 
on ice for 15 min and harvested by centrifugation (4000g, 5 min, 4°C). Pelleted 
cells were resuspended in 400 ml of TfbI (30 mM potassium acetate, 100 mM 
rubidium chloride, 10 mM calcium chloride, 50 mM manganese chloride, 15% 
(v/v) glycerol, pH 5.8) and incubated on ice for 15 min. The cells were 
centrifuged again (4,000g, 5 min, 4°C), and the pellet resuspended in 40 ml of 
TfbII (75 mM calcium chloride, 15% (v/v) glycerol, 10 mM MOPS pH 6.5). The 
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cells, now competent, were split into aliquots, flash-frozen in liquid nitrogen 
and stored at -80°C. 
2.4.1.2  Transformation of expression plasmids into E. coli 
Plasmids were transformed into E. coli according to the method of Hanahan 
(1983). In short, 50 ng of DNA was mixed gently with 50 µl of competent E. coli 
cells, and the mixture incubated on ice for 15 min. The cells were subjected to 
heat-shock (42°C, 1 min), and then placed back on ice for a further 2 min. To 
allow the bacteria to recover, 450 µl of LB was added to the cells. The 
transformation mixture was then shaken at 37°C for 45 min before a 200 µl 
aliquot was spread on an (LS)-LB-agar plate containing the appropriate 
antibiotic(s) (100 µg/ml ampicillin, 20 µg/ml chloramphenicol, 25 µg/ml zeocin). 
[The pGEM T-Easy and pET expression vectors confer ampicillin resistance, 
pPICZA vector zeocin-resistance, and pGro7 chloramphenicol resistance]. Plates 
were incubated for 16 h at 37°C to allow selection of cells containing plasmid. 
2.4.2 Transformation of expression plasmids into P. pastoris  
2.4.2.1  Preparation of electrocompetent cells 
5 ml of YPD broth was inoculated with P. pastoris strain X33 and grown for 16 h 
at 30°C in a shaking incubator. 500 µl of the overnight culture was used to 
inoculate 100 ml of YPD medium in a 500 ml flask, which was then shaken at 
30°C for a further 16 h. Once the cells had reached an OD600 of between 1.3-1.5, 
they were harvested by centrifugation (1500g, 5 min, 4°C). The pellet was 
resuspended in 500 ml of sterile, ice-cold dH20, before the cells were 
centrifuged again (1500g, 5 min, 4°C). This process was repeated a further three 
times, resuspending the cells first in 50 ml of ice-cold dH20, then 4 ml and 
eventually 300 µl of ice-cold 1 M sorbitol. The cells were now competent, and 
used immediately for transformation. 
2.4.2.2  Electroporation 
10-50 µg of recombinant plasmid DNA in a volume of 20 µl was linearised by 
overnight digestion with PmeI, and then gently mixed gently with 80 µl of 
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competent X33 cells. The transformation mixture was incubated in a sterile 0.2 
cm electroporation cuvette on ice for 5 min, and then pulsed (2 Kv, 5 ms) using 
an electroporator. 1 ml of 1 M sorbitol was added immediately to the yeast cells, 
which were then allowed to recover at 30°C for 2 h. The transformation mixture 
was then spread on a series of YPD plates containing 1M sorbitol and increasing 
concentrations of zeocin ranging from 0.2 to 2.0 mg/ml. The plates were 
incubated for 72 h. Colonies were re-streaked onto fresh YPD plates containing 
0.5 mg/ml zeocin, and incubated for a further 24-72 h at 30°C. Colonies were 
then screened to identify the clone expressing the highest levels of recombinant 
protein (Section 2.5.1). 
2.5 Protein expression in P. pastoris 
2.5.1 1 ml cultures in 48-well plates 
Yeast cells that had been transformed with a CLBH-tagged expression plasmid 
were screened to identify the clone which made the highest levels of 
recombinant protein by measuring whole cell iLOV fluorescence. Transformants 
were grown and induced on a 1 ml scale in a 48-well sterile plate. For each 
transformant, two 1 ml cultures were established in BMGY. Following 
inoculation, the deep-well blocks were shaken for 24 h at 30°C. The cells were 
pelleted by centrifugation (1,500g, 5 min, 4°C), and then resuspended in 1 ml of 
BMMY medium, to induce protein expression. The plate was returned to the 
shaking incubator for another 24 h but this time at 22°C. Cells were harvested by 
centrifugation as before, washed twice with and then resuspended in 1 ml of 
dH20. Whole cell iLOV fluorescence levels were measured for each culture in a 
black 96-well plate (Corning) using a BMG LabTech Fluostar optima (λexcitation = 
450 nm, λemission = 520 nm). Glycerol stocks were prepared for the transformant 
found to have the highest expression level of the recombinant protein by mixing 
equal volumes of an overnight culture grown in YPD with 50% (v/v) glycerol in a 
sterile cryovial. The cultures were snap-frozen using liquid nitrogen and stored 
at -80°C. 
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2.5.2 Recombinant protein expression in fermenter culture 
Large scale production of SI-, AdxRed- and CYP11B2-CLBH in P. pastoris was 
carried out using an Applikon 7L bioreactor and ADI 1025 bioreactor system. 
Dissolved oxygen (dO2) was maintained above 25% using a combination of 
agitation (minimum 1000 rpm) and compressed air (0.8 litre min-1). Oxygen (1 
bar pressure) was automatically drawn in as required to maintain the dO2 
setpoint during growth at high cell densities. The culture was maintained at pH 
5.0 through addition of 23% NH4OH. 10% Antifoam A (Sigma-Aldrich) was added 
drop-wise when necessary to reduce foaming during culture growth. 
4 litres of basal salts media (Table 2.1) was autoclaved within the bioreactor, 
and then 15 ml of PTM1 trace salts (Table 2.1) was added. The medium was 
inoculated with ca. 200 ml of yeast that had been grown up overnight in YPD so 
that the initial fermenter culture had an OD600 of 0.5-1.0. The yeast cells were 
grown in basal salts media for 18 h at 30°C. Following this, the culture was fed 
50% glycerol (v/v) for 11 h at a rate of 1.09 ml/min. The yeasts were then 
starved for 1 h to ensure that all of the glycerol had been consumed before the 
culture was adapted for growth on methanol (4 h at 0.07 ml/min followed by 12 
h at 0.09 ml/min). At this stage, the temperature of the culture was reduced to 
22°C for recombinant protein production. Methanol feeding was continued for 12 
h at 0.13 ml/min followed by 0.33 ml/min for another 36 h. Samples were taken 
at regular intervals to assess culture growth by measuring the wet cell weight 
per ml of culture. Recombinant protein expression levels were determined by 
measuring whole-cell iLOV fluorescence. Fermentations were stopped after 96 h, 
and the cells harvested by centrifugation (4,000g, 20 min, 4°C). Cell pellets 
were stored at -20°C, and used as they were required. 
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Table 2.1 Recipes for fermentation media and trace feed solution 
4 litres of basal salts media was prepared and autoclaved immediately prior to beginning a 
fermentation. PTM1 trace salt solution was prepared in advance, stored in 50 ml aliquots at 4°C 
and used as it was required.  
 Components Amount per litre 
 
Basal salts medium 
 
Phosphoric Acid (85%) 
Calcium Sulphate 
Potassium Sulphate 
Magnesium Sulphate – 7H20 
Potassium Hydroxide 
Glycerol 
Water 
 
(26.7 ml) 
0.93 g 
18.2 g 
14.9 g 
4.13 g 
40.0 g 
to 1 litre 
Sterilised by autoclaving 
 
PTM1 trace salts Cupric Sulphate - 5H2O 
Sodium Iodide 
Magnesium Sulphate - H2O 
Sodium Molybdate - 2H2O 
Boric Acid 
Cobalt Chloride 
Zinc Chloride 
Ferrous Sulphate – 7H2O 
Biotin 
Sulphuric Acid 
Water 
6.0 g 
0.08 g 
3.0 g 
0.2 g 
0.02 g 
0.5 g 
20.0 g 
65.0 g 
0.2 g 
5.0 ml 
to 1 litre 
Sterilised by filtration 
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2.6 Recombinant protein production in E. coli 
2.6.1 Medium-scale (500 ml) expression cultures 
2.6.1.1 Adrenodoxin production  
BL21 cells containing the Adx-CLBH expression plasmid were grown up overnight 
from a glycerol stock (Section 2.3.6) in 5 ml of TB containing 100 µg/ml 
ampicillin at 37°C in a shaking incubator with shaking at 190 rpm. The next day, 
1 ml of the starter culture was used to inoculate 500 ml of TB supplemented 
with 100 µg/ml ampicillin in a 2000 ml non-baffled Erlenmeyer flask. The culture 
was replaced in the shaking incubator at 37°C at a setting of 190 rpm. Cell 
growth was monitored at regular intervals by measuring the OD600 of the culture. 
At an OD600 of 0.6, Adx-CLBH expression was induced by adding 1 mM IPTG. The 
culture was shaken for a further 16 h at a temperature of 22°C before the cells 
were harvested by centrifugation (4,000g, 20 min, 4°C). Pellets were stored at -
20°C, and used as required. 
2.6.1.2  Production of adrenodoxin reductase, aldosterone synthase and 
11β-Hydroxylase  
AdxRed-CLBH (Section 2.3.6), CYP11B1/B2-CLBH (Section 2.3.7) and CYP11B1/ 
B2-His6 (Section 2.3.8) constructs were made in E. coli in the same way as for 
Adx-CLBH with the following exceptions. The cultures all contained 20 µg/ml 
chloramphenicol (to select for pGro7) as well as 100 µg/ml ampicillin (to select 
for the pET expression vector). 11β-Hydroxylase and aldosterone synthase 
expression was induced by adding 0.5 mM IPTG as well as 4 mg/ml arabinose 
(which switched on production of the GroEL/ES chaperones from the pGro7 
plasmid). 1 mM δ-Aminolevulinic acid was also added to the media along with 
the chemical inducers to ensure that the bacteria had an abundance of haem to 
incorporate into the recombinant p450 enzymes. AdxRed expression was induced 
by adding 1 mM IPTG and 1 mg/ml arabinose. Aldosterone synthase/11β-
Hydroxylase production was performed at a temperature of 27°C whereas 
AdxRed was expressed at 20°C. All cultures were induced for 16 h overnight. 
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2.6.1.3 Expression of human rhinovirus 3C protease and biotin ligase 
The accessory proteins HRV 3C protease and biotin ligase were expressed in E. 
coli using the same protocol as that for Adx (Section 2.6.1.1) with the exception 
that LB was used for cell growth rather than TB. 
2.6.2 Large-scale (15 litre) expression cultures 
Large scale expression of adrenodoxin, adrenodoxin reductase, aldosterone 
synthase and 11β-Hydroxylase in E. coli was carried out using an Applikon 20l 
bioreactor and ADI 1025 bioreactor system. Dissolved oxygen (dO2) was 
maintained above 30% using a combination of agitation (minimum 1000 rpm) and 
compressed air (0.8 litre min-1). The culture was maintained at pH 7.0 through 
drop-wise addition of either 5 M NaOH or 100% HCl. Samples were withdrawn at 
regular intervals to monitor cell growth. Induction was carried out in the same 
way detailed for the shake-flask cultures (Sections 2.6.1.1 and 2.6.1.2). 
2.7 Isolating membranes 
Following expression of SI-CLBH in P. pastoris and CYP11B2-CLBH in E. coli, 
membranes containing the recombinant proteins were prepared as follows. Cell 
pellets were resuspended in Breaking Buffer (5 mM EDTA, 150 mM NaCl in 50 mM 
Tris HCl pH 7.4) and lysed by passing through a Constant Systems cell disrupter 
three times at a pressure of 20 kPsi for E. coli or 30 kPsi for P. pastoris. 
Following this, 10% glycerol (v/v) and protease inhibitors 
(phenylmethanesulphonylfluoride (PMSF) and benzamidine) were added to the  
cell lysate. A low speed spin (10,000g, 15 min, 4°C) was used to pellet cell 
debris and unbroken cells. The supernatant was retained and centrifuged at high 
speed (150,000g, 30 min, 4°C) to pellet the membranes. Membranes containing 
SI-CLBH were resuspended in 150 mM NaCl, 10% glycerol in 50 mM sodium 
phosphate pH 7.4 whereas those containing B2-CLBH were resuspended in 150 
mM NaCl, 20% glycerol in 50 mM potassium phosphate pH 7.4. The protein 
concentration of the membrane samples was determined by BCA assay (Pierce) 
using BSA as a standard (Section 2.8.5). Membranes were diluted with the 
appropriate buffer to a final concentration of 20 mg/ml, and then stored at        
-20°C in 50 ml aliquots. 
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2.8 Protein purification 
2.8.1 Purification of sterol isomerase 
P. pastoris cell pellets containing SI-CLBH were resuspended in SI Buffer A (150 
mM NaCl, 5 mM EDTA in 50 mM sodium phosphate pH 7.4). Cells were broken 
using a Constant Systems cell disrupter (Section 2.7). 1 mM PMSF, 1 mM 
benzamidine and 10% glycerol were added following cell lysis. Membranes were 
isolated (as described in Section 2.7), and resuspended in SI Buffer B (150 mM 
NaCl, 0.1 mM EDTA, 10% glycerol in 50 mM sodium phosphate pH 7.4) to a final 
concentration of 20 mg/ml. DM was added to the membranes from a 10% (w/v) 
stock solution to a final detergent concentration of 2.5%. The solubilisation 
mixture was stirred for 1 h. Unsolubilised material was removed by 
centrifugation (150,000g, 30 min, 4°C). The supernatant, containing solubilised 
SI-CLBH, was batch-loaded onto a 5 ml His-trap Ni2+ column (GE Healthcare) pre-
equilibrated in SI Buffer B containing 0.15% DM. Following binding, the column 
was washed with 50 ml of SI Buffer C (500 mM NaCl, 75 mM imidazole, 0.1 mM 
EDTA, 10% glycerol in 50 mM sodium phosphate pH 7.4, 0.15% DM). SI-CLBH was 
eluted using SI Buffer D (150 mM NaCl, 300 mM imidazole, 0.1 mM EDTA, 10% 
glycerol in 50 mM sodium phosphate pH 7.4, 0.15% DM). Fluorescent fractions 
were pooled and desalted into SI Buffer B containing 0.15% DM using a PD-10 
column (GE Healthcare) according to the manufacturer’s instructions. The 
sample was incubated overnight at 4°C with 20 µg/ml 3C protease and 1 mM 
DTT. The cleaved sample was applied to a fresh Ni2+ column equilibrated in SI 
Buffer B containing 0.15% DM. The flow-through containing SI was retained and 
concentrated to a final volume of 1 ml using a 50 kDa MWCO centricon 
(Sartorious). Concentrated SI was applied to a Superose 6 gel filtration column, 
pre-equilibrated in SI Buffer B containing 0.15% DM. An ÄKTA prime plus system 
(GE Healthcare) was used to run the Superose 6 gel filtration column at a flow-
rate of 0.3 ml/min, collecting 1 ml fractions. All purification steps were carried 
out at 4°C. The concentration of pure SI was determined using the extinction 
coefficient ε280 = 74160 M-1 cm-1. 
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2.8.2 Purification of adrenodoxin 
E. coli cell pellets containing Adx-CLBH were resuspended in Adx Buffer A 
(150mM NaCl, 0.1 mM EDTA in 50 mM Tris-HCl pH 7.4), and lysed using a 
Constant Systems cell disruptor (3x 20 kPsi). Following mechanical breakage, 1 
mM PMSF, 1 mM benzamidine and 1x complete protease inhibitor tablet (Roche 
Applied Science) was added to the cell lysate to prevent proteolysis of the 
recombinant protein. Cell debris was removed by centrifugation (10,000g, 15 
min, 4°C). The supernatant fraction containing Adx-CLBH was applied to a 5 ml 
HisTrap Ni2+ column (GE Healthcare) equilibrated with Adx Buffer B (50 mM 
imidazole, 300 mM NaCl, 0.1 mM EDTA in 50 mM Tris-HCl pH 7.4). Following 
binding, the column was washed with ten column volumes of Adx Buffer B. Adx-
CLBH was eluted using Adx Buffer C (300 mM imidazole, 0.1 mM EDTA in 50 mM 
Tris-HCl pH 7.4), and then desalted into Adx cleavage buffer (1 mM DTT, 0.1 mM 
EDTA, 150 mM NaCl in 50 mM Tris-HCl pH 7.4). 20 µg of pure 3C protease per ml 
of sample was incubated with enriched Adx-CLBH overnight to ensure complete 
tag removal. Next morning, the cleavage mixture was passed over a fresh Ni2+ 
column equilibrated in Adx Buffer A. Brown-coloured fractions containing Adx 
were collected, pooled and concentrated using a 10 kDa MWCO centricon 
(Sartorious) to a volume of ca. 500 µl. Concentrated Adx was applied to a 
Superose 6 gel filtration column for a final, polishing purification step. The 
column was run at a flow-rate of 0.3 ml/min and 1 ml fractions were collected. 
Fractions containing pure Adx were identified using a Shimadzu UV-1700 
Pharmaspec spectrophotometer, and pooled together. The concentration of the 
purified sample was determined using an extinction coefficient calculated from 
the primary sequence of the recombinant protein; Adx ε280 = 3230 M
-1cm-1. All 
purification steps were carried out at 4°C. 
Thermostability assays were performed on pure Adx (Section 4.6.2). Once 
optimal conditions had been identified, the purification buffers were modified 
to contain sodium phosphate instead of Tris-HCl. Furthermore, to optimise 
stability, NaCl was removed from the final gel filtration buffer. 
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2.8.3 Purification of adrenodoxin reductase 
AdxRed was initially purified in the same way as that for Adx (Section 2.8.2). 
Following CPM thermostability analysis (Section 4.6.3) Tris-HCl was replaced in 
all buffers with HEPES. Moreover, a 50 kDa MWCO centricon (Satorious) was used 
to concentrate the reverse-purified AdxRed before application to the Superose 6 
gel filtration column. The concentration of AdxRed was determined using a 
calculated extinction coefficient of ε280= 4296 M
-1cm-1. 
2.8.4 Attempted nickel-affinity purification of CYP11B2-CLBH 
E. coli cell pellets containing CYP11B2-CLBH were resuspended in B2 Buffer A 
(150 mM NaCl, 5 mM EDTA in 50 mM potassium phosphate pH 7.4). Membranes 
were isolated (Section 2.7) and resuspended in B2 Buffer B (150 mM NaCl, 20% 
glycerol, 0.1 mM EDTA in 50 mM potassium phosphate pH 7.4) to a final 
concentration of 20 mg/ml. Sodium cholate was added to the membranes to a 
final concentration of 2.5%, and the solution stirred with 1 mM PMSF for 1 h at 
4°C. Insoluble material was removed by centrifugation (150,000g, 30 min, 4°C), 
and the supernatant retained for further purification. Solubilised CYP11B2-CLBH 
was passed over a 5 ml HisTrap nickel column (GE Healthcare) three times that 
had been equilibrated in B2 Buffer B containing 0.6% sodium cholate. The 
column was washed with B2 buffer C (300 mM NaCl, 20% glycerol (v/v), 0.1 mM 
EDTA, 0.6% sodium cholate in 50 mM potassium phosphate pH 7.4) containing 
increasing concentrations (25, 50, 75 and 300 mM) imidazole. The aldosterone 
synthase content of the wash fractions was determined by ELISA according to 
Section 2.11.2. 
Purification of CYP11B2-CLBH in DM was attempted also with the 0.6% sodium 
cholate in B2 Buffers C and D replaced with 0.15% DM. The 300 mM imidazole 
elution fraction was desalted into B2 buffer B containing 0.15% DM, and 
incubated overnight with 20 µg HRV 3C protease per ml of protein. The iLOV 
fluorescence of Ni2+-enriched CYP11B2-CLBH before and after cleavage was 
measured using a FLUOstar Optima plate reader (Section 2.10.2). 
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2.8.5 Purification of aldosterone synthase and 11β-Hydroxylase 
E. coli cell pellets containing CYP11B2-His6 were resuspended in p450 Buffer A 
(500 mM sodium chloride, 20% (v/v) glycerol, 0.25 mM EDTA in 50 mM potassium 
phosphate pH 7.4). Cells were homogenised, incubated with lysozyme for 30 min 
on ice before 1.5% sodium cholate and 1% Tween-20 were added. The cells were 
ruptured by sonication using a SONIPREP 150 (Sanyo) with three pulses of 15 s 
duration followed by three that were 8 s in length, all at a power setting of 10 
µA. There was an interval of 1 min between pulses. The cell slurry was then 
centrifuged (90,000g, 15 min, 4°C). The supernatant was retained and mixed 
with Ni2+-sepharose beads (GE Healthcare) that had been equilibrated in p450 
Buffer A for 1 h at 4°C. After loading, the beads were poured into a gravity-feed, 
disposable column (Clontech) and washed with 10 column volumes of p450 
Buffer B (20 mM imidazole, 500 mM NaCl, 20% glycerol, 0.25 mM EDTA, 0.1 mM 
PMSF and 0.1 mM ATP in 50 mM potassium phosphate pH 7.4, 1% sodium cholate, 
1% Tween-20). B2-His6 was eluted from the beads using p450 Buffer C (200 mM 
imidazole, 20% glycerol, 0.25 mM EDTA and 0.1 mM PMSF in 50 mM potassium 
phosphate pH 7.4, 1% sodium cholate, 1% Tween-20). Red fractions containing 
aldosterone synthase were collected, pooled, diluted 5-fold with p450 Buffer D 
(20%  glycerol, 0.25 mM EDTA and 1% sodium cholate), and then applied to a SP 
sepharose ion-exchange column (GE Healthcare) using a peristaltic pump. 
Aldosterone synthase was eluted using an ÄKTA prime plus purification system 
with a 0-400 mM gradient of sodium acetate in p450 buffer E (50 mM potassium 
phosphate pH 7.4, 20% glycerol, 1% sodium cholate). Fractions containing 
aldosterone synthase were pooled and concentrated to a final volume of 500 µl 
using a 30 kDa MWCO concentrator (Sartorious). The protein sample was then 
applied to a Superose 6 gel filtration column pre-equilibrated in p450 buffer F 
(10 mM sodium chloride, 20% glycerol in 50 mM potassium phosphate pH 7.4, 1% 
sodium cholate). Those fractions containing pure aldosterone synthase were 
pooled. All purification steps were carried out at 4°C. 11β-Hydroxylase was 
purified in exactly the same way as described for aldosterone synthase. 
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2.8.6 Purification of accessory enzymes 
2.8.6.1 Human rhinovirus 3C protease  
pET15b-HRV3C was a gift from Dr. Alan Riboldi-Tunnicliffe (University of 
Glasgow). 3C protease expression was carried out according to Section 2.6.1.3. 
HRV 3C protease was purified in the same way as that for Adx (Section 2.8.1) 
until the 3C protease had been loaded onto a 5 ml HisTrap Ni2+ column (GE 
Healthcare). Following binding, the Ni2+ column was attached to a BioCad 700E 
where it was washed with 10 column volumes of 25 mM imidazole, 300 mM NaCl 
in 50 mM Tris-HCl pH 8.0. 3C protease was eluted using a 0-500 mM imidazole 
gradient in 150 mM NaCl, 50 mM Tris-HCl pH 8.0. 1 mM DTT and 1 mM EDTA were 
added to all of the elution fractions. Highly-enriched 3C protease was 
concentrated using a 10 kDa MWCO centricon (Sartorious), and applied to a 
Superose 6 gel filtration column equilibrated in 150 mM NaCl, 50 mM Tris-HCl pH 
8.0. Fractions containing pure HRV 3C protease were collected, snap-frozen with 
liquid nitrogen and stored at -20°C. 
3C protease activity was assessed by FSEC using SI-CLBH as substrate (Section 
2.10.1). 
2.8.6.2  Biotin ligase  
Biotin ligase was expressed as described in Section 2.6.1.3 and purified by Ni2+-
affinity chromatography in the same way as for 3C protease (Section 2.8.4.1). 
However, no DTT or EDTA was added to the elution fractions. After the Ni2+-
affinity step, the biotin ligase was pure so no further chromatographic steps 
were required. Pure biotin ligase was snap-frozen in liquid nitrogen and stored 
at -20°C. 
Recombinant biotin ligase was used to biotinylate SI-CLBH in vitro. 1 mg of pure 
biotin ligase was stirred with SI-CLBH, 50 µM biotin, 20 µM ATP and 10 mM Mg-o-
acetate overnight at 4°C. The next morning, the SI-CLBH was doubly desalted 
into 150 mM NaCl, 50 mM sodium phosphate pH 7.4, 0.15% DM using a PD10 
column. Biotinylated protein was added to streptavidin beads, and mixed by 
rotating on a wheel for 4 h at 4°C. The beads were loaded into a disposable 
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gravity feed column, and washed extensively with 50 mM sodium phosphate pH 
7.4, 0.15% DM. Immobilised SI-CLBH was visualised by placing the column on a 
UV-light source and observing iLOV fluorescence.   
2.8.7  Methods for protein concentration determination 
The protein concentration of membrane aliquots was determined by 
Bicinchoninic Acid (BCA) assay (Pierce) according to the manufacturer’s 
instructions. Bovine serum albumin (BSA) was used as a standard. The 
concentrations of purified proteins were determined according to the Beer-
Lambert law (A = εcl) using a calculated extinction coefficient at 280 nm for 
each protein according to their primary amino acid sequence. 
2.9 SDS-PAGE 
10-15 µg in a volume of 20 µl of each protein sample to be analysed by SDS-PAGE 
was mixed with 5 µl of NuPage LDS sample buffer (Invitrogen), and then heated 
at 70°C for 10 min prior to loading onto either a 10 or 12% Bis-Tris pre-cast gel 
(Invitrogen). 10 µl of SeeBlue2 pre-stained marker (Invitrogen) was loaded into 
one of the wells on each gel to allow estimation of the MW of the proteins being 
analysed. Gels were run in 1x MES buffer (Invitrogen) at 200 V for 45 min. 
Protein bands were visualised by staining with SimplyBlue SafeStain (Invitrogen) 
according to the manufacturer’s instructions. 
2.10 Measuring iLOV fluorescence 
2.10.1 iLOV excitation and emission spectra 
Excitation and emission spectra for pure iLOV (a gift from Dr. John Christie, 
University of Glasgow) were recorded and compared against those for flavin 
mononucleotide (FMN). Measurements were made in a quartz cuvette with a 1 
cm pathlength using a Perkin-Elmer L550B spectrophotometer. Fluorescence was 
measured at right angles to the excitation beam. Excitation spectra were 
recorded between 300 and 460 nm measuring fluorescence emission at 485 nm. 
Emission spectra were recorded from 470 to 600 nm, exciting the samples at 450 
nm. 
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2.10.2 Measuring iLOV fluorescence in 96 well plates 
The iLOV fluorescence of individual samples (e.g. whole cells or FSEC elution 
fractions) was determined using a FLUOstar OPTIMA plate-reader. 200 µl of each 
sample was added to a single well in a black 96-well plate (Corning). Samples 
were excited at 450 nm and iLOV fluorescence emission measured at 520 nm. 
2.11 Analytical size exclusion chromatography 
2.11.1 Fluorescence size exclusion chromatography 
2 ml of yeast membranes (at a concentration of 20 mg/ml) containing SI-CLBH 
were solubilised with n-dodecyl-β-D-maltoside (DDM). 0.6 ml of a 10% detergent 
stock solution was added to the membranes and stirred for 1 h at 4°C. The 
sample was then centrifuged at high-speed (50,000g, 10 min, 4°C) to pellet any 
unsolubilised material. The supernatant containing SI-CLBH was filtered before a 
500 µl aliquot was injected onto a Superose 6 gel-filtration column equilibrated 
in 50 mM sodium phosphate pH 7.4, 5% glycerol, 0.01% DM. The column was run 
at a rate of 0.3 ml/min, and 0.6 ml fractions were collected. iLOV fluorescence 
was measured in all of the elution fractions as detailed in Section 2.10.2. Using 
this data, a FSEC profile was generated. 
HRV 3C activity was investigated by comparing the FSEC profile of SI-CLBH 
before and after treatment with the protease. Furthermore, the effects of DTT, 
EDTA, PMSF, benzamidine and the Roche protease inhibitor cocktail on HRV 3C 
activity were assessed by comparing FSEC profiles of SI-CLBH that had been 
treated with 3C protease in the presence of one these reagents with a fully-
cleaved sample.  
2.11.2 ELISA size exclusion chromatography 
E. coli membranes (at a concentration of 20 mg/ml) containing B2-CLBH were 
solubilised using the detergents Fos Choline-9, sodium cholate, CHAPS, decyl-βD-
maltoside, octyl-βD-thioglucoside (OTG) and CYMAL-5. 0.3 ml of each detergent 
from 10% stock solutions was stirred with 1 ml of membranes in the presence of 
1 mM benzamidine, 1 mM PMSF and Roche protease inhibitor cocktail for 1 h at 
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4°C. The samples were prepared for injection onto the Superose 6 column in the 
same way as detailed for FSEC (Section 2.11.1). The column was equilibrated in 
150 mM NaCl, 0.1 mM EDTA, 50 mM potassium phosphate pH 7.4 containing a 
CMC concentration of detergent (1.2% Fos Choline-9, 0.6% sodium cholate, 0.5%  
CHAPS, 0.15% DM, 0.3% OTG, 0.12% CYMAL-5) prior to injecting the solubilised 
sample. The column was run at 0.3 ml/min and 0.6 ml fractions were collected. 
For each detergent, 50 µl aliquots of fractions 15-35 were applied in triplicate to 
a 96-well ELISA plate (Corning). 50 µl of a coating buffer (0.1 M sodium 
bicarbonate pH 8.4) was also added to each well to promote protein binding to 
the side of the wells. The plate was incubated at 4°C overnight with gentle 
shaking. The next day, the wells were washed three times with TBST (150 mM 
NaCl, 50 mM Tris-HCl pH 7.6, 0.1% Tween 20) before blocking them with TBST-
BSA (TBST with 5% BSA) for 30 min at room temperature. Following this, the 
wells were washed three times with TBST. Primary antibody (anti-aldosterone 
synthase Ab that had been diluted 1:2000 with TBST) was added to each well, 
and the plate incubated on ice for 30 min. [Anti-human aldosterone synthase Ab 
was a gift from Professor Kunai Muniaki, Keio University, Japan]. Following this, 
the plate was incubated at room temperature for 1 h with gentle shaking. Wells 
were washed three times with TBST before they were incubated with secondary 
antibody (goat anti-rabbit (DAKO), 1:1000 dilution) for 1 h at room temperature 
with gentle shaking. Before developing, wells were washed five times with TBST. 
100 µl of developing solution (Sigma-Aldrich) was added to each well to generate 
an ELISA signal. Plates were incubated for 30-60 min in the dark. The A450 
intensity in each well was measured using a Fluostar Optima plate reader. 
2.12 Thermostability analysis 
 
2.12.1 Thermal denaturation of adrenodoxin 
Thermal denaturation of Adx was performed in clear 96-well plates (Corning). In 
each well, Adx had a final concentration of 13 mg/ml in a total volume of 200 
µl. Along with the protein, each well contained 20 µl of a 10x buffer solution 
and 20 µl of a 10x additive (e.g. salt) solution. The final volume was made up to 
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200 µl with dH20. Once a plate had been made up, it was incubated in a 
spectrophotometric plate-reader (Molecular Devices Spectra Max Plus 384) at 
45°C for 4 h. The A414 of the sample was measured at 60 s intervals. 
Measurements were made in triplicate for each condition. 
2.12.2 Analysis of adrenodoxin reductase stability by CPM assay 
A stock solution of CPM reagent (7-Diethylamino-3-(4-maleimidophenyl)-4-
methylcoumarin) (Sigma-Aldrich) was made by first dissolving it in dimethyl 
sulfoxide (DMSO) to a concentration of 25 mg/ml, and then diluting it with H20 
to a final concentration of 4 mg/ml. CPM dye was stored in the dark to prevent 
photobleaching. 
CPM thermal denaturation assays were performed in black 96-well plates 
(Corning). For each condition investigated, protein and buffer control 
measurements were made in triplicate. Each protein well contained 10 µl (5 µg) 
of pure AdxRed, 20 µl of a 10x buffer solution as well as 20 µl of either a 10x 
additive (such as a salt) or dH2O. The buffer controls contained 10 µl of dH2O 
instead of protein. All wells were made up to a final volume of 200 µl with dH20. 
Plates were incubated at room temperature for 5 min before 10 µl of CPM 
reagent was added. The plate was then transferred to a fluorescence plate-
reader at a temperature of 45°C. Fluorescence intensity readings were taken at 
regular intervals over a 3 h period. Baseline fluorescence recorded in the buffer 
controls were subtracted from the values recorded in the protein wells, before 
the three difference values for each condition were averaged. Curves showing 
AdxRed denaturation were plotted as an increase in fluorescence over time. 
2.13 Circular dichroism 
All CD measurements were made by Dr. Sharon Kelly at the Biophysical 
Characterisation Unit, University of Glasgow. Far- (190-260 nm) and near-
UV/visible (250-550 nm) circular dichroism spectra of pure Adx, AdxRed, 
aldosterone synthase and 11β-Hydroxylase were recorded on a Jasco J-810 
spectropolarimeter using quartz cuvettes with 0.02 and 0.5 cm pathlengths, 
respectively. 
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2.14 Crystallisation trials of adrenodoxin and 
adrenodoxin reductase 
The commercial sparse-matrix crystallisation screens JCSG, Morpheus (Molecular 
Dimensions), Peg/Ion 1&2 and Hampton 1&2 (Hampton Research) were used to 
identify putative crystallisation conditions for Adx and AdxRed. Both proteins 
were concentrated to ca. 20 mg/ml. A Cartesian HoneyBee nanolitre dispensing 
system (Genomic Solutions Ltd.) was used to form 1 µl crystallisation drops by 
mixing 500 nl of the concentrated Adx/AdxRed solutions with 500 nl of the 
reservoir solution in each of the wells. The plates were stored in a Rhombix 
Crystal Plate Imager (ThermoScientific) at 20°C. Trays were monitored over a 3 
month period. Photos of each crystallisation condition were taken at regular 
intervals. Possible crystal hits were viewed manually under a microscope, and 
then tested for diffraction using the in-house X-ray facility (consisting of a 
Rigaku MicroMax 007 rotating anode generator coupled with MarResearch 345 
image plate detector). 
2.15 Reduced carbonmonoxide difference spectrum 
The reduced carbonmonoxide difference spectra of purified aldosterone 
synthase and 11β-Hydroxylase were obtained using the original method 
described by Omura and Sato (Omura and Sato, 1964). All measurements were 
taken using a Shimadzu UV-1700 Pharmaspec spectrophotometer. 1ml of pure 
protein was divided between two 500 µl quartz cuvettes. Carbon monoxide was 
bubbled into the sample cuvette at a rate of approximately 1 bubble per second 
for 1 min. 1 mg of sodium dithionite was added immediately to both sample and 
reference cuvettes. The cuvettes were inverted repeatedly until the sodium 
dithionite had dissolved. The spectrum was then recorded from 400 to 600 nm 
every 30 s until the peak at 450 nm had reached its maximum intensity.  
Aldosterone synthase and 11β-Hydroxylase concentrations were calculated by 
the Beer-Lambert Law measuring absorption at 450 nm and using the known 
p450 extinction coefficient ε450 = 91 mM
-1cm-1.  
 Chapter 3 – A tailored system for the recombinant 
expression, purification and immobilisation of 
human membrane proteins 
 
3.1 Introduction  
The main goal of my Ph.D. was to develop expression and purification systems 
for the p450 enzymes aldosterone synthase and 11β-Hydroxylase, as well as their 
electron transfer proteins adrenodoxin and adrenodoxin reductase. Aldosterone 
synthase and 11β-Hydroxylase are both human membrane proteins (Section 
1.8.5), suggesting that their expression in a heterologous host and functional 
purification might be difficult. To address this issue, my first task was to create 
an in-house expression system specifically tailored for use with human 
membrane proteins. 
The Fraser group routinely overexpress human membrane proteins in the yeast 
P. pastoris using the commercially-available pPICZ(α)vector series (Invitrogen) 
(Fraser, 2006). To facilitate processes such as expression screening, FSEC, 
affinity purification and protein immobilisation, the Fraser group have created 
an in-house version of the pPICZA expression vector (termed CLBH) for use with 
human membrane proteins. The in-house vector has a 3C protease cleavage site 
– iLOV – biotin acceptor domain – His10 (CLBH) tag immediately downstream of 
the NotI cloning site (Figure 3.1). When the CLBH tag was conceived, it was 
envisaged that (i) the 3C protease site could be used for efficient tag removal, 
(ii) the fluorescent reporter iLOV could be used for tracking the production and 
purification of recombinant proteins as well as FSEC, (iii) the biotin acceptor 
domain could be used for immobilising target proteins on surfaces coated with 
streptavidin, and (iv) the His10 tag could be used for high-affinity Ni
2+ 
purification. At the start of this project, the P. pastoris CLBH vector had been 
made but not yet used with any human membrane protein. Therefore, a full 
characterisation of this novel expression system was performed using the 
cholesterol biosynthetic enzyme sterol isomerase (SI) as a test protein. SI was 
The CLBH tag 
chosen for optimisation studies as it has excellent stability for a human integral 
membrane protein, and 
personal communication). This Chapter describes the properties and applications 
of the CLBH tag. 
 
Figure 3.1  Schematic diagram of the SI
The P. pastoris expression vec
a novel (CLBH) tag between the 
Rhinovirus 3C protease site followed by the i
reporter, a biotin acceptor domain and a His
cloned between the Eco
Gillian Young. 
 
3.2 iLOV: a novel fluorescent reporter with membrane 
protein applications
In recent years, it has become common practice to fuse green fluorescent 
protein (GFP) to the C
tracking of the recombinant protein through the expression and purification 
processes (Drew et al.
fluorescence reporter with membrane proteins in both 
and S. cerevisiae (Newstead
cultures of P. pastoris
chromophore formation. In contrast, 
oxygen availability 
GFP. For this reason, iLOV had been incorporated into 
CLBH tag. 
 
is expressed at high levels in P. pastoris
-CLBH expression construct
tor pPICZA (Invitrogen) was modified by the Fraser group to include 
NotI and XbaI cloning sites. The CLBH tag consists of a Human 
mproved Light Oxygen Voltage (i
10 tag. A cDNA encoding human sterol isomerase was 
RI and NotI restriction sites. The SI-CLBH vector was 
 
-terminus of target membrane proteins, facilitating 
, 2008). While GFP has been successfully used as a 
E. coli
 et al., 2007), it is not ideal for use with shake
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pPICZA as part of the 
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Here, the absorption and fluorescence properties of iLOV were characterised, 
and its use as a reporter of membrane protein expression a
demonstrated. 
3.2.1 The spectral properties of iLOV and 
LOV domains fluoresce green upon excitation with UV
al., 1999; Christie, 2007
mononucleotide (FMN) c
central cavity through a combination of hydrogen bonds and van der Waals 
interactions. FMN and iLOV both have strong absorptions in t
nm (Figure 3.2). To identify the optimal wavele
iLOV over FMN, fluores
chromophores (Figure 3.3A
for both iLOV and FMN
350, 370 and 450 nm whereas the FMN 
only (Figure 3.3A). Thus, it is possible to excite iLOV 
using light with a wavelength of 450 nm. The iLOV emission spectrum has a 
Figure 3.2  The absorption spectra of iLOV and flavin
iLOV has two prominent absorptions in the visible region (a peak at 355 nm with a shoulder at 375 
nm, and a second peak at 450 nm with shoulders at 425 and 4
spectrum consists of two broad absorptions (one in the region 320
For experimental detail, see Section 2.10.1.
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Figure 3.3  The fluorescence prope
(A) Excitation spectra were recorded 
at 485 nm. (B) Following 
region 470-600 nm. These 
450 nm, whereas emission can be 
experimental detail, see Section 2.10.1.
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chromophore excitation at 450 nm, emission spectra were recorded 
experiments showed that the optimal wavelength for exciting iLOV is 
effectively measured in the range 485
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distinctive peak at 485 nm with a pronounced shoulder at 525 nm. In contrast, 
the emission profile for FMN consists of a single broad peak between 510 and 540 
nm (Figure 3.3B). The best wavelength for selectively measuring emission from 
iLOV but not FMN is 485 nm. However, the shape of its emission spectrum means 
that iLOV fluorescence can be measured effectively in the range 485 to 530 nm. 
3.2.2 Using iLOV to monitor recombinant protein production  
In heterologous expression hosts, the production levels of human membrane 
proteins are often low. To ensure that maximal amounts of proteins of interest 
are obtained, expression optimisation experiments must be performed. If the 
production level of a target membrane protein has to be determined by either 
radioligand binding or Western Blotting, the optimisation process can be 
unnecessarily time-consuming. However, by fusing the protein of interest to a 
fluorescent reporter, this potential bottleneck can be overcome. To explore the 
utility of iLOV as a reporter of membrane protein expression, a time course of 
SI-CLBH production in a fermenter culture of P. pastoris was performed (Figure 
3.4). 
The yeast culture was grown on glycerol for 30 h to increase cell biomass before 
the carbon source was changed to methanol, inducing production of SI-CLBH. 
Samples were taken at regular intervals throughout the fermentation. At each 
time-point, the level of iLOV fluorescence in intact cells was measured and the 
wet cell weight per litre of culture determined. From these two values, it was 
possible to calculate expression levels for SI-CLBH. Using iLOV fluorescence as a 
measure of the amount of recombinant protein present within the yeast cells, it 
was possible to determine the expression level of SI-CLBH at each time-point 
within 30 minutes of taking the sample. This speed of analysis is highly 
beneficial allowing time courses of recombinant membrane protein production 
to be followed in real-time. When maximal levels of the target protein have 
been reached, the fermentation can be stopped and the cells harvested. 
Furthermore, if expression of a target protein is not successful or 
unsatisfactorily low, this can be quickly detected and the fermentation aborted. 
Here, maximal levels of SI-CLBH were obtained by feeding the yeast methanol 
for ca. 50 h (Figure 3.4).  
The CLBH tag 
  
Figure 3.4  Time-course of Sterol Isomerase
Yeast were grown on glycerol for 30
changed to methanol inducing production of SI
regular intervals throughout the fermentat
the weight of the pellet recorded
line). The cells were then wa
resuspended in water and whole cell iLOV fluorescence measured
production level of SI-CLBH was expressed as iLOV fluorescence per amount of w
cells (green line). 
3.2.3 Assessing membrane protein aggregation status using iLOV
Aggregation is a common problem encountered when working with membrane 
proteins, and is usually caused by protein instability in the detergent used for 
solubilisation and purification purposes
fluorescence size-exclusion chromatography (FSEC) has been developed which 
allows the aggregation status of a fluorescently
monitored throughout the purification process following membrane 
solubilisation, even in the presence of other proteins 
2006). Usually, the membrane protein of interest is tagged with GFP. Here, the 
utility of iLOV as a fluorescence reporter for FSEC purposes was assessed.
Membranes containing SI
maltoside (DM). Following centrifugation, the supernatant was applied to a 
Superose 6 gel filtration column. iLOV fluorescence was measured in all of the 
elution fractions. The elution profile consisted of a single symmetric fluorescent 
peak showing that SI is monodisperse in DM (Figure 3.5). 
 
-CLBH expression in fermenter culture
 h to increase cell biomass, before the carbon source was 
-CLBH (Section 2.5.2). Samples were taken at 
ion. At each time point, 1 ml cells was spun down, and 
. From this, the wet cell weight of the culture was calculated 
shed twice in water (to remove free flavin present in the media), 
 (Section 2.10.2)
. Recently, an approach called 
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(Kawate and Gouaux, 
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Figure 3.5  FSEC analysis of SI
Membranes containing SI
was centrifuged and the supernatant
iLOV fluorescence was measured in each of the 
generated.  
This simple experiment
that the iLOV fluorescent reporter is compatible with FSEC.
3.3 Removal of the CLBH tag using 3C protease
Site-specific proteases are commonly used to remove tags from recombinant 
proteins following their purification 
enzymes include thrombin, Factor X and Tobacco Etch Virus (TEV) protease.
In the CLBH vector, a cleavage site (LEVLFQ
protease is positioned between the recombinant protein and the iLOV domain
(Figure 3.1). HRV 3C 
has high catalytic power even at low temperatures (4
for use with membrane proteins with poor stability 
purification protocol for 3C protease was developed, and its 
catalytic activity assessed by FSEC.
His-tagged HRV 3C was expressed in 
affinity and size-exclusion chromatography
 
-CLBH solubilised in DM 
-CLBH were solubilised in 2.5% decyl-βD-maltoside (DM). 
 applied to a Superose 6 gel filtration column
elution fractions (Section 2.10.2)
 shows that SI is stable in DM. More importantly, it shows 
(Arnau et al., 2006). Frequent
|GP) for human rhinovirus (HRV) 3C 
had been chosen for use with the in-house vector because it 
°C), making it compatible 
(Waugh, 2011
  
E. coli and purified by a combination of Ni
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were obtained (Figure 3.6
analysed by SDS-PAGE (Figure 3.7
observed, showing that the 3C protease was indeed pure.
Having successfully 
the activity of the recombinant protein. SI
maltoside (DDM) was incubated with 3C protease overnight at 4
containing 1 mM EDTA and 1 mM DTT. The sample was then applied to a 
Superose 6 gel filtration co
measured (Figure 3.8). An elution profile for untreated SI
generated (Figure 3.8). SI
treatment with 3C protease, however, a single fluorescent 
volume of 20 ml was observed. This mobility shift on the gel
was due to cleavage of the CLBH tag by HRV 3C, demonstrating that the 
recombinant protease was catalytically active.
  
Figure 3.6  Purification of human rhinovirus
A highly-enriched sample of 3C
and applied to a Superose 6 gel filtration column equilibrated in 1 mM DTT, 1 mM EDTA, 150 mM 
NaCl in 50 mM Tris HCl pH 7.4. The 
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purified 3C protease, a simple assay was devised 
-CLBH solubilised with dodecyl
lumn and the fluorescence of the elution fractions 
-CLBH was also 
-CLBH had an elution volume of 15 ml. Following 
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major elution peak (at ca. 60 ml) was 3C protease.
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Figure 3.7  SDS-PAGE analysis of pure human rhinovirus
The peak fractions eluted from the gel filtration col
(Section 2.9). A single, strong band with a MW of 
(predicted MW 22 kDa) was observed across the elution peak.
Figure 3.8  Assessing the catal
The catalytic activity of recombinant HRV 3C was assessed by FSEC analysis using SI
substrate for the protease. 
split into two samples, one of which was incubated with 
50 mM sodium phosphate, 1mM EDTA, 1 mM DTT, 
day, both samples were
elution fractions measured
the sample treated with 3C protease (blue) eluted at 20 ml.
 
 3C protease
umn (Figure 3.6) were analysed by
ca. 25 kDa corresponding to pure 3C protease 
 
ytic activity of recombinant human rhinovirus
SI-CLBH was solubilised 2.5% n-dodecyl-β−D
20 µg/ml 3C pro
5% glycerol and 0.01% DDM, pH 7.4.
 applied to a Superose 6 gel filtration column and the fluorescence of the 
 (Section 2.11.1). The untreated sample (red) eluted at 15 ml whereas 
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To optimise the conditions for cleavage by HRV 3C, SI-CLBH solubilised in DDM 
was incubated with the protease in different buffer conditions. Following 
treatment with 3C protease, the cleavage mixtures were analysed by FSEC 
(Figure 3.9). SI-CLBH was only fully-cleaved in the presence of 1 mM DTT. In 
contrast, EDTA was not required for 3C protease activity (Figure 3.9). 
When purifying a recombinant protein, inhibitors must be included in all of the 
buffers to prevent the target protein from being degraded by proteases 
endogenous to the heterologous host. There is an obvious risk that these will 
inhibit HRV 3C also, preventing cleavage of the CLBH tag. Therefore, the effects 
of three of the most commonly used protease inhibitors, namely 
phenylmethanesulfonylfluoride (PMSF), benzamidine and the Roche complete 
protease inhibitor cocktail were tested. 
SI-CLBH solubilised in DDM was incubated with 3C protease either alone or with 
one of the inhibitors. The cleavage mixtures were then analysed by FSEC (Figure 
3.10). The presence of PMSF did not inhibit tag removal. However, incomplete 
cleavage of SI-CLBH by 3C protease was observed in the presence of both the 
Roche inhibitor cocktail and benzamidine. It was therefore concluded that PMSF 
but not Roche Complete or benzamidine could be used in conjunction with 3C 
protease. 
3.4 Recombinant protein purification using the CLBH tag 
The CLBH vector was designed in a way that would enable purification of 
recombinant proteins in four simple steps comprising: (i) Ni2+-affinity 
purification, (ii) cleavage of the CLBH tag using 3C protease, (iii) reverse Ni2+-
affinity purification, and (iv) size exclusion chromatography (SEC) (Figure 3.11). 
When required, a second affinity purification step could be performed by 
biotinylating the CLBH tag in vitro with biotin ligase and then applying the 
protein mixture to (strept)avidin resin (Section 3.5). 
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Figure 3.9  Buffer requirements for HRV 3C protease activity
SI-CLBH solubilised in DDM was incubated with 
Following this, the cleavage mixtures were 
both 1mM DTT and 1mM 
CLBH tag was fully cleaved when the proteolysis cocktail contain
without (green) EDTA). I
Figure 3.10  The effect of protease inhibitors on 
SI-CLBH solubilised in 
alone (green) or in the presence of a commonly used protease inhibitor (
benzamidine (red) or 1X Roche c
mixtures were analysed by FSEC
However, incomplete cleavage of the CLBH tag by HRV 3C was 
Roche complete PI tablet
 
 
3C protease in a range of buffer conditions. 
analysed by FSEC (Section 2.11.1)
EDTA (yellow), incomplete tag cleavage was observed.
ed 1 mM DTT (with (blue
n the presence of 1mM EDTA alone (purple), tag removal was incomplete
HRV 3C protease activity
2.5% DDM was incubated with 20 µg/ml 3C protease 
omplete protease inhibitor (PI) tablet (yellow)). 
 (Section 2.11.1). 3C protease activity was not inhibited 
observed
 and benzamidine. 
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Figure 3.11  Cartoon representation of the strategy used to purify CLBH
The cell lysate is (1) purified by Ni
nickel resin. (2) Fractions from the Ni
desalted and then cleaved overnight with 3C protease. (3) The next day, the cleavage mixture is 
passed over a fresh Ni2+
contaminants from the sample. (4) Finally, 
to a gel filtration column, from which fractions containing pure target protein are collected
 
 
2+
-affinity chromatography through binding of the His
2+
 column containing the CLBH-tagged protein are pooled, 
 column. This removes cleaved CLBH, His-tagged HRV 3C and His
the reverse-purified protein is concentrated and applied 
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To test the usefulness of the CLBH tag for obtaining milligram amounts of pure 
protein, SI was purified
FSEC analysis had shown that SI i
that SI could be stably purified to homogeneity in this detergent. Membranes 
containing SI-CLBH (resuspended in 
with DM. Following centrifugation, the supernatant fraction (containing SI
was applied to a Ni
tracking the CLBH-tagged fusion protein throughout the purification
Binding of SI-CLBH to the Ni
column to UV-radiation and observin
efficiency of SI-CLBH binding to the column could also be readily calculated by 
measuring the fluorescence of the solubilised sample before and after it had 
been passed over the column. Typically, at least 80% of the SI
the Ni2+-column (results not shown).
 
Figure 3.12  Visualisation of SI
The iLOV fluorescence reporter provided a simple way of tracking SI
Ni2+-affinity purification step. Detergent
column (right). Successful binding of the recombinant protein to the column was readily visualised 
by observing fluorescence from iLOV following illumination with UV
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SI Buffer B (Section 2.8.1)
2+ column. The iLOV reporter provided a simple way of 
2+-column could be readily visualised by exposing the 
g iLOV fluorescence (Figure 3.12
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The column was washed with buffer containing 500 mM NaCl and 75 mM 
imidazole (Section 2.8.1) 
the column via ionic interactions and His
CLBH was then eluted using buffer containing 300 mM imidazole. Fluorescent 
fractions containing SI
incubated overnight with HRV 3C protease. The next day, cleaved SI was passed 
over a fresh Ni2+-column to remove cleaved CLBH, His
His-rich contaminants (that bound to the original Ni
affinity-purification step. The flow
collected, concentrated and applied to a Superose 6 ge
3.13). The SEC elution profile consisted of a single, large symmetric peak wh
suggested that SI was both pure and monodisperse. Peak fractions were pooled 
and analysed by SDS
stages (Figure 3.14
Figure 3.13  Elution of p
A highly-enriched sample
equilibrated in 150 mM NaCl, 0.1 mM EDTA, 10% glycerol, 0.15% DM, 50 mM sodium phosphate 
pH 7.4 at a flow-rate of 0.3 ml/min
3.14). 
 
to remove proteins that had bound non
-rich contaminants, respectively. SI
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-tagged 3C protease and 
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l filtration column (Figure 
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SDS-PAGE analysis showed that SI
purification, with a major band visible at 
the sample at this stage can be explained in terms of the SI
level in yeast membranes. On membrane solubilisation, there was so much SI
CLBH in solution that only a few contaminant proteins were able to bind to the 
Ni2+ column. Thus, 
chromatographic step. Following cleavage with 3C protease, new bands 
appeared at ca. 22 and 23 kDa corresponding to SI and the 
respectively (Figure 3.14
pure with a major band at 22 kDa 
filtration step did not result in any further
faint band at ca. 42 kDa that was observed in both the reverse
samples was thought to
                   
Figure 3.14  SDS-PAGE analysis of samples from different stages of
purification 
The CLBH tag was successful
and purified by Ni2+-affinity chromatography 
protease, generating CLBH and 
fresh Ni2+ column, and (iv)
filtration column (SEC) 
analysed by SDS-PAGE
after Ni2+-affinity purification
ca. 22 and 23 kDa corresponding to 
purification, the SI was essentially pure 
result in any further purification of SI (lane 4). 
 
-CLBH was largely pure following Ni
ca. 45 kDa (Figure 3.14
the sample was largely pure following a single 
). After reverse-purification, the sample was essentially 
corresponding to SI (Figure 3.14
 purification of SI (Figure 3.14
 be an SDS-induced dimer of SI. 
 
ly used to purify SI in four steps: (i) SI-CLBH was solubilised in DM 
(NP), (ii) the fusion protein was cleaved with 
SI, (iii) the cleavage mixture was reverse
 highly-enriched SI was concentrated and applied to a 
(Section 2.8.1). Samples from each stage of the purification process were 
 (Section 2.9). SI-CLBH (the major band at ca. 44 kDa
 (lane 1). Following cleavage with 3C protease
SI and the CLBH tag, respectively (lane 2). After reverse
(lane 3). Application to the gel-filtration column did not 
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3.5 Immobilising recombinant membrane proteins using 
the CLBH tag 
Fusion of the P. shermanii transcarboxylase biotin acceptor domain to the C-
terminus of selected GPCRs increases their expression in P. pastoris by up to 5-
fold (Grünewald et al., 2004; Andre et al., 2006; Lundström et al., 2006). The 
primary reason for including this domain within the CLBH tag, therefore, was to 
increase the production levels of target membrane proteins. However, 
biotinylation of this domain would also enable immobilisation of target proteins 
on (strept)avidin-coated surfaces, potentially allowing: (i) the purification of 
low-abundance membrane proteins; and/or (ii) the interaction between small 
molecules and proteins of interest to be probed using methods such as target 
immobilised NMR screening (TINS) (Siegal and Hollander, 2009) and surface 
plasmon resonance (SPR) (Navratilova and Hopkins, 2010).  
Biotinylated proteins are rare in nature with only one known in E. coli (Fall, 
1979), five in S. cerevisiae (Lim et al., 1987) and four in mammalian cells 
(Robinson et al., 1983; Chandler and Ballard, 1988). Although the P. shermanii 
biotin acceptor domain can be biotinylated endogenously by S. cerevisiae, only a 
small fraction of the available sites were modified (Cronan, 1990). To overcome 
this problem, a system was developed that allows CLBH-tagged proteins to be 
biotinylated in vitro. 
Biotin ligase was amplified from E. coli strain 0157 genomic DNA by PCR, cloned 
into pGEM T-Easy and then transferred to the E. coli expression vector pET15b 
(Figure 3.15). 
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Figure 3.15  PCR amplification of biotin ligase and cloning into pET15b
(A) Biotin ligase (BirA) was amplified by PCR from 
pGEM T-Easy. Recombinant 
fragments of 3.0 (corresponding to pGEM
was sub-cloned from pGEM 
restriction digestion with 
 
Biotin ligase was expressed in 
chromatography by virtue of a His
recombinant protein. Elution fractions from the Ni
SDS-PAGE. A single band with a MW of 37 kDa was observed, indicating that 
biotin ligase had been successful
The activity of recombinant biotin ligase was assessed by biotinylating 
detergent-solubilised SI
was incubated with biotin ligase, 50 
magnesium-o-acetate overnight at 4
desalted twice (to remove the biotin) before 
Following this, the beads were transferred to a gravity
were washed extensively. When 
streptavidin beads were brightly fluorescent indicating that SI
successfully immobilised. T
was active. 
 
E. coli strain 0157 and (B) sub
plasmids were identified by digesting with Eco
) and 1.0 Kb (BirA). (C) The cDNA encoding b
T-Easy to pET15b. Recombinant plasmids were identified by 
PvuI, yielding fragments of 5.6 (pET15b) and 1.
E. coli, and purified by Ni2+-affinity 
6 tag located at the N-terminus of the 
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Figure 3.16  SDS-PAGE analysis of pure biotin ligase
Recombinant biotin ligase was 
(Section 2.8.6.2). Peak elution 
corresponding to pure BirA was observed.
 
Figure 3.17  Immobilisation of SI
SI–CLBH was biotinylated 
was desalted and loaded onto a 
viewed under UV light. 
had been successfully immobilised.
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3.6 Conclusion 
The CLBH tag is an attractive system for the recombinant expression, 
purification, characterisation and immobilisation of human membrane proteins. 
In this chapter, the properties and applications of the CLBH tag were 
investigated. 
iLOV is a novel fluorescent reporter derived from the LOV2 domain of A. thaliana 
phototropin 2. Here, the spectral properties of iLOV were characterised, and 
optimal wavelengths for selective excitation of (λ = 450 nm) as well as 
measuring fluorescence emission from (λ = 485 nm) iLOV identified. Using these 
wavelengths, it was possible to monitor CLBH-tagged membrane proteins both in 
vivo and in vitro. For example, the expression level of SI-CLBH in fermenter 
culture could be monitored by measuring iLOV fluorescence, eliminating the 
need for time-consuming methods such as radioligand binding or Western 
Blotting to establish the production level of the protein of interest. By 
measuring whole cell iLOV fluorescence at regular intervals, the expression of 
CLBH tagged membrane proteins can be readily optimised. In vitro, iLOV can be 
used for determining the aggregation status of CLBH-tagged membrane proteins 
in detergent solution by FSEC as well as for tracking recombinant proteins 
throughout their purification. 
Using the CLBH tag, human sterol isomerase was purified to homogeneity in four 
simple steps (Ni2+-affinity purification; cleavage with 3C protease; reverse Ni2+- 
affinity purification; gel filtration). Allowing for the exceptionally high 
expression levels observed with SI, it should be possible to purify other CLBH-
tagged membrane proteins in the same way. Where necessary, however, a 
second affinity purification step could be introduced by biotinylating the CLBH 
tag in vitro with biotin ligase, and then applying the protein mixture to 
(strept)avidin resin. 
The ability to immobilise target proteins on (strept)avidin-coated surfaces was 
particularly exciting as it opens up the possibility of studying the interaction of 
small molecular fragments and proteins of interest by techniques such as TINS 
and SPR, an important step in designing highly-specific novel drugs. In relation 
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to this thesis, if aldosterone synthase and 11β-Hydroxylase could be immobilised 
on a streptavidin surface, it may be possible to identify molecular fragments 
which bind to one enzyme and not the other, allowing specific inhibitors to be 
designed. 
Having developed a generic approach for making and purifying recombinant 
proteins, the CLBH tag was used to obtain pure adrenodoxin and adrenodoxin 
reductase (Chapter 4), and gave critical insights into the expression and 
purification of aldosterone synthase and 11β-Hydroxylase (Chapter 5). 
 Chapter 4 - Expression, purification and 
characterisation of human adrenodoxin and 
adrenodoxin reductase 
  
4.1 Introduction 
My primary research goal was to purify milligram quantities of functional human 
11β-Hydroxylase and aldosterone synthase for structural studies and drug 
discovery purposes. Before either p450 could be used in crystallisation trials or 
high-throughput screening assays, however, it was necessary to show that the 
enzymes were fully functional. P450 activity can be measured in several 
different ways including determining the rate of substrate consumption, product 
formation or NADPH oxidation. Irrespective of which approach is chosen, any 
activity assay developed for use with either 11β-Hydroxylase or aldosterone 
synthase will require inclusion of their electron donors adrenodoxin (Adx) and 
adrenodoxin reductase (AdxRed). 
In Chapter 3, a generic system for the recombinant expression and purification 
of human proteins was described. Here, the CLBH tag was used to obtain 
milligram amounts of pure Adx and AdxRed with a view to developing a 
reconstituted electron transfer system in vitro for use with both 11β-
Hydroxylase and aldosterone synthase. Furthermore, initial results from the 1000 
genomes project has revealed that there are a large number of non-synonomous 
SNPs in the coding regions of both Adx and AdxRed in the general population 
(www.1000genomes.org). As yet, how these SNPs affect the rates of aldosterone 
and cortisol synthesis in vivo, if at all, is not known. As a first step towards 
understanding the properties of naturally occurring Adx and AdxRed variants in 
vitro, the wild-type proteins have been biophysically characterised and 
crystallisation efforts attempted. 
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4.2 PCR amplification of mat
adrenodoxin reductase
Although Adx and AdxRed function in the mitochondria, they are both nuclear
encoded and translated in the cytoplasm as pre
(MW) of 19 and 54 kDa, respectively. Following import
N-terminal targeting sequences are removed to give mature forms of both 
proteins (Adx, MW 13 kDa; AdxRed, 50 kDa) 
Vonrhein et al., 1999
cDNAs encoding the mature 
were generated by PCR and transferred into the cloning
(Section 2.3.4). Recombinant
AdxRed cDNAs were identified by restriction digestion with 
and then sequenced to check that no mutations had been 
PCR step. 
  
Figure 4.1  Restriction analysis of pGEM plasmids containing human Adx and AdxRed
cDNAs encoding the mature forms of human Adx and AdxRed were generated by PCR 
2.3.2) and sub-cloned into pGEM T
restriction digestion with 
DNA fragments of size 3.0 (pGEM T
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 plasmids containing mature human Adx and 
introduced during the 
 
-Easy (Section 2.3.4). Recombinant plasmids were identified by 
EcoRI. The digests were resolved on a 1% agarose gel
-Easy), 0.4 (Adx) and 1.5 Kb (AdxRed) were observed. 
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4.3 Expression an
reductase
4.3.1 Vector construction
Initially, the expression of AdxRed was attempted using
expression system described 
was excised from pGEM T
then transferred into the equivalent cloning sites in the (pPICZ)A
Recombinant plasmids were identified by restriction digestion
NotI (Figure 4.2). The AdxRed
P. pastoris strain X33 by electroporation (Section 
Figure 4.2  Restriction analysis of pPICZA 
The cDNA encoding mature AdxRed was sub
the restriction enzymes 
containing AdxRed were identified by digesting the yeast vector with 
were resolved on a 1% agarose gel
AdxRed were observed at 
 
  
d partial purification of adrenodoxin 
 using the P. pastoris CLBH system
 
 the 
in Chapter 3. The cDNA encoding human AdxRed 
-Easy by digestion with EcoRI and 
-CLBH construct was subsequently transformed into 
2.4.2.2). 
- AdxRed - CLBH 
-cloned from pGEM T-Easy to pPICZA
EcoRI and NotI (Section 2.3.5). Recombinant expression plasmids 
Eco
 (Section 2.3.1.2). Bands corresponding to pPICZA
ca. 4.0 and 1.5 Kb, respectively. 
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P. pastoris CLBH 
NotI, isolated and 
-CLBH vector. 
 with EcoRI and 
 
-CLBH using 
RI and NotI. Fragments 
-CLBH and 
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4.3.2 Production of AdxRed-CLBH in P. pastoris  
Following transformation of an expression plasmid into P. pastoris, a range of 
colonies must be screened to identify the clone expressing the highest levels of 
recombinant protein (Macauley-Patrick et al., 2005). The expression level of a 
CLBH-tagged recombinant protein in whole cells can be rapidly determined by 
measuring fluorescence from the iLOV reporter (Section 3.2.3). Clonal selection 
was performed on a series of AdxRed-CLBH yeast colonies. Transformants were 
grown up overnight at 30°C in 1 ml cultures of BMGY (a basal medium) in a 48-
well plate. AdxRed-CLBH expression was induced by replacing the BMGY with 
BMMY (an induction medium), and the yeast incubated for a further 24 h at 
22°C. The test expression experiments for each colony were performed in 
duplicate. Cells were harvested by centrifugation, washed twice and then 
resuspended in 1 ml of water. The cells were then transferred (in duplicate) to a 
96-well plate, where iLOV fluorescence was measured (λexcitation = 450 nm, 
λemission = 520 nm). For each transformant, the quantity of whole cell iLOV per ml 
of culture was determined (Figure 4.3). Disappointingly, the fluorescence levels 
in the AdxRed transformants were not much higher than the X33 control, 
suggesting that P. pastoris is a poor host for expressing AdxRed. Despite the 
production levels of AdxRed-CLBH being low, the transformant that expressed 
the most recombinant protein was retained for further analysis. 
The highest expressing Adx-CLBH yeast transformant was grown in fermenter 
culture to purify the recombinant protein. In a bioreactor, the yeast’s growth 
environment (including dissolved oxygen content, media pH, growth 
temperature and carbon source feed rates) can be tightly controlled ensuring 
that maximal cell densities and recombinant protein expression levels are 
obtained. AdxRed expression in fermenter culture was carried out as described 
in Section 2.5.2. In short, the yeast was first grown on glycerol to increase the 
culture’s biomass. After this, the culture was starved (to ensure that all of the 
added glycerol had been consumed) before the carbon source was switched to 
methanol. When the induction phase was complete, the cells were harvested.  
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Figure 4.3  Clonal analysis of 
AdxRed-CLBH transformants were grown up overnight at 30
Recombinant protein production was induced by replacing the media with BMMY and then 
incubating the yeast at 22
iLOV fluorescence from whole cells
 
Figure 4.4  SDS-PAGE analysis of Ni
AdxRed that had been expressed in 
Fluorescent elution fractions containing AdxRed
resolved on a 10% Bis-Tris gel. A band at 
(actual MW 73 kDa).  
  
P. pastoris transformants expressing AdxRed
°C in 1 ml cultures of BMGY. 
°C for 24 h. AdxRed production levels were determined by measuring 
 (Section 2.5.1).  
2+
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P. pastoris was purified by Ni2+-affinity chromatography. 
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ca. 75 kDa was tentatively identified as AdxRed
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Cells were resuspended in buffer A (150 mM NaCl in 50 mM Tris HCl pH7.4), and 
lysed using a cell disrupter. Cellular debris was removed by centrifugation at low 
speed (10,000g). The supernatant, which contained the AdxRed-CLBH, was 
retained. Consistent with the clonal selection results, the iLOV fluorescence in 
the supernatant was low, indicating that AdxRed-CLBH is expressed at low levels 
in P. pastoris even in fermenter culture. 
A purification of AdxRed was attempted from 1.5 kg of yeast cell biomass. 
Following disruption, the cell lysate volume was so large that, to make the 
purification manageable, ammonium sulphate precipitation was performed and a 
series of fractions generated. The fraction that had the highest fluorescence was 
dialysed overnight at 4°C against buffer B (75 mM imidazole, 150 mM NaCl in 50 
mM Tris HCl pH 7.4), before it was applied to a Ni2+ column. The column was 
washed with 10 column volumes of buffer B before AdxRed-CLBH was eluted 
using buffer C (300 mM imidazole, 150 mM NaCl in 50 mM Tris HCl pH 7.4). 
Elution fractions which were fluorescent (and therefore expected to contain 
AdxRed-CLBH) under UV-illumination were analysed by SDS-PAGE (Figure 4.4). A 
band observed at ca. 75 kDa was tentatively identified as AdxRed-CLBH. 
However, the presence of numerous other contaminant proteins in the elution 
fractions suggested that further purification steps would be required before pure 
AdxRed could be obtained. 
Ultimately, the expression level of AdxRed in P. pastoris was too low for easy 
purification. It was concluded, therefore, that it would be necessary to use an 
alternative expression system for AdxRed.  
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4.4 An E. coli CLBH expression vector for expressing 
adrenodoxin and adrenodoxin reductase 
Having encountered difficulties in making AdxRed in P. pastoris, expression of 
Adx and AdxRed in E. coli was now explored. Modified pET21a expression vectors 
containing the –CLBH tag and either the mature Adx or AdxRed cDNA were 
generated by way of a two-step ligation strategy (Figure 4.5). The –CLBH tag was 
amplified by PCR using the pPICZA vector as template (Figure 4.6A). The 
oligonucleotide primers used for PCR amplification contained restriction sites 
that would allow the CLBH tag to be cloned into pET21a (5’-3’ primer, NotI; 3’-
5’, BamHI). In the first instance, however, the CLBH PCR product was 
transferred into pGEM T-Easy. Recombinant plasmids containing the CLBH cDNA 
were identified by restriction analysis (Figure 4.6B). The –CLBH tag was released 
from pGEM T-Easy by digesting with NotI and BamHI. The mature human Adx and 
AdxRed cDNAs, previously amplified and sub-cloned into pGEM T-Easy (Figure 
4.1), were released from the vector using NdeI (part of the pGEM multi-cloning 
site) and NotI. The Adx and AdxRed cDNAs were ligated to CLBH via their NotI 
overhangs (Figure 4.5A). The Adx(Red)-CLBH fragment was then ligated to 
pET21a vector that been previously treated with NdeI and BamHI (Figure 4.5B). 
Correctly assembled, recombinant pET21a - Adx(Red) - CLBH vector (Figure 
4.5C) was identified by restriction analysis with NdeI (Figure 4.7).
 Figure 4.5  Schematic diagram illustrating the two
Adx(Red) – CLBH E. coli
(A) Mature Adx and AdxRed cDNAs were ligated first to the CLBH tag, and then (B) to the pET21a vector to 
create (C) pET21a - Adx(Red) 
-step ligation strategy used to make the pET21a 
 expression vectors 
– CLBH. 
 
– 
  
Figure 4.6  PCR amplification of the CLBH tag and restriction analysis of pGEM
(A) The -CLBH tag was amplified by PCR using the pPICZA vector as tem
into pGEM T-Easy (Section 2.3.3)
with EcoRI, yielding fragments of 
Figure 4.7  Restriction analysis of pET21a 
Recombinant plasmids were identified by restriction analysis with 
AdxRed vectors with Nde
consistent with correct assembly of the recombinant plasmids.
. (B) Recombinant plasmids were identified by restriction analysis 
ca. 3.0 (vector) and 0.6 Kb (CLBH). 
– Adx(Red) – CLBH 
NdeI. Digestion of the Adx and 
I gave fragments with sizes (Adx, 5.4 and 0.7; AdxRed, 5.4 and 1.8 Kb) 
 
 
-CLBH 
plate and sub-cloned 
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4.5 Purification of adrenodoxin and adrenodoxin 
reductase from E. coli 
4.5.1 Expression of adrenodoxin and adrenodoxin reductase in E. 
coli 
Adx- and AdxRed-CLBH were expressed in E. coli as described in Section 2.6.1, 
and then harvested by centrifugation. Cell pellets were resuspended in 150 mM 
NaCl, 0.1 mM EDTA in 50 mM Tris-HCl pH 7.4. Expression of both CLBH-tagged 
proteins could be easily monitored by illuminating the cells with UV light and 
observing fluorescence from the iLOV reporter. In contrast to the poor 
expression levels of AdxRed in P. pastoris, substantial whole cell iLOV 
fluorescence was observed for both Adx and AdxRed following expression in E. 
coli. This allowed quick progression to the development of purification protocols 
for both electron transfer proteins. 
4.5.2 Purification of adrenodoxin 
Following expression, the E. coli cells were lysed by mechanical rupturing and 
Adx-CLBH purified by Ni2+-affinity chromatography as described for AdxRed-CLBH 
expressed in P. pastoris (Section 4.3.2). Following elution from the nickel 
column, fractions containing partially purified Adx-CLBH were brown in colour 
and fluoresced green when viewed under UV light (Figure 4.8 A, B). When the 
Ni2+-enriched sample was analysed by SDS-PAGE, a strong band with a molecular 
weight of ca. 38 kDa thought to correspond to Adx-CLBH was observed (Figure 
4.8C). The fluorescent fractions were pooled and desalted to remove the 
imidazole present in the elution buffer. The –CLBH tag was removed from Adx by 
incubating the sample with 3C protease at 4°C overnight. Adx was then further 
purified by reverse Ni2+-affinity chromatography. The cleavage mixture was 
applied to a fresh Ni2+ column which bound the –CLBH tag, His-tagged 3C 
protease as well as contaminant proteins that had non-specifically bound to the 
original Ni2+ column but not Adx. Brown fractions containing Adx were pooled 
and concentrated before they were applied to a Superose 6 gel filtration 
column. The SEC elution profile consisted of a single sharp, symmetrical peak 
(Figure 4.9A), suggesting that Adx was both pure and monodisperse. Peak 
fractions from the gel filtration step were analysed by SDS-PAGE. A single band 
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was observed at ca.
Purified human Adx had a characteristic ferrodoxin absorption spectrum with 
 
Figure 4.8  Visualisation and SDS
Fractions containing Ni2+
fluorescent green following illumination with UV
column were analysed by SDS
which was thought to be Adx
  
 13 kDa confirming that the Adx was pure (Figure 4.9B). 
-PAGE analysis of Ni2+-affinity purified Adx
-enriched Adx-CLBH were (A) brown under natural light and (B) 
-radiation. (C) The elution fractions from the Ni
-PAGE. The gel showed a major band clearly visible at 
-CLBH (predicted MW 37 kDa). 
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Figure 4.9  Pure Adx 
Highly-enriched Adx was applied to a Superose 6 gel filtration column
elution profile consisted 
monodisperse. (B) Peak fractions were analysed by SDS
observed at ca. 13kDa confirming that
 
Figure 4.10  Absorption spectrum of pure human Adx
The absorption spectrum of pure human Adx displays a characteristic ferrodoxin absorption 
spectrum with maxima at 322, 414 and 455 nm
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maxima arising from the iron-sulfur cluster at 322, 414 and 455 nm (Figure 4.10). 
The concentration of pure Adx was determined using a calculated extinction 
coefficient based on the amino acid content of the recombinant protein (Adx ε280 
= 3230 M-1cm-1). 
4.5.3 Purification of adrenodoxin reductase 
AdxRed-CLBH was purified by Ni2+-affinity chromatography in the same way as 
that for Adx-CLBH (Section 4.5.2). Elution fractions from the Ni2+ column were 
yellow when viewed under natural light (Figure 4.11A), and fluorescent green 
when illuminated with UV radiation (Figure 4.11B). SDS-PAGE analysis of the Ni2+ 
elution fractions showed that AdxRed-CLBH was only partially pure (Figure 
4.11C). A band with a MW of ca. 70 kDa was tentatively identified as AdxRed-
CLBH. Next, the partially purified AdxRed-CLBH was desalted, cleaved by 
overnight incubation with 3C protease and reverse-purified using a fresh Ni2+ 
column. The highly-enriched AdxRed sample was applied to a Superose 6 gel-
filtration column. The SEC elution profile had a single sharp peak suggesting that 
AdxRed was both pure and monodisperse (Figure 4.12A). Peak fractions were 
analysed by SDS-PAGE. A single band with a MW of ca. 49 kDa was observed, 
showing that AdxRed was pure (Figure 4.12B). The absorption spectrum of 
human AdxRed consists of a broad absorption peak in the region 360-380 nm and 
a second peak at 450 nm with shoulders at 425 and 475 nm (Figure 4.13). 
The concentration of pure AdxRed was determined using a calculated extinction 
coefficient based on the amino acid content of the recombinant protein (AdxRed 
ε280 = 45295 M
-1cm-1). 
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Figure 4.11  Visualisation and SD
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Figure 4.12  Pure AdxRed
A highly-enriched, concentrated AdxRed sample was applied to a Superose 6 gel filtration column
(Section 2.8.3). (A) The SEC elution profile consisted of a single sharp sym
that AdxRed was both pure and monodisperse. (B) Peak fractions 
(Section 2.9). A single band was observed at 
 
Figure 4.13  Absorption spectrum of pure AdxRed
The absorption spectrum of human AdxRe
380 nm, with a second maximum at 450 nm flanked by
experimental detail, see Section 2.8.3.
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4.6 Biophysical characterisation of adrenodoxin and 
adrenodoxin reductase 
The primary need for purifying human Adx and AdxRed was to develop activity 
assays for both aldosterone synthase and 11β-Hydroxylase. In recent years, 
however, it has become apparent that there are a substantial number of natural 
variants in both Adx and AdxRed that may affect blood pressure in humans. 
These proteins are, therefore, worthy of further study in their own right. 
4.6.1 Natural variants of adrenodoxin and adrenodoxin reductase 
The 1000 genomes project4 is a comprehensive resource on human genetic 
variation that lists all of the SNPs that have been identified through sequencing 
the genomes of numerous people. Thus far, 7 non-synonymous (amino-acid 
changing) SNPs have been identified in the coding regions of Adx (Table 4.1), 
with a further 41 discovered for AdxRed (Table 4.2). Although certain of the 
amino acid changes are conservative in nature (e.g. Adx, Asp132Glu and 
Val85Ala) others are considerably less so (e.g. Adx, His122Tyr; AdxRed, 
Pro358Ser and Arg139Trp). To assess whether these amino acid sequence 
variations affect the rate of electron transfer from NADPH to aldosterone 
synthase and 11β-Hydroxylase in vivo, it will be necessary to construct a series 
of mutants and test them in vitro. Unfortunately, due to time restrictions this 
was beyond the scope of this thesis. However, as a first step towards expressing, 
purifying and analysing the properties of the naturally-occurring variants in 
vitro, a biophysical characterisation of both wild-type proteins was performed. 
  
                                         
4
 www.1000genomes.org 
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Table 4.1 Non-synonymous SNPs in the coding regions of Adx 
 
Variant Amino acid change 
219 C/A 
254 T/C 
364 C/T 
388 A/G 
396 T/A 
428 G/C 
532 A/G 
73 Asn/Lys 
85 Val/Ala 
122 His/Tyr 
130 Ile/Val 
132 Asp/Glu 
143 Gly/Ala 
178 Ile/Val 
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Table 4.2 Non-synonymous SNPs in the coding regions of AdxRed 
 
Variant Amino acid change  Variant Amino acid change 
20 G/T 7 Arg/Leu  866 C/T 289 Thr/Met 
120 G/T 40 Gln/His  919 C/T 307 Arg/Cys 
235 C/T 79 Arg/Cys  979 C/T 327 Arg/Trp 
296 C/T 99 Thr/Met  994 G/A 332 Val/Ile 
368 G/A 123 Arg/Gln  1052 C/T 351 Thr/Met 
415 C/T 139 Arg/Trp  1061 T/A 354 Met/Lys 
419 C/T 140 Ala/Val  1072 C/T 358 Pro/Ser 
515 C/T 172 Pro/Leu  1102 T/A 368 Tyr/Asn 
538 G/A 180 Val/Met  1103 A/G 368 Tyr/Cys 
616 C/A 206 Leu/Ile  1111 C/T 371 Arg/Cys 
620 T/G 207 Leu/Trp  1133 C/T 378 Pro/Leu 
624 C/G 208 Cys/Trp  1145 A/G 382 Lys/Arg 
641 C/T 214 Thr/Met  1220 G/A 407 Arg/Lys 
656 G/T 219 Gly/Val  1270 G/A 424 Gly/Ser 
680 A/C 227 Lys/Thr  1297 G/T 433 Ala/Ser 
748 A/T 250 Met/Leu  1349 T/G 450 Leu/Arg 
761 C/T 254 Pro/Leu  1369 C/T 457 Arg/Trp 
767 C/T 256 Ala/Val  1432 A/G 478 Thr/Ala 
769 C/T 257 Arg/Trp  1441 C/T 481 Pro/Ser 
827 C/A 276 Pro/His  1477 C/T 493 Arg/Cys 
863 G/A 288 Arg/Gln    
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4.6.2 Optimising adrenodoxin stability 
When a protein of interest is used in activity assays or for characterisation 
studies (including structure determination), it is essential that the protein is 
robust and does not denature. A protein’s stability can be affected by a variety 
of factors including the type, pH and ionic content of the buffer in which it 
resides. Protein stability can be assessed by measuring the rate of protein 
denaturation upon exposure to high temperature. Unstable proteins denature 
more rapidly than stable ones. Protein denaturation can be followed in different 
ways (e.g. changes in the secondary structure composition of a protein can be 
followed by circular dichroism (CD)). For those proteins that have co-factors 
which absorb in the visible region, changes in the spectral properties of the 
bound chromophore can be used as a reporter of protein denaturation.  
The absorption spectrum of Adx has maxima at 322, 414 and 455 nm. The effect 
of prolonged heat treatment on the absorption profile of Adx was assessed by 
incubating pure Adx (in 150 mM NaCl, 0.1 mM EDTA in 50 mM Tris HCl pH 7.4) at 
45°C for 1 h and recording the spectrum every 5 min (Figure 4.14). The 
absorption maxima decreased steadily in intensity with time. By 45 min, the 
maxima at 414 and 455 nm could no longer be distinguished (Figure 4.14). It was 
concluded that the rate of decrease in absorption at 414 nm that occurs on 
heating at 45°C for 1 h could be used as a measure of Adx thermostability.  
The Adx denaturation assay was adapted for use in a 96-well plate format so 
that several different buffers could be tested simultaneously. For each 
condition, measurements were made in triplicate and the decrease in A414 
plotted against time. 
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Figure 4.14  Changes in the absorption spectrum of Adx upon prolonged incubation at 45
An initial absorption spectrum
HCl, 150 mM NaCl, pH 7.4
at 45°C for 1 h . Adx spectra were recorded
To identify the optimal buffer for purifying and storing Adx, a series of thermal 
denaturations were performed in a range of buffers at different pH (MES, pH 5
6; MOPS, 6.5-7.5; HEPES, 6.5
9.5-11). Adx used in the thermostability assays had
7.4. Tris is widely regarded as a harsh buffer
including a temperature dependent pKa and
7.5 (Good et al., 1966
tendencies that Tris shows with many proteins 
conditions in which A
  
 of Adx was recorded at room temperature 
. To monitor the denaturation of Adx over time,
 at 5 min intervals.  
-7.5; Tris, 7.5-8.5; sodium phosphate, pH 5
 been purified in Tris at pH 
 and has several drawbacks 
 poor buffering capacity below pH 
; Stoll and Blanchard, 1990). Here, the mildly destabilising 
was used to identify buffer 
dx had maximum thermostability. 
119 
 
°C 
(black line) in 50 mM Tris-
 the sample was heated 
-
-8; CAPS, 
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Figure 4.15  Adx stability in MOPS buffer at different pH
Adx was unfolded in the presence of 50 mM 
incubation at 45°C. The rate of Adx denaturation was determined by measuring the decrease in
A414 with time (Section 2.12
Representative data showing Adx denaturation in MOPS buffer at pH 6.5, 7.0 and 
7.5 is presented in Figure 4.15. The results clearly showed that 
denaturation increased as the pH of the MO
MOPS, Adx was most stable at pH 7.5.
To compare Adx stability 
absorption remaining at 90 min (5400 s) was determined for each condition and 
plotted as a bar chart (Figure 4.16
of Adx had denatured during the course of the assay. The higher the percentage, 
the more stable Adx was. Adx was 
pH value of 8. In this condition, only 15% of the original 
at 5400 s, indicating excellent Adx thermostability. All subsequent Adx 
purifications were carried out using sodi
  
 
MOPS at three different pH
.1).  
PS buffer decreased (Figure 4.15
 
in different buffers, the percentage of the original A
). This value is a measure of 
most stable in sodium phosphate buffer with a 
A414
um phosphate buffers at pH 
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 values by extended 
 
the rate of Adx 
). In 
414 
what proportion 
 signal had been lost 
7.4.
 Figure 4.16  Adx stability in different
Adx was unfolded in the presence of a range of buffers 
percentage of the original Adx A
bar chart. The higher the percentage, the 
 buffer solutions 
with differing pH by extended incubation at 45°C
414 absorption remaining at 90 min was determined for each buffer condition and plotted as a 
smaller the amount of Adx that had denatured. 
 
 (Section 2.12.1). The 
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4.6.3 Optimising adrenodoxin reductase stability 
AdxRed has a prominent absorption in the region 425 to 475 nm. It was 
envisaged that a wavelength in this range could be selected for studying the 
thermal denaturation of AdxRed in a similar way to that used with Adx (Section 
4.6.2). An initial experiment was carried out to determine the extent and rate of 
decrease in A450 (wavelength of AdxRed maximum absorption) upon incubating 
the protein at 45°C. However, it was found that AdxRed was highly unstable; 
after only five minutes at 45°C the AdxRed had not only fully-denatured but 
precipitated out of solution also (Figure 4.17). 
The extreme instability of AdxRed precluded the option of following a decrease 
in its absorption by the FAD co-factor with time on heating as an index of 
stability. Rather, the fluorescence-based CPM assay (Alexandrov et al., 2008) 
was used to identify buffer conditions in which AdxRed had increased stability as 
it is sensitive to small changes in protein structure. Mature AdxRed contains 7 
Cys residues and is, therefore, suitable for use with the CPM assay. AdxRed was 
denatured at a fixed temperature of 45°C. Measurements were made on a 96-
well plate which allowed several buffer conditions to be screened at once. The 
amount of fluorescence due to unfolding of AdxRed was determined by 
subtracting the background fluorescence in a buffer control from that measured 
in the presence of protein. AdxRed unfolding was studied in the buffers MES, 
MOPS, HEPES, Tris, CAPS and sodium phosphate over the pH range 5.5-11 (Figure 
4.18). 
With HEPES, the CPM fluorescence increased with time until a plateau was 
reached, a typical unfold plot. In certain buffer conditions, however, there was 
a rapid increase in fluorescence which fell back with time (e.g the unfold 
experiments in Tris). In these conditions, AdxRed was so unstable that following 
rapid unfolding the protein precipitated out of solution, explaining the decrease 
in fluorescence. AdxRed had good stability in MES (pH 5.5, 6), HEPES (6.5, 7., 
7.5), MOPS (7.5, 8) and sodium phosphate (4, 5, 6, 7). Of these, HEPES pH 7 was 
chosen as the optimal buffer for purification purposes. 
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4.6.4 Crystallisation of human adrenodoxin and adrenodoxin 
reductase 
Milligram quantities of stable Adx and AdxRed were purified in sodium phosphate 
and HEPES buffer, respectively. Pure protein was concentrated to between 20-40 
mg/ml, and then used with a series of sparse-matrix crystallisation screens 
(JCSG+, Morpheus, Peg/Ion 1& 2 and Hampton 1&2). A series of sitting-drop 
trays were set up in which 0.5 µl of the concentrated protein was added to 0.5 
µl of the precipitant solution. Crystallisation trays were incubated at 20°C in a 
Rhombix plate hotel. Wells were photographed regularly to monitor crystal 
formation. 
With Adx, initial crystallisation attempts resulted in the formation of spherulites 
(Figure 4.19A) and salt crystals (Figure 4.19B). Subsequent efforts resulted in the 
formation of small protein crystals (Figure 4.19C). However, these did not 
diffract in an X-ray beam. No successful crystallisation ‘hits’ were observed with 
AdxRed. Further work will be required to obtain crystals of human Adx and 
AdxRed that diffract to high-resolution. 
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Figure 4.19  Adx crystallis
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4.6.5 Characterisation of adrenodoxin and adrenodoxin reductase 
by circular dichroism 
Circular dichroism (CD) refers to the differential absorption of left- and right-
handed polarised light by chiral molecules. CD signals only occur at those 
wavelengths where the asymmetric molecule absorbs. Proteins have several 
chromophores which absorb electromagnetic radiation. These include peptide 
bonds (which absorb between 180 and 240 nm), aromatic amino acids (260 to 
320 nm) and disulphide bonds (260 nm). 
The different kinds of secondary structure (e.g. α-helices and β-sheet) that 
occur in proteins have characteristic CD spectra in the far-UV (which arise from 
the chiral arrangement of the peptide bonds in each structure). A number of 
algorithms have been developed that provide an estimate of a protein’s 
secondary structure from its far-UV CD spectrum (Kelly et al., 2005). 
Proteins also have measurable CD in the near-UV (region 260 – 320 nm) arising 
from their constituent aromatic amino acids (Trp, Tyr, Phe). The actual shape 
and intensity of the CD-signal in the far-UV is different for each type of protein, 
and depends on the number of each type of aromatic amino acid present, their 
mobility and their environment (H-bonding, proximity of polar groups and 
polarisability). The near-UV CD spectrum of a protein provides a valuable 
fingerprint of its tertiary structure, and can be used to compare, for example, 
the structural similarity of wild-type and mutant forms of the protein (Kelly et 
al., 2005). 
CD spectra of Adx and AdxRed were recorded both in the far-UV (Figure 4.20) 
and near-UV/visible regions (Figure 4.21). Measurements were performed in the 
laboratory of Dr. Sharon Kelly (University of Glasgow). The far-UV spectra were 
fitted using the CONTIN-LL alogorithm (Provencher and Glockner, 1981; Van 
Stokkum et al., 1990; Whitmore and Wallace, 2008). The root-mean-squared 
deviation values of both fits were too high to allow accurate predictions of the 
secondary structure content of either protein. However, the spectra are still 
useful because they can be used as references for assessing the structural 
integrity of Adx and AdxRed mutants. The near-UV/visible CD spectrum for Adx 
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Figure 4.20  Far-UV CD spectra of Adx and AdxRed
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Figure 4.21  Near-UV/visible CD spectra of Adx and 
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4.7 Conclusion 
This chapter describes the successful expression and purification of the electron 
transfer proteins Adx and AdxRed. Initial efforts to make AdxRed in P. pastoris 
were abandoned as the production levels of the recombinant protein were too 
low to allow its purification on a milligram scale. This necessitated the use of 
another heterologous host. cDNAs encoding Adx and AdxRed were introduced 
into the E. coli expression vector pET21a along with the CLBH tag. In this 
system, Adx and AdxRed could be made on a milligram scale and purified to 
homogeneity in four simple steps (Ni2+-afffinity, 3C cleavage, reverse Ni2+-
affinity and gel-filtration). 
The primary purpose for obtaining pure Adx and AdxRed was to develop activity 
assays for both aldosterone synthase and 11β-Hydroxylase. Over the course of 
the last few years, however, it has become apparent that there are a substantial 
number of natural variants in both Adx and AdxRed that may affect blood 
pressure in people. As a first step towards expressing, purifying and analysing 
the properties of naturally-occurring variants of Adx and AdxRed in vitro, a brief 
biophysical characterisation of the wild-type proteins was performed. 
The stability of Adx in a range of buffer conditions was investigated using an 
absorption-based thermal denaturation assay. Adx was found to have greatest 
stability in sodium phosphate buffer with a pH between 7 and 8. AdxRed stability 
was explored using the CPM assay. AdxRed is considerably less stable than Adx. 
Maximal stability was observed in MOPS buffer closely-followed by HEPES pH 7.   
All subsequent purifications were performed in the buffers that gave maximal 
thermostability (Adx, sodium phosphate pH 7.4; AdxRed, HEPES pH 7). 
Crystallisation trials were performed for both Adx and AdxRed. As yet, no 
diffracting crystals have been obtained. CD spectra were recorded for both 
proteins in the far-UV and near-UV/visible regions. In the future, these spectra 
will be used as references to assess the structural integrity of any Adx or AdxRed 
natural variants made by recombinant expression prior to their use in activity 
assays in vitro. 
    
Chapter 5 – Expression and purification of human 
aldosterone synthase and 11β-Hydroxylase 
  
5.1 Introduction 
The primary aim of my Ph.D. was to purify functional human aldosterone 
synthase and 11β-Hydroxylase for structural studies and drug-screening 
purposes. As both enzymes are monotopic membrane proteins, they were 
expected to be  challenging to make in a heterologous host on a milligram-scale 
as well as purify in an active form (Gonzalez and Korzekwa, 1995). Previously, a 
range of expression systems have been used to make cytochrome p450s including 
E. coli (Sandhu et al., 1994), yeast (Eugster et al., 1990), insect (Aoyama et al., 
1990) and mammalian cells (Patten et al., 1992). Initial efforts to express both 
aldosterone synthase and 11β-Hydroxylase were focused on the P. pastoris CLBH 
expression system detailed in Chapter 3. P. pastoris has been successfully used 
to make a range of cytochrome p450s of varying origins, including spiny dogfish 
shark CYP17 (Trant, 1996), plant CYP79D1 (Andersen et al., 2000) and human 
CYP2D6 (Dietrich et al., 2005), suggesting that it may be a good host for the 
expression of aldosterone synthase and 11β-Hydroxylase also. However, no 
expression of either aldosterone synthase or 11β-Hydroxylase was observed in P. 
pastoris. An alternative E. coli-based expression system was developed that 
yielded milligram amounts of both aldosterone synthase and 11β-Hydroxylase, 
from which pure and functional protein was obtained. This Chapter details all 
efforts to express and purify aldosterone synthase and 11β-Hydroxylase. 
5.2 Expression of aldosterone synthase and 11β-
Hydroxylase in P. pastoris 
5.2.1 Vector construction 
Aldosterone synthase and 11β-Hydroxylase are synthesised in the cytosol as 
precursor proteins, and then targeted to mitochondria via N-terminal (αα 1-24) 
leader sequences. Following their import, mature forms of both enzymes are 
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Figure 5.1 Construction of CYP11B1/B2
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forms of aldosterone synthase and 11β-Hydroxlase were generated by PCR, and 
cloned into pGEM T-Easy (Figure 5.1B). Recombinant plasmids were identified by 
restriction digestion with EcoRI, and then sequenced to ensure that no mutations 
had been introduced during the PCR step. 
The modified aldosterone synthase and 11β-Hydroxylase cDNAs were then sub-
cloned from pGEM T-Easy to pPICZA-CLBH. Recombinant expression plasmids 
were identified by digesting the yeast vector with EcoRI and NotI (Figure 5.1C). 
5.2.2 Production of aldosterone synthase and 11β-Hydroxylase in 
P. pastoris 
Both CYP11B1- and B2-CLBH constructs were transformed into the P. pastoris 
strain X33 by electroporation (Section 2.4.2.2). Multi-copy integrants were 
selected using zeocin. Clonal selection was performed for aldosterone synthase 
and 11β-Hydroxylase in the same way described for AdxRed (Section 4.3.2). In 
short, following induction with methanol, the expression levels of 11β-
Hydroxylase and aldosterone synthase in the transformants were assessed by 
measuring the levels of whole cell iLOV fluorescence. Unexpectedly, 
fluorescence levels in the transformants were essentially the same as the control 
yeast, suggesting that P. pastoris is unable to make either 11β-Hydroxylase or 
aldosterone synthase (Figure 5.2). 
Although the clonal selection results suggested that P. pastoris is unable to make 
aldosterone synthase, an aldosterone synthase transformant was grown and 
induced in a 7 litre bioreactor to assess whether any aldosterone synthase 
expression could be detected in fermenter culture. Samples were taken at 
regular intervals throughout the fermentation. At each time point, the wet cell 
weight of the culture was determined and the production level of B2-CLBH 
assessed by measuring whole cell iLOV fluorescence (Figure 5.3). Consistent with 
the clonal selection results, negligible levels of iLOV fluorescence were observed 
in fermenter culture, confirming that P. pastoris is unable to make aldosterone 
synthase. It was concluded, therefore, that an alternative expression system 
would be needed to produce aldosterone synthase. 
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5.3.2 Optimisation of B2-CLBH expression in E. coli 
pET21a-CYP11B2-CLBH was transformed into the E. coli BL21 expression strain 
together with pGro7 (a plasmid encoding the bacterial chaperones GroEL and 
GroES). Cells were grown at 37ºC in LB until the culture had an OD600 of 0.6. At 
this stage, 1 mM IPTG and 1 mM arabinose were added to induce expression of 
B2-CLBH and GroEL/ES, respectively, and the temperature reduced to 27ºC. 
Cells were harvested 4, 16, 24 and 48 h post-induction. All of the samples had 
measurable levels of iLOV fluorescence, suggesting that E. coli is able to express 
aldosterone synthase (Figure 5.5). 
B2-CLBH was expected to be membrane-associated. To establish whether or not 
this was the case, the cells were lysed by mechanical disruption, cytosolic and 
membrane fractions prepared by centrifugation, and the fluorescence content of 
the samples measured. Surprisingly, both the cytosolic and membrane fractions 
of all the time-points were fluorescent. To understand why this was the case, a 
series of FSEC experiments were performed. Membranes were solubilised using 
CHAPS (an ionic-detergent that had been successfully used with other 
mammalian p450s (e.g. Annalora et al., 2010)), and the supernatant applied to a 
Superose 6 gel-filtration column. Elution profiles were generated for all four 
time points (Figure 5.5A). The samples harvested at 16 and 24 h both had two 
major peaks in their elution profiles. The peak at ca. 13 ml corresponded to B2-
CLBH. A second peak eluting at ca. 20 ml was observed. Previous studies with SI 
showed that cleavage of the CLBH tag with 3C protease yielded a FSEC peak at 
ca. 20 ml also (Figure 3.8). This suggested that there is a proteolytically-
sensitive region in aldosterone synthase towards its C-terminus, close to the 3C 
cleavage site in the fusion protein. The fluorescent peak for the breakdown 
product was greater in magnitude than that for the intact fusion protein, 
illustrating how sensitive B2-CLBH is to proteolysis. The optimal induction time 
for maximal B2-CLBH expression was between 16 and 24 h. Elution profiles were 
also generated for each of the cytosolic fractions (Figure 5.5B). The samples 
that been induced for 16 and 24 h had a single major peak at ca. 20 ml 
corresponding to the breakdown product. None of the cytosolic fractions 
contained intact B2-CLBH (Figure 5.5B).  
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Together, these results suggested that: (i) B2-CLBH localises to the membrane, 
(ii) the fusion protein is sensitive to proteolytic cleavage in a region of 
aldosterone synthase towards its C-terminus proximal to the 3C recognition site, 
and (iii) the breakdown product is water-soluble.  
Having determined that an induction period of 16 h yielded the highest levels of 
recombinant protein, the effects of temperature on the synthesis and proteolysis 
of B2-CLBH were explored. Expression cultures were induced at four different 
temperatures (15, 22, 30, 37ºC) for 16 h. Cells were harvested and membranes 
isolated.  Following this, the membranes were solubilised using CHAPS, and the 
resulting supernatants analysed by FSEC. In all four elution profiles, peaks 
corresponding to B2-CLBH (elution volume 13 ml) and the breakdown product (20 
ml) were observed (Figure 5.5C, D). At low induction temperatures (15 and 
22ºC), there was more breakdown product than intact protein (Figure 5.5C), 
suggesting that the recombinant protein was being cleaved by endogenous 
proteases faster than it was being made. At 37°C, there was an equal amount of 
B2-CLBH and breakdown product (Figure 5.5D). Only at an induction temperature 
of 30°C did more B2-CLBH accumulate than breakdown product (Figure 5.5D). 
This suggested that the optimal temperature for expressing B2-CLBH in E. coli 
was 30°C. 
Cleavage of the B2-CLBH fusion protein by endogenous bacterial proteases was 
highly undesirable. This problem was overcome by including 5 mM EDTA in the 
buffer used for cell lysis suggesting that aldosterone synthase was being cleaved 
by (a) metalloprotease(s). 
5.3.3 ELISA-SEC: assessing the polar surface availability of 
aldosterone synthase in detergent solution  
Following on from the successful expression of aldosterone synthase in E. coli, it 
was now necessary to identify a suitable detergent for solubilising, purifying and 
crystallising the enzyme. 
For use with a target membrane protein, a detergent must fulfil three criteria: 
(i) the detergent must efficiently remove the protein from the membrane, (ii) 
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the membrane protein must be stable/monodisperse in the chosen detergent, 
and (iii) for structural studies, it is essential that the detergent-solubilised 
protein has sufficient polar surface area available for the formation of lattice 
contacts. 
By fusing a fluorescence reporter (such as GFP or iLOV) to the C-terminus of a 
membrane protein of interest, it is possible to assess the protein's aggregation 
status by FSEC as well as calculate the efficiency of solubilisation (Kawate and 
Gouaux, 2006). However, there is not an established technique for assessing the 
extent of a membrane protein's polar surface exposure in detergent solution. To 
address this deficiency, a new methodology called ELISA-SEC (ESEC) was devised 
which allows the aggregation status and polar surface availability of a target 
membrane protein in detergent solution to be probed at the same time. 
ESEC is a simple adaptation of the FSEC technique. A detergent-solubilised 
sample is applied to a gel filtration column. Elution fractions are collected, and 
analysed by ELISA using an Ab that binds to the surface of the target protein 
(Figure 5.6). Similar to FSEC, the aggregation status of a target membrane 
protein can be evaluated in the presence of other proteins as the ELISA signal 
comes from an antibody specific to the protein of interest. However, ESEC has 
notable advantages over FSEC. First, ESEC can be used with any membrane 
protein where there is an antibody available against an antigenic epitope on the 
surface of the protein. In contrast, FSEC can only be used with membrane 
proteins that have been engineered to have a fluorescent reporter attached to 
either their N- or C-termini. Second, in detergent solution, the antibody will only 
be able to bind to the target protein if the surface epitope is not covered by 
detergent. For this reason, the size of the ELISA signal gives insights into the 
extent of the protein's surface exposure.  
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Figure 5.6 ELISA-SEC
ELISA-SEC is a simple adaptation of the absorption (A)SEC/FSEC methodologies used to assess 
membrane protein stability in detergent solution. In ESEC, a detergent
applied to a gel filtration column, elution fractions collected and then analysed using an antibody 
that binds to a surface epitope on the target protein by ELISA. Using ESEC, insights into the 
aggregation status and the polar surface exposure of
solution can be gained.
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Figure 5.7 ESEC analysis of CYP11B2
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5.3.4 Solubilisation and attempted purification of CYP11B2-CLBH 
using a nickel column  
After sodium cholate had been identified as the optimal detergent for 
solubilising aldosterone synthase, a trial Ni2+-affinity purification of B2-CLBH was 
attempted. Membranes containing B2-CLBH were solubilised using sodium 
cholate. Insoluble material was removed by centrifugation, and the absorption 
profile of the supernatant recorded in the region 350-700 nm (Figure 5.10). The 
absorption spectrum had a haem Soret peak absorption at 413 nm. This was 
unexpected. In their low spin state, cytochrome p450s have a Soret peak 
absorption at ~420 nm. In their high spin state, the p450 Soret absorption band is 
at ~390 nm. Free haem absorbs maximally at 408 nm. The Soret absorption of 
the supernatant fraction at 413 nm was, therefore, difficult to interpret. It may 
have suggested that the supernatant contained some correctly folded 
aldosterone synthase in its low spin state along with a considerable amount of 
free haem (released on breakdown of the p450 enzyme). Alternatively, the haem 
absorption from B2-CLBH may have been so small compared to that from 
endogenous bacterial haem containing proteins that the aldosterone synthase 
contribution could not be seen. In short, it was not possible to say anything 
conclusive about either the abundance or the spin state of B2-CLBH in the 
detergent-solubilised sample from its absorption spectrum. 
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Figure 5.9 ELISA analysis of the wash fractions 
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suggested that fusion of the CLBH tag to aldosterone synthase was causing 
fluorescence from the iLOV reporter to be quenched.
 
Figure 5.10 Fusion of the CLBH tag to aldosterone synthase quenches iLOV fluorescence
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5.3.5 CYP11B1/B2
5.3.5.1 Vector construction
The N-terminally modified aldosterone synthase and 11
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5.3.5.2 ESEC analysis and at
B2-His6 was expressed in C43 cells using the optimised induction conditions 
identified with the CLBH construct. Following this, membranes were isolated and 
solubilised with sodium cholate. The supernatant was applied to
gel-filtration column. Fractions were collected and their aldosterone synthase 
content determined by ELISA. The ESEC profile consisted of a
showing that B2-His
that which had been observed with the B2
expected, B2-His6 eluted from the gel
(Fraction 35-36 v Fraction 30) consistent with it having a smaller size (MW 50 v 
73 kDa).  
 
Figure 5.12 ESEC analysis of CYP11B2
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Figure 5.13 ELISA analysis 
purification of B2-His6
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5.3.5.3 Purification of 11β-Hydroxylase and aldosterone synthase 
Towards the end of my Ph.D., a paper was published by Rita Bernhardt’s lab 
reporting the purification and characterisation of aldosterone synthase (Hobler 
et al., 2012). Having read the details of the paper, it became apparent that 
there was substantial overlap between what I had been doing and what had been 
accomplished by Bernhardt and her team. In particular, the expression construct 
used, the induction conditions as well as the detergent used for solubilisation 
and purification purposes (sodium cholate) were largely similar. 
However, three subtle but significant differences were noted between my 
protocol and that of Bernhardt, which turned out to be essential for functional 
purification of both aldosterone synthase and 11β-Hydroxylase. First, I used a 
mechanical cell disruptor to break open the bacteria. Following this, I isolated 
membranes and solubilised them with detergent. In contrast, Bernhardt’s group 
lysed the cells by sonication in the presence of detergent. Second, Bernhardt's 
team used the gentle detergent Tween-20 along with sodium cholate for 
solubilising aldosterone synthase. Third, Bernhardt and co-workers used Ni2+-
sepharose beads rather than a fixed Ni2+-column for the IMAC step. These small 
differences between protocols turned out to be the difference between success 
and failure in purifying both aldosterone synthase and 11β-Hydroxylase. 
5.3.5.4  Cell lysis and aldosterone synthase functional integrity 
Following expression in a heterologous host, cells must be lysed to release the 
recombinant protein for purification purposes. There are many different 
methods for breaking open cells. These include enzymatic digestion of cell walls 
(e.g. with lysozyme), permeabilisation of the cell membrane with detergent as 
well as using mechanical force (e.g. using a French Press). In the Fraser lab, all 
cells are routinely broken open using a Constant Systems Cell Disruptor. 
Following this, membranes are isolated and later solubilised with detergent 
immediately prior to starting a purification experiment. When this strategy was 
applied to B2-His6 made in E. coli, the detergent-solubilised material always had 
a prominent absorption in the visible region at 413 nm, irrespective of what 
detergent was used to break-up the membranes even when a combination of 
sodium cholate and Tween-20 was used (Figure 5.14). However, when the same 
Aldosterone synthase and 11
cells were treated with lysozyme, and sonicated in the presence of sodium 
cholate and Tween
nm (Figure 5.14), corresponding to aldosterone synthase in its
was clear, therefore, that mechanical breakage of the 
Disruptor was damaging the recombinant protein but why this was happening 
was not understood.
 
Figure 5.14 The effect of the method of cell disruption on the absorption spectrum of an 
coli cell lysate containing B2
E. coli cells containing B2
mechanical force using a Constant Systems cell disruptor. Following this, membranes were 
isolated and then solubilised using a combination
were treated with lysozyme prior to disruption by sonication in the presence of the same 
detergents. The absorption spectra of the resulting lysates were subtly but significantly different. 
The cells lysed mechanically had a haem Soret absorption maximum 
cells lysed by sonication had a main peak at 423 nm (black). As sonication unequivocally yielded 
aldosterone synthase in its low
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5.3.5.5 Partial purification of CYP11B2-His6 using nickel sepharose beads 
Having successfully expressed aldosterone synthase and found a way to lyse the 
cells keeping the enzyme in its low-spin state, efforts were focused on purifying 
the recombinant protein. Up until this point, all Ni2+-affinity purifications had 
been carried out using pre-packed Ni2+ columns (GE Healthcare). In the 
Bernhardt protocol, however, Ni2+-sepharose beads were used. Here, E. coli cells 
expressing B2-His6 were disrupted by sonication in the presence of sodium 
cholate and Tween-20. The cell lysate was centrifuged, and the supernatant 
containing detergent-solubilised aldosterone synthase mixed with Ni2+ beads. 
Following loading, the beads were transferred to a gravity-feed column and 
washed with a buffer containing 20 mM imidazole, 1% sodium cholate and 1% 
Tween-20. Bound protein was eluted in buffer containing 300 mM imidazole, 1% 
sodium cholate and 1% Tween-20 (Figure 5.15A). A series of red-coloured 
fractions were collected (Figure 5.15B), and then pooled together. The 
combined eluate had a strong absorption band at 423 nm with maxima at 536 
and 560 nm, typical of a p450 enzyme in its low-spin state (Figure 5.15C). The 
Ni2+-purified sample was analysed by SDS-PAGE (Figure 5.15D). A band at ca. 49 
kDa was tentatively identified as aldosterone synthase. Last, some of the pooled 
eluate was applied to a Superose 6 gel-filtration column for ESEC analysis. A 
single, sharp peak was observed which showed that the partially-purified B2-His6 
was monodisperse (Figure 5.15E). Of note, however, the elution fraction which 
contained most aldosterone synthase was number 31. Previously, ESEC analysis 
of B2-His6 solubilised with sodium cholate alone peaked around fractions 35 and 
36 (Figure 5.12). This suggested that the aldosterone synthase had bound a 
significant amount of Tween-20 giving the recombinant protein a significantly 
higher apparent MW than in the presence of sodium cholate alone, explaining its 
early exit from the gel-filtration column.  
For reasons not well understood, B2-His6 bound well to loose Ni
2+-sepharose 
beads but not to a pre-packed Ni2+ column. All subsequent purifications were 
performed using Ni2+ beads. 
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5.3.5.6 Purifying aldosterone synthase and 11β-Hydroxylase 
Following Ni2+-affinity purification, although highly-enriched, the aldosterone 
synthase sample was not pure. To achieve a homogenous sample, further 
purification steps were required. In the Bernhardt protocol, Ni2+-enriched 
aldosterone synthase was passed over an anion-exchange column and the flow-
through collected. Next, the sample was applied to a cation-exchange column on 
which the aldosterone synthase bound. The column was washed extensively, and 
the recombinant protein eluted using a sodium acetate salt gradient. The buffers 
used for the ion-exchange step contained sodium cholate but not Tween-20. 
Fractions containing aldosterone synthase were pooled, and exchanged into a 
final purification buffer containing both sodium cholate and Tween-20 by 
repeatedly concentrating the sample and diluting it with the new buffer. 
Bernhardt’s protocol was unnecessarily complicated, and the opportunity existed 
to develop a methodology that was substantially easier to use. First, the anion-
exchange purification was dispensed with, as one ion-exchange step was deemed 
sufficient. Second, to check the aggregation status of the purified protein, a 
size-exclusion purification step was included following the ion-exchange process.  
Last, the purification buffers used for ion-exchange and size-exclusion 
chromatographies contained only sodium cholate. Tween-20 was omitted as it is 
a large, heterogenous detergent incompatible with protein crystallisation. It was 
hoped that by using sodium cholate alone, pure protein could be obtained that 
would be useful for structural studies.  
Both aldosterone synthase and 11β-Hydroxylase were purified using a 3-step 
protocol consisting of: (i) Ni2+-affinity chromatography using Ni2+ sepharose 
beads, (ii) ion-exchange using a negatively charged SP-sepharose column, and 
(iii) gel-filtration using a Superose 6 column (Figure 5.16). 
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Hydroxylase was eluted using a 0-400 mM sodium acetate gradient. Ion-exchange 
buffers contained 1% sodium cholate but not Tween-20. 
The fractions containing aldosterone synthase/11β-Hydroxylase were pooled and 
concentrated before application to a Superose 6 column. The recombinant 
protein could be satisfactorily concentrated to ca. 1 mg/ml. Of critical 
importance, it was noted that above this concentration both p450 enzymes 
precipitated out of solution. The elution profile from the gel-filtration column 
typically showed a single, sharp peak suggesting that the recombinant protein 
was both pure and monodisperse (Figure 5.17A). Peak gel-filtration fractions 
from purifications of aldosterone synthase and 11β-Hydroxylase were analysed 
by SDS-PAGE. In both cases, a dominant band was observed at ca. 49 kDa, 
suggesting that the recombinant proteins had been successfully purified (Figure 
5.17B, C). In order to confirm their identity, the protein bands were excised and 
sent for analysis by tandem mass spectrometry at the University of Dundee 
Proteomics Facility. For both bands, numerous peptides were identified that 
mapped to the primary acid sequences of the modified aldosterone synthase and 
11β-Hydroxylase constructs, thus confirming that human 11β-Hydroxylase and 
aldosterone synthase had been successfully purified (Figure 5.18).  
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Figure 5.17 Purified aldosterone synthase and 11
(A) Highly-enriched aldosterone synthase was concentrated and applied to a Superose 6 gel
filtration column. The elution profile contained a single, sharp peak suggesting that the aldosterone 
synthase was both pure and monodisperse. (B) The peak SEC elutio
SDS-PAGE. A dominant band at 
synthase was largely pure. (C) 11
aldosterone synthase. SDS
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5.4 Biophysical characterisation of aldosterone synthase 
and 11β-Hydroxylase 
5.4.1 UV/Vis absorption spectroscopy 
Cytochrome p450 enzymes have characteristic absorption spectra. They can 
exist in either a high- or a low-spin form, depending on the spin-state of the 
haem-iron. In the low-spin form, the haem Soret absorption maximum is at ca. 
420 nm whereas the Soret peak in the high-spin form is around 390 nm. On 
binding substrate, p450s enzymes are shifted from their low- to high-spin states.  
Both aldosterone synthase and 11β-Hydroxylase were purified in their low-spin 
state with Soret maxima at 418 nm (Figure 5.19A, B). Addition of 50 µM 11-
deoxycorticosterone to aldosterone synthase shifted it to its high-spin form with 
the haem Soret maximum now at 392 nm (Figure 5.19A). 11β-Hydroxylase could 
be shifted to a high-spin form through adding a high concentration (200 µM) of 
11-deoxycorticosterone but not by adding 11-deoxycortisol (its natural substrate) 
(Figure 5.19B). This result was unexpected. 
Cytochrome p450s are so-called as they have a strong characteristic absorption 
at 450 nm when the enzyme is reacted with carbon monoxide under reducing 
conditions. Here, reduced carbon monoxide difference spectra were obtained 
for both aldosterone synthase and 11β-Hydroxylase. The p450 enzymes were 
split in two, one of which was bubbled with carbon monoxide gas. Following this, 
both samples were reduced by adding sodium dithionite.  
Reduced carbon monoxide difference spectra were obtained by recording the 
absorption spectra of the reduced samples treated with carbon monoxide using 
the untreated reduced samples as a reference (Omura and Sato, 1964). A 
defined peak at 448 nm was clearly visible in the difference spectrum for both 
aldosterone synthase and 11β-Hydroxylase, demonstrating that the recombinant 
proteins had retained some of their functionality throughout the purification 
process (Figure 5.19C, D; Figure 5.20). Protein concentration was estimated 
using an extinction coefficient of 91 mM-1 cm-1 at 448 nm. 
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Figure 5.19 Spectral characterisation of pure aldosterone synthase and 11
(A) Aldosterone synthase has a Soret absorption maximum at 418 nm (red) in its low
state (blue)) upon addition of 50 µM 11-deoxycorticosterone
red) was observed upon addition of 200 µM DOC to purified 11
Hydroxylase were obtained (Section 2.15). Defined peak
Hydroxylase and aldosterone synthase had retained their activity throughout the purification process
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A novel technique (called ESEC) was developed which allowed the simultaneous 
assessment of the aggregation state and the polar surface exposure of 
aldosterone synthase in a range of different detergents. Using ESEC, sodium 
cholate was identified as the optimal detergent for solubilising and purifying 
aldosterone synthase.  
Using CYP11B1/B2-His6 constructs, both aldosterone synthase and 11β-
Hydroxylase were purified in a partially functional form using a simple three 
step protocol consisting of Ni2+-affinity, ion-exchange and size-exclusion 
chromatographies. For success, it was essential to break the cells open by 
sonication in the presence of sodium cholate and Tween-20. Furthermore, the 
Ni2+-affinity step had to be performed using Ni2+ sepharose beads and not a pre-
packed column to ensure efficient binding of the recombinant protein. 
Tween-20 was not required for functional purification of aldosterone synthase. 
However, in sodium cholate alone, when aldosterone synthase was concentrated 
to >1 mg/ml, aldosterone synthase precipitated out of solution. This suggested 
that when aldosterone synthase is in sodium cholate there are still hydrophobic 
patches on the surface of the protein not covered with detergent, which gives 
the protein a propensity to aggregate at high concentration. Presumably, 
Tween-20 stabilises aldosterone synthase and 11β-Hydroxylase by covering over 
these hydrophobic patches. However, as Tween-20 is a large, heterogenous 
detergent, it is not useful for crystallisation purposes. This means that an 
alternative additive will have to be found that prevents the p450 enzymes from 
aggregating at high concentration and yet can be used in crystallisation trials. 
Once this issue has been addressed, it will be possible to solve the structures of 
both proteins. Additionally, as aldosterone synthase and 11β-Hydroxylase can be 
purified in an active form, it will be possible to use the pure protein in drug-
screening experiments to identify small molecules that specifically inhibit 
aldosterone synthase.
 Chapter 6 - General discussion and future 
perspectives 
  
Aldosterone plays a key role in regulating body fluid balance in people, 
stimulating sodium uptake, potassium excretion and water retention in the distal 
tubules and collecting ducts of the kidney nephron. Considering the physiological 
function of aldosterone, it is not surprising that many patients with essential 
hypertension have relative aldosterone excess too (Connell et al., 2008). Drugs 
that block aldosterone action through antagonising mineralocorticoid receptor 
function significantly reduce blood pressure in vivo (Pitt et al., 1999; Pitt et al., 
2003). To circumvent side-effects commonly observed with mineralocorticoid 
receptor antagonists, considerable research effort is currently being invested in 
trying to discover specific inhibitors of aldosterone synthase that reduce plasma 
aldosterone levels in people. Identifying molecules that selectively interact with 
aldosterone synthase but not 11β-Hydroxylase is extremely challenging as the 
two enzymes have 93% sequence identity. However, by solving the 3-dimensional 
structures of both p450s, it should be possible to design small molecules that 
bind with high-affinity to aldosterone synthase but not 11β-Hydroxylase. 
Sustained crystallisation trials require milligram quantities of pure, functional 
protein. The primary aim of my Ph.D. was to develop a system for expressing 
and purifying aldosterone synthase and 11β-Hydroxylase for structural studies. 
With a view to creating activity assays for both aldosterone synthase and 11β-
Hydroxylase in vitro, protocols for making and purifying the electron transfer 
proteins adrenodoxin (Adx) and adrenodoxin reductase (AdxRed) were 
established.  
 
At the outset of this thesis, it was expected that a eukaryotic cell type would be 
required for producing the proteins of interest as they were all of human origin. 
For this reason, the “CLBH” expression and purification system was developed in 
Pichia pastoris with sterol isomerase (SI) as a test protein, fully expecting to use 
the modified yeast vector at a later stage with aldosterone synthase, 11β-
Hydroxylase, Adx and AdxRed. Although SI could be made in P. pastoris on a 
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milligram scale, this was not the case for aldosterone synthase, 11β-Hydroxylase 
or AdxRed. Although unexpected, these results help to show that the usefulness, 
or otherwise, of a particular heterologous host cell for making a specific target 
protein can only be determined by experiment. In general, this means that 
several different expression systems may have to be tried before one is found 
that is suitable for making the protein of interest. To enhance the rate of 
expression screening, it is now common to fuse a fluorescent reporter (typically 
GFP) to either the N- or C-terminus of a target protein. Here, the production of 
several different CLBH-tagged proteins in both P. pastoris and E. coli was 
monitored by measuring iLOV fluorescence. It was found that aldosterone 
synthase, 11β-Hydroxylase, Adx and AdxRed could all be successfully made in E. 
coli on a milligram scale. 
 
The CLBH tag enabled purification of SI, Adx and AdxRed using a generic 
approach consisting of four simple steps (Ni2+-affinity, cleavage with 3C 
protease, reverse Ni2+-affinity, gel-filtration). The purification process could be 
simplified further by performing the 3C cleavage step on the first Ni2+ column 
when the recombinant protein is bound to it, eliminating the need for a reverse-
purification step. With hindsight, the problems encountered trying to purify B2-
CLBH by Ni2+-affinity chromatography were not caused by the CLBH tag. Rather, 
it was subsequently discovered that His-tagged aldosterone synthase and 11β-
Hydroxylase would only bind to Ni2+-sepharose beads but not to a pre-packed Ni2+ 
column. This means that, at least in principle, it should be possible to purify 
both aldosterone synthase and 11β-Hydroxylase using the CLBH constructs. In 
general, the CLBH tag can be used for purifying both soluble and membrane 
proteins to homogeneity. Indeed, since its inception, the CLBH tag has been 
used in the Fraser lab to purify a diverse range of proteins including PscD and 
PscB (subunits of the photosynthetic reaction centre from green bacteria), the 
EGF-binding domains of uromodulin as well as several different G-protein 
coupled receptors (Niall Fraser, personal communication). 
 
The CLBH tag can be biotinylated in vitro using recombinant biotin ligase, which 
allows proteins of interest to be immobilised on (strept)avidin coated surfaces. 
This is an elegant feature of the CLBH system, and is compatible with drug-
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design techniques such as target immobilised NMR screening (TINS) (Siegal and 
Hollander, 2009) and surface plasmon resonance (SPR) (Navratilova and Hopkins, 
2010) where the target protein has to be immobilised on a surface prior to 
screening molecular and/or fragment libraries. If time had allowed, it would 
have been interesting to have immobilised aldosterone synthase and 11β-
Hydroxylase on an appropriate surface and screened both enzymes against a 
fragment library by SPR to identify small molecules that bind to aldosterone 
synthase but not 11β-Hydroxylase. Aldosterone synthase and 11β-Hydroxylase 
could be immobilised using the CLBH tag. However, the structures of several 
steroidogenic p450s have shown that the enzyme's C-terminus is located in/near 
the membrane, with its active site facing the membrane (Mast et al., 2011; 
Strushkevich et al., 2011; DeVore and Scott, 2012). This may suggest, therefore, 
that a C-terminal tag is not ideal for immobilising aldosterone synthase or 11β-
Hydroxylase for drug screening by SPR as it would position the active site of the 
enzyme towards the immobilisation surface away from the flow of molecular 
fragments. Alternatively, the p450 enzymes could be immobilised using 
antibodies. The anti-B2 Abs used in the ESEC experiments recognise an epitope 
on the surface of aldosterone synthase in a region equivalent to the β-strands 1 
and 2 of the side-chain cleavage enzyme structure (Strushkevich et al., 2011). If 
these antibodies were used to immobilise aldosterone synthase, the enzyme 
active site would be correctly orientated (pointing towards the flow of 
molecular fragments) for drug-screening experiments. 
  
Fusion of the iLOV fluorescence reporter to the C-terminus of aldosterone 
synthase, 11β-Hydroxylase, Adx and AdxRed gave critical insights into their 
expression, purification, stability and integrity. In particular, the protease-
sensitive region towards the C-terminus of aldosterone synthase would not have 
been identified if the enzyme had been expressed with a His6 rather than a CLBH 
tag. Arguably the most intriguing result from my thesis was the dramatic 
increase in iLOV fluorescence that was observed when partially-purified B2-CLBH 
was cleaved with 3C protease. The putative quenching of iLOV fluorescence by 
the p450 haem group is an unusual phenomenon, and one that I would liked to 
have explored given more time. Potentially, the B2-iLOV fusion could be used as 
a reporter of protease activity both in vitro and in vivo, taking advantage of the 
Discussion  165 
8-fold increase in iLOV fluorescence that occurs when the reporter is cleaved 
from the C-terminus of the p450. By introducing different protease recognition 
sites between aldosterone synthase and iLOV, the biosensor could be readily 
adapted for use with any protease from any organism. Potentially, the B2-iLOV 
biosensor has several advantages over existing technologies aimed at measuring 
protease activity. First, as the B2-iLOV fusion relies on flavin and haem co-
factors (which are ubiquitous in nature), it is likely that the biosensor could be 
used in most, if not all, cell types. Second, as the biosensor is a protein it can be 
readily made and purified for use in high-throughput screening studies to 
identify novel inhibitors of protease activity in vitro. Third, as the B2-iLOV 
fusion can be expressed in vivo, it can be used to assess the biological activity of 
cell permeable protease inhibitors in living cells. Furthermore, as iLOV has a 
strong fluorescence in the absence of oxygen, the B2 fusion protein could be 
used to monitor protease activity in hypoxic conditions (e.g. such as in solid 
tumours). However, before the B2-iLOV fusion could be used as a biosensor, it 
would have to be engineered to make the protein water-soluble (rather than 
membrane associated).  
 
A novel technique called ELISA size-exclusion chromatography (ESEC) was 
developed which allowed the simultaneous assessment of the aggregation state 
and the polar surface exposure of aldosterone synthase in a range of different 
detergents. ESEC is a simple adaptation of FSEC (the current method of choice 
for determining the optimal detergent for solubilising and purifying target 
membrane proteins with). Similar to FSEC, the aggregation status of a target 
membrane protein can be evaluated in the presence of other proteins as the 
ELISA signal is generated via an antibody specific to the protein of interest. 
However, ESEC has a couple of notable advantages over FSEC. First, ESEC can be 
used with any membrane protein where there is an antibody available against an 
antigenic epitope on the surface of the protein. In contrast, FSEC can only be 
used with membrane proteins that have been engineered to have a fluorescent 
reporter attached to either their N- or C-termini. Second, the antibody will not 
be able to bind to the target protein if the surface epitope is covered by 
detergent. For this reason, the size of the ELISA signal gives insights into how 
much of the protein's surface is exposed to the aqueous environment. Using 
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ESEC, sodium cholate was identified as the optimal detergent for solubilising and 
purifying aldosterone synthase. 
 
After considerable effort, protocols were obtained that allowed functional 
aldosterone synthase and 11β-Hydroxylase to be purified. En route, two unusual 
preparative problems were discovered. First, it was found that mechanical 
disruption of E. coli cells expressing aldosterone synthase rendered the 
recombinant protein inactive. This was observed as a prominent absorption in 
the visible region at 413 nm following solubilisation of membranes containing 
aldosterone synthase with detergent. However, when the same cells were 
treated with lysozyme, and sonicated in the presence of sodium cholate and 
Tween-20, the haem Soret band absorption had a maximum at 423 nm, 
indicating the presence of aldosterone synthase in its low spin state. Although it 
is not understood why mechanical disruption should affect the spectral 
properties of aldosterone synthase in the way that was observed, it suggests that 
aldosterone synthase is sensitive to high-pressure forces. Second, it was found 
that CYP11B2-His6 bound with high-efficiency to Ni
2+-sepharose beads but not to 
pre-packed Ni2+ columns. This observation is hard to rationalise. It is possible 
that when the recombinant protein was passed over the column the His6 tag was 
masked by detergent prevent binding to the immobilised Ni2+ ions. When the cell 
lysate was mixed by rotation with Ni2+ beads, however, the dynamic loading 
environment may have resulted in exposure of the His6 tag allowing capture of 
the recombinant protein on the Ni2+ beads. 
 
The detergent Tween-20 was included in the buffers used for breaking open E. 
coli cells expressing CYP11B1/B2-His6 as well as those for Ni
2+-affinity 
purification in accordance with the aldosterone synthase purification protocol 
published recently by Rita Bernhardt's group (Hobler et al., 2012). Tween-20 is 
an extremely mild detergent, traditionally used as a washing agent in Western 
Blots where it helps to prevent non-specific Ab binding. Although Tween-20 can 
be used to solubilise membrane proteins, it is not compatible with crystallisation 
trials as it is a large, heterogenous detergent. Therefore, ion-exchange and gel-
filtration purification steps with nickel-affinity enriched aldosterone synthase 
and 11β-Hydroxylase were performed in the presence of sodium cholate alone. It 
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was found that functional purification of aldosterone synthase does not require 
Tween-20. However, in sodium cholate alone, when purified aldosterone 
synthase was concentrated to >1 mg/ml, the p450 enzyme precipitated out of 
solution. This suggested that in sodium cholate  there must be hydrophobic 
patches on the surface of aldosterone synthase not covered with detergent that 
drive enzyme aggregation at high protein concentrations. As Tween-20 can not 
be used for structural biology purposes, an alternative additive/detergent will 
have to be found that prevents the p450 enzymes from aggregating at high 
concentration and yet can be used in crystallisation trials. One possibility are 
the facial amphiphiles (Zhang et al., 2007) which have been used by others to 
obtain high-resolution structures of selected mammalian p450 enzymes including 
CYP24A1 (Annalora et al., 2010), CYP2B6 (Gay et al., 2010) and CYP2B4 (Gay et 
al., 2011). Furthermore, prior to starting crystallisation trials, thermostability 
assays need to be performed to identify the optimal buffer conditions for use 
with aldosterone synthase and 11β-Hydroxylase. One these issues have been 
addressed, it should be possible to obtain crystals of both aldosterone synthase 
and 11β-Hydroxylase that diffract to high-resolution. 
 
In the next phase of the work, the electron transfer proteins (Adx, AdxRed) will 
be reconstituted in vitro with both aldosterone synthase and 11β-Hydroxylase to 
determine whether or not the p450 enzymes are catalytically active. Enzyme 
activity could be assessed by measuring the rate of substrate consumption (11-
Hydroxylase, deoxycortisol; aldosterone synthase, 11-deoxycorticosterone) or 
production (11-Hydroxylase, cortisol; aldosterone synthase, aldosterone) 
formation. However, it will likely be easier to monitor the rate of NADPH 
oxidation by AdxRed through measuring changes in A340. Once assays have been 
developed for both aldosterone synthase and 11β-Hydroxylase, they can be used 
to determine IC50 values for any molecular ‘hits’ identified in drug-screening 
experiments. Additionally, once activity assays have been established, the effect 
of non-synonymous mutations in Adx or AdxRed on the rate of aldosterone or 
cortisol production can be investigated. If any of the non-synonymous 
polymorphisms affect steroid biosynthesis in vitro, it would be very interesting 
to look at the prevalence of the SNPs in a hypertensive population cohort 
compared to matched control patients.  
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In conclusion, this thesis describes the successful expression, purification and 
characterisation of the human cytochrome p450 enzymes aldosterone synthase 
and 11β-Hydroxylase, as well as their associated electron transfer proteins, Adx 
and AdxRed. This work provides a solid foundation for future efforts to solve the 
structures of aldosterone synthase and 11β-Hydroxylase to atomic resolution. In 
addition, the purified proteins can be used in drug-screening experiments to 
identify novel specific inhibitors of aldosterone synthase for the treatment of 
hypertension. 
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